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vABSTRACT
At the behavioral level drug addiction is defined as compulsion to take a drug with loss of control over apparently
voluntary acts of drug seeking and drug taking. At the neuronal level drugs elicit two types of responses: neuronal
adaptations, i.e. homeostatic responses to excessive stimulation, and synaptic plasticity. At the molecular level both
processes are paralleled by changes in gene expression pattern in the mesolimbic dopaminergic system. The genes
differentially expressed upon drug treatment include transcription factors, neurotransmitter and axon guidance cues.
The detailed picture of gene expression changes is necessary in order to dissect the role of different molecules in the
development of the distinct temporal and functional phases of drug addiction. Therefore, in the present study the
screening for differentially expressed genes upon acute cocaine withdrawal was performed in three brain regions: the
striatum, the tegmentum and the hippocampus. Two modifications of differential display of mRNA were introduced
allowing first for increased reproducibility and easy handling of the method, and second for a gene-specific screening
for the semaphorins, a family of axon guidance cues. The differentially expressed candidates displayed a high range of
functional characteristics, illustrating the complexity and the variability of neuroplastic changes induced in the brain by
psychostimulant treatment. In particular, CD81, a tetraspanin, was found to be overexpressed in the nucleus accumbens
upon cocaine treatment. In situ hybridization studies allowed for localization of CD81 mRNA in the brain regions
functionally related to the regulation of cardiovascular function and fluid homeostasis, most of them also expressing the
neuropeptide galanin. In addition, CD81-deficient mice exhibited sex-dependent altered sensitivity to cocaine, as well
as modified dopamine metabolism. One protein related to neurodegenerative processes in the brain, g-synuclein, was
found to be overexpressed in the tegmentum upon cocaine treatment, suggesting a link between the neuroplasticity
changes related to neural degeneration and drug addiction. Finally, one new vertebrate member of the semaphorin
family and five novel rat orthologues of class 3, 4 and 7 semaphorins have been identified, whereas the application of
newly developed method of Enriched Differential Display allowed for finding of semaphorin differential regulation in
various brain regions upon cocaine treatment.
RESUME
Au niveau comportmental la dépendance est définie comme un désir compulsif de prendre de la drogue avec perte de
controle d’actes apparemment volontaires comme la recherche et la consommation de stupéfiants. Au niveau neuronal
les stupéfiants provoquent deux types de réponses: des adaptations neuronales, c'est-à-dire des réponses homeostatiques
à une stimulation excessive, et la plasticité synaptique. Au niveau moleculaire ces deux effets sont liés à des
changements simultanés du mode d'expression de gènes dans le système dopaminergique mésolimbique. Les gènes
différentiellement exprimés après traitement aux drogues, comprennent des facteurs de la transcription, des
neurotransmetteurs, et des molecules de guidance axonale. Une image détaillée des changements d'expression genique
est nécessaire pour disséquer le rôle des différentes molécules dans le développement des diverses phases temporelles et
fonctionnelles associées à la dépendance. C'est pourquoi, dans l'étude présente, on a effectué la recherche des gènes
différentiellement exprimés après traitement aigu à la cocaine et après retrait, dans trois régions du cerveau: le striatum,
le tegmentum et l'hippocampe. Deux modifications de la méthode de display différentiel de mARN ont été introduites,
permettant, premièrement, d'augmenter la reproductibilité et de faciliter le maniement de la méthode, et deuxièmement,
d'effectuer une recherche spécifique de sémaphorines, une famille des molécules de guidance axonale. Les gènes
exprimés différentiellement representent une large palette de candidats aux charactéristiques fonctionnelles diverses,
illustrant la complexité et la variabilité des changements neuroplastiques induits par un traitement à un psychostimulant
dans le cerveau. En particulier, nous avouns trouvé que le CD81, une tetraspanine, est surexprimé dans le noyau
accumbens après treatment à la cocaine. Une étude par hybridisation in situ a permis de localizer le mARN de CD81
dans des régions du cerveau fonctionnellement liées à la régulation de la fonction cardiovasculaire et de l'homéostase
des fluides. La plupart de ces régions expriment aussi le neuropeptide galanine. En plus, les souris déficientes pour le
gène du CD81, démontraient des changements de la sensibilité à la cocaine, variables selon le sexe, ainsi que des
modifications du métabolisme de la dopamine. En outre, nous avons montré qu’une proteine, liée aux processus
neurodegeneratifs dans le cerveau, la g-synucleine, était sur-exprimée dans le tegmentum après traitement à la cocaine,
ce qui suggère un lien entre les changements neuroplastiques liées à la neurodégénérescence et la dépendance.
Finalement, un nouveau membre de la famille des sémaphorines de vertebrés et cinq orthologues de sémaphorines des
classes 3,4 et 7 chez le rat, ont été identifiés, alors que l'application de la nouvelle méthode du Display Différentiel
Enrichi que nous avons developpé a permis de démontrer la régulation différentielle des sémaphorines dans diverses
régions du cerveau après traitement à la cocaine.
1I. INTRODUCTION
The present study was aimed at investigating molecular
cues involved in the action of cocaine, one of the major
drugs of abuse, and in the establishment of drug
addiction. To achieve this purpose, the screening of
differentially expressed genes was performed in the
structures of the brain related to the dopaminergic
(DAergic) system and basal ganglia (BG). Before the
presentation and discussion of the results, a general
introduction will be given to familiarize the reader with
the subject.
1. Dopamine
DA is synthesized in the presynaptic terminal from
tyrosine which is converted into L-DOPA with tyrosine
hydroxylase (TH) (Figure 1), then into DA by aromatic
amino acid decarboxylase. DA is then taken up and
stored in synaptic vesicles in the presynaptic terminal.
After the release of DA from the vesicles into the
synaptic cleft, reuptake by the dopamine transporter
(DAT) in the presynaptic membrane occurs after which
the DA is transported back into vesicles or is degraded
to DOPAC by type B monoamine oxidase (Olivier et
al., 2000; Shih et al., 1999).
DAT is densely concentrated in the substantia nigra,
pars compacta (SNc) and scattered throughout the
ventral tegmental area (VTA) (Freed et al., 1995). Both
regions contain high concentrations of DAT mRNA.
The relative abundance of DAT mRNA varies across
subregions: it is highest in SNc, medium in the
parabrachial pigmentosis and lowest in the
intrafascicular nucleus (Burchett and Bannon, 1997).
Low levels of DAT mRNA are present in the central
gray and hypothalamus. In addition, DAT mRNA can
be detected in the amygdala, caudate-putamen, nucleus
accumbens (NAcc), pons/medulla, globus pallidus
(GP), pituitary and frontal cortex (Maggos et al., 1997).
Figure 1. DAergic terminal with cycle of synthesis,
storage, release and removal of DA. AADC, aromatic
amino acid decarboxylase; MAO-B, type B
monoamine oxidase; TH, tyrosine hydroxylase
(adapted from (Cooper and Bloom, 1996))
DA receptors are G-protein-coupled seven
transmembrane proteins and include two major classes,
D1-type and D2-type. D1-type include D1 and D5
receptors (Emilien et al., 1999) and activate the
ad nylyl cyclase via a Gs-subunit leading to an
increase in cAMP concentration (Kebabian and Calne,
1979). One important pathway of D1 signaling
includes DA- and cAMP-regulated phosphoprotein
(DARPP)-32 phosphorylation by protein kinase A
(PKA) which inhibits dephosphorylation of NMDA
receptors via inhibition of an endogenous protein
phosphatase-1, thus enhancing NMDA responses
(Blank et al., 1997). It occurs synergistically with
cAMP/PKA-dependent NR1 subunit phosphorylation
and provides a link between DA signaling and synaptic
plasticity (Greengard et al., 1999).
D2-type comprise D2, D3 and D4 receptors (Emilien et
al., 1999) and inhibit the adenylyl cyclase via a Gia-
subunit or are linked to the phosphatidylinositol
turnover or to potassium and calcium channels (Vallar
et al., 1988).
D1 receptors are abundant in the caudate-putamen,
NAcc and olfactory tubercle (OT), as well as the
cerebral cortex, limbic system, hypothalamus, thalamus
(Mengod et al., 1989) and in striato-nigral axons in the
substantia nigra, pars reticulata (SNr) (Ariano et al.,
1989). Activation of D1 receptors increases immediate
early genes (IEG) expression in the striatum and
conductance through the NMDA receptor. c-fos, but
not zif268, induction is at least partially mediated by
NMDA receptor activity (Keefe and Gerfen, 1996).
Despite the opposite action of D1 and D2 receptors on
adenylyl cyclase activity, some D1 effects depend on
the synergistic action of D2 receptor (LaHoste et al.,
2000). For example, the expression of zif268 is
reduced by application of a D2 receptor agonist,
whereas the simultaneous application of D1 and D2
receptor agonists increases the induction of zif268
compared to D1 receptor agonist alone (Keefe and
Gerfen, 1995). This synergistic action results from the
interaction between different neurons, since D1 and D2
receptors are normally not expressed in the same cells
(Gerfen et al., 1995). It plays an important role in the
case of drug self-administration, where D2 receptors
mediate the reinforcement of the stimulant drug and D1
receptors play a permissive role (Missale et al., 1998).
D2 receptors are highly expressed postsynaptically in
the caudate-putamen, NAcc and OT (Mengod et al.,
1989) and as autoreceptors on DAergic dendrites in the
medial two thirds of the SNc, with lesser density in the
dorsal VTA (Akaoka et al., 1992).
D3 receptors are expressed in the OT, NAcc, the
islands of Calleja, the hypothalamus and as
autoreceptors in DAergic cells laterally in the SN-VTA
(Bouthenet et al., 1991). D3 receptors are localized
preferentially in limbic brain areas and affect
locomotion and perhaps reinforcement and reward
(Shafer and Levant, 1998).
2D4 receptors are present in the frontal cortex, midbrain,
amygdala, and medulla (Van Tol et al., 1991). Their
affinity is not limited to DA, but expands also to
adrenaline and noradrenaline, explaining their role in
coordinating signaling between the different
catecholamine neurotransmitter systems (Hartman and
Lanau, 1997; Lanau et al., 1997).
D5 receptors are expressed in the hippocampus,
hypothalamus and pretectal nucleus (Ciliax et al.,
2000; Meador-Woodruff et al., 1992). Remarkably, DA
is 10-fold more potent at the D5 receptor than at the D1
receptor.
Among all types of DA receptors only D2 and D3
subtypes are expressed presynaptically. The regulation
of DA release is modulated principally by D3
autoreceptors, whereas the regulation of DA
biosynthesis and metabolism is mediated by D2
autoreceptors (Raevskii, 1998).
2. The neuroanatomy of the basal ganglia
The DAergic system of the brain is historically
classified into the neuroanatomical groups A8-A17,
with numbers increasing caudo-rostrally in the brain,
starting in the midbrain with A8 at the retrorubral field
and terminating with A17 in the retina. The major
groups of DAergic neurons, and the most relevant to
the present study, are groups A9 and A10 (SNr and
VTA respectively). These groups of cells are intimately
related to another large complex of brain regions called
the BG. In fact, the substantia nigra (SN) is considered
an integral part of this complex.
Historically the term BG was applied to the entire basal
forebrain region, then only the regions primarily
related to motor control were considered (caudate-
putamen and GP). Then the ventral borders of the BG
were expanded to include the NAcc and OT (ventral
striatum) based on similarities of projections and
cellular organization. Later, the subthalamic nucleus
(STN) and the SN were also included. The VTA is
intimately related to the SN both in cytoarchitecture
and function, and therefore these two structures will be
discussed together.
2.1. SN-VTA complex.
The SN receives its name from the black pigment
melanin, a product of DA degradation. "Substantia
nigra" literally means "black substance". This region
attracted particular attention due to the fact that
DAergic neurons degenerate in Parkinson’s disease.
Moreover, the projections of the striatonigral pathway
are lost in Huntington’s chorea. SN together with VTA
are implicated in thought and in affective disorders
such as schizophrenia and manic-depressive illness. In
addition, deregulation of the DAergic system has been
linked to Tourette’s syndrome, attention deficit
hyperactive disorder and the generation of pituitary
tumors (Vallone et al., 2000). Finally, the entire
complex plays a key role in the generation of reward,
motivation and drug addiction. The SN is also
fascinating in its general neurochemical profile. The
processing occurring there resides more on the
chemical specificity of the neurotransmitters than on a
very precise anatomical specificity (Greenfield, 2000).
2.1.1. General topography and organization of SN-
VTA
The SN-VTA lies in the ventral tegmentum of the
mesencephalon, 2.5 mm long rostro-caudally and 3
mm wide medio-laterally. SN and VTA share
neurochemical and functional properties, and thus form
a complex structure. However, important differences
exist between the two regions.
The SN comprises three parts, the SNc, a sheet of
mainly DAergic (90%) neurons overlying the SNr, and
the pars lateralis (SNl), a lateral extension of the SNc.
The SNr is a pallidal structure composed of
GABAergic neurons, which form a major output of the
BG. The SNc is composed of DAergic neurons that
extend posteriorly in the retrorubral field.
Medial and dorsomedial to the SNc and SNr lies the
VTA. The VTA comprises the rostral VTA, the
parabrachial pigmented nucleus, the paranigral
nucleus, the rostral linear nucleus, the interfascicular
nucleus and the caudal linear nucleus. The VTA is a
more homogenous structure than the SN. 80% of the
VTA cells are DAergic neurons of a wide range of
sizes and shapes (Halliday and Tork, 1986; Phillipson,
1979; Phillipson, 1979; Swanson, 1982). The rat VTA
is more similar to the human VTA in its cellular
distribution than to the VTAs of nonhuman primates
(Halliday and Tork, 1986) and is, therefore, a good
model for the study of the general mechanisms of
higher brain function.
2.1.2. Cytoarchitecture of SN-VTA
The SNc contains densely packed, medium-sized,
DAergic neurons, approximately 11x20 µm in somal
size. The SNc is divided into a ventral and a dorsal tier.
Adjacent DAergic neurons in the ventral tier of SNc
often give rise to closely apposed clusters of “apical”
dendrites that invade the SNr (Figure 2A,D) (Bjorklund
and Lindvall, 1975). These dendrites release DA
(Cheramy et al., 1981) which interacts with DA
autoreceptors, DA receptors on adjacent DAergic
dendrites, striatonigral neurons (expressing D2
receptors), or a combination thereof. This feature
defies the textbook view of how neurons work because,
n contrast to the classical situation, these dendrites are
found in both pre- and post-synaptic positions
simultaneously.
The dorsal tier of the SNc does not contain cells with
inverted “apical” dendrites; rather its neurons are
typically medium-sized and fusiform (Fallon and
Moore, 1978). This arrangement of separate dendritic
fi lds is the basis for the functional separation of input
and output domains in the SNc. The dorsal-most sheet
of SNc neurons is continuous with the more medially
placed parabrachial pigmented nucleus neurons of the
VTA. Neurons of the dorsal SNc are functionally and
anatomically related to VTA neurons. Instead of the
usual SNc-VTA opposition, it may be best to
distinguish between the ventral tier of the SNc and
VTA versus the dorsal tier of the SNc (calbindin-
3positive in rat), especially with regards to their cortical
inputs (Figure 2B,C).
A
B
C
D
Figure 2. Coronal sections of the
right side of the SN-VTA through a
midrostral level. The locations of cell
bodies, containing the DA (A) and
28-kDa calcium-binding protein
calbindin (CaBP 28K, B), are shown.
Cell types (D) and zones (C) in the
SN-VTA, defined on the basis of
inputs from limbic and cortical
structures, and the striatum (patch
and matrix). The projections from the
patch overlie DAergic cell bodies in
the SNc and SNr (adapted from
(Paxinos, 1995))
2.1.3. Development of SN-VTA
The SN-VTA is derived from a primordial cell group
in the ventral mesencephalon, which is first detectable
at approximately E12.5 (Specht et al., 1981). By E17,
this cell group divides to form the A8, A9, and A10
groups. DAergic fibers can be visualized by E14.5. In
early postnatal development, the innervation of the
caudate-putamen has an island appearance that seems
to correspond to the patch-matrix organization (van der
Kooy, 1984). This and the very early development of
this system led to the hypothesis that SN-VTA cells
might control striatal development.
2.1.4. SN-VTA connections
2.1.4.1. Inputs
The inputs to the SN-VTA are summarized in Figure 3.
Striatal matrix neurons, expressing GABA, dynorphin
(Dyn) and substance P (SP), project to GABAergic
SNr neurons (and distal dendrites of DAergic neurons).
GABA receptors are numerous in SNr, but
predominantly GABA-A are present (Bowery et al.,
1987). The striosomes or striatal patch neurons,
containing GABA and enkephalin (Enk), send their
axons to ventral SNc neurons (with dendrites in SNr).
Opioid peptides may facilitate neurotransmission in
SN-VTA DA neurons through mu-receptor-mediated
inhibition of inhibitory interneurons in the SN-VTA
(Johnson and North, 1992). Also k and d opioid
receptors are present in SN-VTA (Clarke and Pert,
1985).
The STN is the source of excitatory glutamatergic
(Glu-ergic) projections to SNr neurons (Groenewegen
and Berendse, 1990). The GP and the ventral pallidum
(GABAergic) project to SN and VTA (Haber and
Nauta, 1983). These projections are organized
topographically (ventrodorsally) (for review: (Gerfen,
1992; Gerfen, 1992)). Other inputs include the
amygdala (Shinonaga et al., 1992), the hypothalamus
(Nauta et al., 1978), the preoptic area, and the cortex,
especially the frontal and the cingulate areas (Wyss and
Sripanidkulchai, 1984), all sending their axons to both
the SNc and the VTA (especially the dorsal-most tier).
Prefrontal cortex projections use glutamate (Glu) in the
SN and aspartate in the VTA. The AMPA-receptors are
predominant in the SNc (Petralia and Wenthold, 1992),
and NMDA-receptors in the SNr (Monaghan and
Cotman, 1985).
Figure 3. Inputs to the SN-VTA from the brain areas
noted (adapted from (Paxinos, 1995)).
The inputs from the brainstem include serotonergic
projections from the dorsal and median raphe nuclei
(primarily to SNr) (Steinbusch, 1981). Serotonin (5-
HT) receptors are largely confined to striato-nigral
terminals of the SNr (Palacios et al., 1990; Pazos et al.,
1987). The noradrenergic inputs are represented by the
projections en route from the locus coeruleus to the
forebrain through the VTA (Fallon and Moore, 1978)
as well as cholinergic inputs from the
4pedunculopontine and tegmental nuclei. The SN-VTA
themselves contain some cholinergic bodies (Gould et
al., 1989; Martinez-Murillo et al., 1989; Martinez-
Murillo et al., 1989).
2.1.4.2. Outputs
2.1.4.2.1 DAergic
The DAergic projections from the SN-VTA are
summarized in Figure 4. Ventral and intermediate
sheets of the SNc and the ventro-lateral VTA project to
the caudate putamen (nigrostriatal pathway), whereas
the dorsal and middorsal VTA and medial SNc send
their axons to the NAcc and OT in the ventral striatum
(mesolimbic pathway). Other targets include the
amygdala (from the VTA, the lateral SNc and the SNl)
and the lateral septum (from the paranigral nucleus and
the medial SNc). The dorsal-most sheet of the SNc and
the VTA send their projections to the prefrontal,
cingulate, perirhinal, and entorhinal cortices
(mesocortical pathway). In addition there are sparse
DAergic projections to other regions: the cerebellum,
the dorsal lateral geniculate nucleus, the hypothalamus,
the raphe, the hippocampus, the ventral pallidum, and
the locus coeruleus. Cortical, striatal and pallidal
projections arise topographically and predominantly
(95%) ipsilaterally. Many DAergic projections also
contain cholecystokinin (CCK) and other
neuropeptides. Although cortical outputs come from
the dorsal tier of the SNc and the VTA as one complex,
the outputs to the NAcc remain primarily reserved to
the VTA.
Figure 4. Localization of DAergic neurons in the SN-
VTA, giving rise to mesotelencephalic projections
(adapted from (Paxinos, 1995)).
2.1.4.2.2 Non-DAergic
The SNr projects to the thalamus (ventromedial,
dorsomedial and intralaminar nuclei, in turn projecting
essentially to the frontal cortex), the superior colliculus
(Williams and Faull, 1985) and mesencephalic motor
regions (pedunculopontine nuclei and surrounding
mesopontine tegmentum) (Faull and Mehler, 1978).
SNl neurons send their axons to the inferior colliculus
(Moriizumi et al., 1992), whereas the VTA projects to
the visual cortex (Dinopoulos and Parnavelas, 1991).
In addition, there are some other, less dense,
projections.
2.1.5. General principles of SN-VTA inputs and
outputs organization
SNr neurons receive an excitatory input from the STN,
which is under the direct influence of the cortex and
the striatum. The GABAergic neurons of SNr, but also
the "apical" dendrites of DAergic neurons of the
ventral tier of the SNc will be influenced by GABA,
SP and Dyn-containing terminals arising from the
atrix of the striatum. This allows striatal inputs to
influence both systems (GABAergic and DAergic) at
the same time. DAergic neurons of the ventral tier
receive motor inputs, whereas the dorsal tier, which
receives less inputs from the striatum, is more under
the influence of cortical, hypothalamic, amygdaloid
and other "limbic" regions of the forebrain. The
differential inputs are mirrored by differential ion
conductances in these various sectors.
Together, SN-VTA neurons can integrate both limbic
and motor activity. A distinction between limbic and
nonlimbic extrapyramidal zones in the SN-VTA is
based on the dorsal-ventral dichotomies of inputs,
outputs, and dendritic domains of the DAergic neurons.
Connections within the DAergic system are
summarized below and in Figure 5:
1. frontal and cingulate cortices, as well as NAcc and
OT, project to the dorsal tier (direct limbic) of the
SN-VTA
2. limbic cortices project to the striosomes that, in
turn, innervate the intermediate neurons between
the dorsal and ventral tier (indirect limbic)
3. sensorimotor cortices project to the striatal matrix
whose neurons, in turn, send their axons to the SNr
(with dendrites of the ventral tier) (motor)
At the level of outputs, the dorsal tier projects to the
cortex, the ventral striatum and limbic structures as
well as to the striatal matrix, whereas the ventral tier
projects to the dorsal striatum (striosomes). Overall,
DA facilitates most of the loops and outputs in the
extrapyramidal motor system.
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Figure 5. General scheme of DAergic
system connections. NAcc: nucleus
accumbens, OT: olfactory tubercle,
PPTN: pedunculopontine tegmental
nucleus, SC: superior colliculus, SM:
sensorimotor cortical projections, SNc:
substantia nigra, pars compacta, SNr:
substantia nigra, pars reticulata, VTA:
ventral tegmental area.
2.2. Basal ganglia
Figure 6. General scheme of BG components and their
interconnections in primates. The system is slightly
different in rat. The external segment of primates is
represented in rat by GP (lateral GP in Rat Brain Atlas
(Paxinos and Watson, 1998)). Internal pallidal segment
of primates is represented in rat by entopeduncular
nucleus (medial GP in Rat Brain Atlas (Paxinos and
Watson, 1998)).
2.2.1. BG topography, neurochemistry and
cytoarchitecture
2.2.1.1. Striatum
The striatum has different levels of
compartmentalization. A functional separation into
dorsal (dorsolateral) and ventral (ventromedial)
striatum matches the type of information processed and
the particular topography of their efferents. The dorsal
striatum receives the inputs mostly from the neocortex
while the ventral striatum is innervated by the axons
from the allocortex and mesocortex. The differences
are gradual rather than abrupt, and significant overlap
between allocortical-mesocortical-amygdaloid
projection fields exists. Accordingly, a precise
boundary between the ventral and the dorsal striatum is
difficult to draw.
The dorsal striatum is separated into caudate and
putamen, although in rats this distinction is not
significant because of poor development of the internal
capsule. The ventral striatum comprises ventromedial
parts of the caudate-putamen, the NAcc, and the
medium-sized cells in the OT (Heimer et al., 1991).
The NAcc is further subdivided into the core and the
6surrounding shell (Zaborszky et al., 1985). The rostral
pole of the NAcc is a distinct region because it does
not show a core-shell dichotomy (Heimer and Alheid,
1991; Zahm and Heimer, 1993).
BG display characteristic border regions sharing the
properties of neighboring structures. For example, the
shell of the NAcc has neurochemical and connectional
features more common to the closely localized
extended amygdala, e.g., strong CCK and angiotensin
II (ATII) immunoreactivity and projections to the
hypothalamus (Heimer and Alheid, 1991; Zaborszky et
al., 1985). However, these two structures represent
separate, even if highly interacting, functional
anatomical entities (Zahm, 1998). The extended
amygdala projects to the posterior lateral hypothalamus
with major final outputs in autonomic centers at the
brainstem, whereas the shell of the NAcc and the
ventromedial ventral pallidum project throughout the
lateral hypothalamic area and send essentially all BG
projections to the prefrontal cortex.
A second level of compartmentalization of the striatum
is its “striosomal”, or patch-matrix organization
(Graybiel et al., 1978). A relatively constant ratio of
15% striosomes to 85% matrix is maintained in the
striatum of rat, rhesus monkey and human. The
striosomes form a branched three-dimensional
labyrinth within the matrix (Groves et al., 1988). The
average number of striosomes stays constant from rat
to human with a corresponding increase in striosome
volume. The histochemical markers used for the matrix
compartment are AChE or calbindin (in the rat),
whereas the mu-opiate receptor binding and
immunohistochemical staining for enkephalin are the
markers of striosomes (Johnston et al., 1990; Pert et al.,
1976). Striosomes and the matrix as defined in the
dorsal striatum are not present in the ventral striatum.
In the rat 90-95% of striatal neurons are medium spiny
neurons. These cells have perikaryi with diameters
ranging between 12 and 18 µm and 4-8 dendrites that
are relatively devoid of spines proximal to where they
first branch, but beyond are very densely spined all the
way to their tips, which are typically 100-250 µm away
from the cell body. GABAergic medium spiny neurons
are both projection neurons and interneurons. The
interneurons with their dendritic tree form the basket
on the cell bodies of projection neurons. These
interneurons receive major inputs not only from the
cortex, but also from downstream BG nuclei, and thus
present an important level of regulation for projection
neurons. Each projection neuron receives inputs from
about 50 GABAergic interneurons.
A minor but critical proportion of the striatal neurons
(less than 2% in rats) are cholinergic interneurons
(Phelps et al., 1985; Walaas and Fonnum, 1979) which
play an important role in the integration of signals and
in the modulation of the striatal output (Dimova et al.,
1993; Pickel and Chan, 1991).
2.2.1.2. Pallidum
The pallidum consists of a larger external component,
the GP, and a smaller intracapsular component, the
entopeduncular nucleus (EP), which also includes the
SNr. In rodents the EP represents the homologue of the
primate internal pallidal segment. The pallidum is
usually separated into the ventral and dorsal divisions
but, as in the striatum, there is no way to mark a border
in-between. Because of inputs from the ventral
s riatum, the ventral pallidum is positive for SP (Haber
et al., 1985; Haber and Nauta, 1983; Haber and
Watson, 1985) and represents both external and
internal pallidal segments (Alheid and Heimer, 1988;
Groenewegen et al., 1993). The SNr shares many
his ological features with the internal segment of the
GP (i.e. the EP). Both are characterized by dense SP
(Inagaki and Parent, 1984), epidermal growth factor
(Alheid and Heimer, 1988; Fallon et al., 1984) and
GABA immunoreactivity (Oertel et al., 1982).
2.2.1.3. Subthalamic nucleus
The STN is an ovoid nucleus partly embedded in the
dorsomedial part of the pes pedunculi. It contains a
homogeneous collection of densely packed, medium-
sized Glu-ergic neurons with relatively long dendrites,
which contain few or a moderate number of spines
(Yelnik and Percheron, 1979). In the rat, as opposed to
primates, the distal dendrites occasionally cross the
borders of the nucleus (Hammond and Yelnik, 1983).
The STN, like the striatum, influences motor activities
primarily through its prominent projections to the EP
and the SNr. Accordingly the majority of STN neurons
are projection neurons, whose axons bifurcate
projecting to both output nuclei and in addition emit
few collaterals that are distributed within the nucleus.
2.2.2. BG connections
A detailed scheme of BG subregions in the rat brain is
presented in the Figure 7.
Figure 7. BG Outline. The BG and a few other
structures (hypothalamus and sublenticular extended
amygdala) are identified in a parasaggital section of a
rat brain. ac, anterior commissure; Acb: nucleus
accumbens; CPu, caudate-putamen; EP,
entopeduncular nucleus; GP, globus pallidus; SLEA,
sublenticular extended amygdala; SNC, substantia
nigra, pars compacta; SNR, substantia nigra, pars
reticulata; STh, subthalamic nucleus; Tu, olfactory
tubercle; VP, ventral pallidum.
72.2.2.1. Inputs
All cortical areas are connected to the striatopallidal
system, and the heterogeneity of the system itself
probably serves different needs of various cortical
regions (Figure 8).
Figure 8. Schematic drawing of the corticostriatal
projections.
The distinction between dorsal and ventral striatum is
based on the difference at the level of cortical inputs.
Cortical areas themselves receive the input from
different thalamic nuclei as follows:
Ventroanterior-ventrolateral nuclei of the thalamus
project to the motor-premotor cortex with the final
output in the dorsal part of the striatopallidal system,
while the mediodorsal thalamic nucleus projects to
prefrontal cortex neurons sending, in turn, their axons
to the ventral striatopallidal system.
Corticostriatal projections use Glu (Christie et al.,
1987; Fonnum et al., 1981). CCK may also be involved
(Meyer et al., 1982; Zaborszky et al., 1985). Cortical
projections reach the striatum in a direct fashion,
resulting in a topographic projection system, with all
parts of the cortex projecting to the adjacent parts of
the caudate-putamen (Figure 8). The projections to the
ventral striatum from both the allocortex and the
medial mesocortex (retrosplenial, anterior cingulate,
prelimbic, and infralimbic areas) and from the lateral
mesocortex (sulcal areas, agranular insular area, and
perirhinal area) project topographically to a ventral
striatal territory, which includes the OT, the NAcc, and
a large ventromedial territory of the caudate-putamen.
The involvement of the ventromedial caudate-putamen
is more extensive for the mesocortical areas than for
the allocortex. Each allocortical and mesocortical area
projects bilaterally, with an ipsilateral predominance
and with longitudinally extended striatal projection
fields (Beckstead et al., 1979).
Amygdalostriatal projections originate mainly in the
cortical-like basolateral amygdaloid complex (Figure
8) (Carlsen and Heimer, 1988).
The thalamocortical projections are a major source of
topographically organized striatal afferents that
originate primarily in the midline and intralaminar
nuclei of the thalamus (Beckstead, 1984; van der Kooy,
1979). These thalamostriatal projections also include
afferents from areas such as the ventral thalamic nuclei
(Jones and Leavitt, 1974), the lateral posterior and
posterior thalamic nuclei (Veening et al., 1980). The
thalamocortical projections are topographically
organized in anteroposterior and mediolateral
directions. The fact that the striatopetal thalamic nuclei
also project to the cortex suggests that these two
projections may, at least to some extent, represent
collaterals of single neurons (Jones and Leavitt, 1974).
The thalamostriatal input is excitatory and presumably
Glu-ergic (Kitai et al., 1976), but afferents from the
thalamus and from the cerebral cortex do not converge
on the same striatal spiny neuron (Dube et al., 1988).
Mesostriatal DA projections represent about 20% of
striatal inputs (Figure 9A). DAergic terminals synapse
on the very same neurons as corticostriatal terminals,
NMDA-receptors being expressed on the spinal head
and DA receptors on the spinal neck. Other ascending
afferent projections include 5-HT from the dorsal raphe
to striatum and pallidal complex (Figure 9A) (Azmitia
and Segal, 1978; Veening et al., 1980) and seemingly
cholinergic projections (Woolf and Butcher, 1986)
from the mesopontine reticular formation (including
the pedunculopontine tegmental nucleus) (Figure 9B).
Figure 9. Mesencephalic inputs to the BG. MPT,
dorsal mesopontine tegmentum; VTA, ventral
tegmental area. See Figure 7 for other abbreviations.
2.2.2.2. Outputs
The striatum projects either directly or indirectly via
the STN to BG output nuclei (GP, EP, and SNr)
(Figure 10). These three output regions share many
similarities, but also differences. For ex., only the
ventral pallidum, EP and SNr receive a dense SP/Dyn
8innervation from the striosomes (Beckstead and
Kersey, 1985; Haber and Nauta, 1983; Vincent et al.,
1982). Alternatively, the EP and SNr do not receive a
comparable Enk-ergic input from the striatal matrix in
the rat. Only the GP and the ventral pallidum project to
the STN.
Figure 10. Schematic drawing of dorsal striatofugal
projections.
Spiny projection neurons in the dorsal striatum can be
differentiated onto several groups:
1) Neurons with local axon collaterals restricted to
the parent dendritic domain (most common),
including Enk-ergic striatopallidal  projections
(expressing D2 receptors) and SP/Dyn-ergic
striatonigral projections (expressing D1 receptors
(Kawaguchi et al., 1990)), which may send a
collateral axonal branch to the EP;
2) Neurons with more widely spread collateral
branches (Bishop et al., 1982; Kawaguchi et al.,
1990).
The matrix compartment of the striatum projects to the
SNr, which contains GABA-ergic neurons and the
distal dendrites of DA neurons (Gerfen et al., 1985;
Gerfen and Sawchenko, 1985), whereas the projections
to the ventral tier of the SNc originate in striosomes
and synapse at a neurochemically distinct subset of
DAergic cell bodies. This represents two parallel
corticostriato-pallidonigral pathways through the
patch-matrix compartments, which differentially
regulate the BG output directly or through a loop on
DAergic cells (Gerfen, 1992; Gerfen, 1992). The
ventral striatum projects primarily to DA neurons
which innervate the matrix. The core of the NAcc
projects to the dorsolateral part of the ventral pallidum,
EP, the lateral part of the VTA, and to the SNc, which
affects the activity of the dorsal striatum via the DA
system (Wouterlood et al., 1992). In contrast, the shell
of the NAcc and the rostral pole project to the
ventromedial parts of the ventral pallidum, EP, the
VTA, and the mediodorsal SNc (which are the typical
projections for BG structures), and also to the extended
amygdala and the lateral preoptic-hypothalamic
continuum (Zahm and Heimer, 1993), thus resembling
the extended amygdala projections. The shell also has
more pronounced projections to the mesopontine
reticular formation and the periaqueductal gray.
The BG output nuclei project to the cortex with a relay
in the thalamus as well as the superior colliculus, the
lateral habenula, and the reticular formation in the
general region of the pedunculopontine tegmental
nucleus.
In more detail, the GP projects to STN, EP, SNc and
SNr, the superior colliculus (Carter and Fibiger, 1978)
and carries projections back to the striatum and to the
cortex (Figure 11A) (Spooren et al., 1996; Spooren et
al., 1991). The ventral pallidum, in turn, projects to
STN and SN (from dorsolateral part), the mediodorsal
thalamus, EP-lateral hypothalamic area, and VTA
(from ventromedial part).
EP and SNr project to the thalamus (ventromedial-
ventrolateral complex, the centromedian-parafascicular
complex, the mediodorsal nucleus and the adjacent
intralaminar nuclei), the superior colliculus and the
pedunculopontine tegmental nucleus (Figure 11B)
(Jackson and Crossman, 1981).
Figure 11. Major output BG projections. Hb, habenula;
MD, mediodorsal thalamic nucleus; MPT, dorsal
mesopontine tegmentum; MRF, medullary reticular
formation; PV, paraventricular thalamic nucleus; Rt,
reticular thalamic nucleus; SC, superior colliculus; VL-
VM, ventrolateral-ventromedial thalamic complex.
Thus, both the lateral and the ventral pallidum in their
output projections can undergo two alternative ways,
which basically defines the dir ct and the indirect
processing pathways in BG, the latter using the STN as
a relay station. Accordingly, the two major projections
of the STN are the GP and the SNr (Figure 12) (Kita et
al., 1983). An overwhelming majority of STN neurons
send a descending axonal branch to the SN and an
9ascending branch that terminates in both the EP and the
GP (Parent and Hazrati, 1995; Sato et al., 2000).
Figure 12. STN connections. DR, dorsal raphe
nucleus; MPT, dorsal mesopontine tegmentum; PF,
parafascicular thalamic nucleus.
2.2.3. Information processing in BG
2.2.3.1. Parallel vs convergent BG circuitry
The question of whether cortical inputs are processed
in a parallel or a convergent way in the BG is still
debated. Different facts argue for both possibilities. For
example, pallidal neurons have perpendicular dendritic
trees allowing for cortical inputs to converge on several
neurons simultaneously. But the same cortical axons
also make multiple synapses en passant on the same
neuron, thus forcing this neuron to be its preferential
target. This latter observation supports the idea of
preferentially parallel processing.
BG outputs represent a significant condensation of the
information presented to the BG by corticostriatal
afferents. From these outputs a considerable proportion
is directed to subcortical and brain stem targets, but
also back to the cortex as reentrant circuits along basal
ganglia-thalamocortical pathways. The question about
the type of processing remains open for the entrant-
reentrant pathways. One hypothesis proposes the
parallel processing, i.e. the BG-processed information
returns back to the same cortical area where the
corticostriatal afferents originated. This hypothesis is
well supported in regard to "motor" and "oculomotor"
circuits, originating in supplementary motor area and
frontal eye field, respectively (Alexander et al., 1990;
Alexander et al., 1986). The same hypothesis was
postulated for BG-thalamocortical circuit, originating
from the prefrontal cortex (Groenewegen et al., 1993;
Groenewegen et al., 1999). An alternative viewpoint is
that the output of ventral BG-thalamocortical pathways
is directed largely at cortical areas adjacent to those in
which the circuits originate (Brog et al., 1993; Zahm
and Brog, 1992), thus forming the spiral BG-
thalamocortical reentrant circuits. Such a spiral
pathway appears to proceed, for example, from the
piriform cortex and other allocortical areas toward
premotor/supplementary motor areas through the
ventral BG (Brog et al., 1993; Zahm and Brog, 1992).
The different spiral tours, passing through the ventral
BG, form the distinct channels with pronounced
morphological and neurochemical specialization,
particularly in regard to DAergic neurotransmission
(Deutch and Cameron, 1992; Zahm, 1991). This
configuration allows for differential modulation by DA
of cortical impulses conducted through various
channels of the ventral BG. Such differential DA
modulation exists already in the dorsal striatum and is
the basis of direct vs indirect information processing.
2.2.3.2. Direct vs indirect pathway
The output projections of the BG are organized in two
parallel pathways (Figure 13). The dorsal striatum
contains two types of medium spiny neurons, different
in their DA receptor expression and output projections.
D1 containing GABA-ergic neurons, also synthesizing
SP and Dyn, project directly to the internal segment of
the GP (EP in rats) and SNc, thus forming the direct
pathway. D2-expressing GABA-ergic neurons, also
containing Enk, project first to the external segment of
GP and constitute the first part of the indirect pathway.
The axons of the external segment project to the STN
which, in turn, sends its axons to both SNc and SNr as
well as back to the external segment.
SNc, making DAergic projections to both types of
striatal neurons, will however regulate them in opposite
ways; inhibitory through D2 receptors on the indirect
pathway and excitatory through D1 receptors on the
direct pathway (Gerfen et al., 1990). In addition, the
eurons of the direct pathway of the striatum receive
m re pronounced inputs from the thalamus than ones
of the indirect pathway. By counteracting the effects
exerted by DA, the opioids expressed by GABAergic
striatal neurons, serve as negative feedback elements to
prevent the excessive stimulation of striatal neurons in
which they are expressed (Steiner and Gerfen, 1999;
Steiner and Gerfen, 1998). DA neurons are, in turn,
regulated by striatal inputs, originating exclusively in
striosomes and thus carrying information from the
limbic cortex (Gerfen et al., 1985; Jimenez-Castellanos
and Graybiel, 1989).
Similar parallel loops of direct and indirect pathways
cross the ventral striatum and pallidum and include the
prefrontal cortex, a relay in mediodorsal thalamic
nucleus and the DAergic input from the VTA. Even if
the ventral pallidum is not morphologically separated
into the external and internal segments, the two
pathways remain clearly separated.
The clinical importance of such parallel processing of
information is clearly demonstrated in Parkinson's
disease (PD). In PD patients the DAergic pathway
b tween the striatum and SN is degenerated and DA
levels in the striatum are drastically reduced. The
depletion of DA disbalances the direct and indirect
p thways from the striatum, which causes the thalamus
to be overstimulated. As a result, the frontal cortex is
less activated accounting for most of the Parkinsonian
symptoms.
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Figure 13. Major input-output
relationships of the SNc
(DAergic) and SNr (GABA-
ergic) neurons with other
components of the
extrapyramidal motor system,
illustrating the separation of
“direct” and “indirect” pathways
through the BG. Neurons in
black are inhibitory GABA-ergic
neurons, and neurons in white
are excitatory neurons. The SNc
DAergic neurons (in white) are
both excitatory and inhibitory
(on D1- or D2-expressing
medium spiny neurons in the
striatum, respectively). DA,
dopamine; EAA, excitatory
amino acids; GPe, external
segment of the globus pallidus;
GPi, internal segment of the
globus pallidus; PPN,
pedunculopontine tegmental
nucleus; SNC, substantia nigra,
pars compacta; SNR, substantia
nigra, pars reticulata; Sth,
subthalamic nucleus.
2.2.3.3. Reward and motivation and an application to drug addiction
Reward serves as the basis for reinforcement learning.
The psychological concept of positive reinforcement
was formulated by Thorndike (1911) as follows: “Any
act which in a given situation produces satisfaction
becomes associated with that situation so that when the
situation recurs the act is more likely than before to
recur also”. Thus, the neuroanatomical basis of
reinforcement should include two systems: one
executing the motor act, and the second, able to detect
the positive effects produced by this act and
consequently specifically facilitate the occurring of this
act in the same situation in the future. At the cellular
level the reinforcement is explained by the
phenomenon of heterosynaptic plasticity: the synaptic
strength of one pathway (leading to motor activity in
this case) is modified by the activity in another
pathway (reward-detecting) (Wickens and Kötter,
1995). It has been known for a long time that the
corticostriatal inputs constitute the motor pathway
through the BG. Concerning the second pathway,
multiple studies suggest the role of DAergic neurons in
the activation of behavioral reinforcement. The
vidence comes from studies on electrical brain
stimulation, lesions and psychopharmacology. For
example, electrical stimulation of the medial forebrain
bundle, the main pathway by which the DAergic
terminals reach the cortex, is highly reinforcing. The
most effective electrical brain stimulation reward sites
are the ones that directly or indirectly activate the
DA rgic neurons in the midbrain (Wise and Hoffman,
1992). These and other data suggest, but do not prove,
at DAergic neurons projecting to the neostriatum are
a major branch of a “final common pathway” for
positive reinforcement (Wise and Bozarth, 1984). In
this context, positive reinforcers stand for signals that
are able to reinforce the behavior leading to their
appearance.
To play a role in reinforcement, DAergic stimulation
s ould be able to strengthen the corticostriatal
p thway. In fact, it was shown that application of DA
can produce long-lasting facilitation of synaptic
tra smission in non-DAergic pathways. Concerning the
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striatal output, DA increases output from the most
active cells (a small number of neurons), and decreases
output from the less active cells, thus augmenting the
“signal-to-noise” ratio. The increased activity is
probably due to the strengthened excitatory input from
the cortex. Actually, the immediate effect of DA
release is probably a reduction in postsynaptic
excitability, thus permitting only the strongest inputs to
bypass the threshold. In the long term, however, these
focused rare projections will be potentiated (Schultz et
al., 1995). At the behavioral level, the increased
behavioral activity occurs in limited categories of
response.
The accepted function of DAergic neurons as
reinforcers of corticostriatal input does not explain the
precise nature of DAergic activation itself. An early
theory explained the role of the DAergic system as one
that determines the relative pleasure of incoming
stimuli (Wise, 1982). This theory suggests that the DA
system mediates the pleasure produced by natural
reinforcers. Upon addition of DA antagonists, all
pleasures lose the ability to arouse the animal,
therefore the term “anhedonia hypothesis” was given to
this theory, which was later rejected by Wise himself
(Wise, 1994). Another theory suggests the role of the
DA system in attributing the incentive salience to
otherwise neutral rewards (Berridge and Robinson,
1998). This theory makes a distinction between the
phenomena of "liking" and "wanting", and their brain
substrates, in relation to a particular stimulus. The
DAergic system is related to "wanting", whereas the
brain substrate of "liking", i.e. the brain structure that
decides if a particular stimulus is pleasant, is not
known so far. Such a structure, which would be the
origin of the primary reinforcement, could be,
according to different authors, the amygdala, the lateral
hypothalamus (Hoebel et al., 1989; Wise and Bozarth,
1984), the pedunculopontine tegmental nucleus or the
subthalamic nucleus. One example, illustrating such a
distinction between “wanting” and “liking” in relation
to DA, is the opioid action. Both mu and kappa
receptor agonists are addictive; however, the self-
administration of kappa-agonist is rapidly extinguished
when a progressive ratio schedule compared to heroin.
Kappa agonist administration, inversely to heroin,
decreases the DA concentration in the NAcc. This
suggests that changes in accumbal DA do not correlate
with the ability of the stimulus to induce reward or
aversion, but with the drive to reach a positive
reinforcer (Marinelli et al., 1998).
A reward has two functions in the process of
conditioning. First it brings about learning of a new
behavioral response, and second it has the capacity of
maintaining an established behavioral response. The
DA neurons are activated only in response to
unpredicted rewards, i.e. primary reinforcement as well
as secondary reinforcement signals, suggesting their
role in the first function of reward, related to learning.
In contrast, striatal, amygdalar and cortical responses
to reward occur independently on the level of
prediction, suggesting a function in the maintaining of
conditioning. In this case the activation of striatal
n urons will be accomplished probably by the input
from the amygdala (Schultz et al., 1995). The two
theories do not explain the ability of DAergic neurons
t  respond to unpredicted stimuli and then switch to
respond to a conditioned stimulus upon learning. This
particular pattern of activation can be well explained
by adaptive critics-actor model.
The adaptive critic is a device that learns to anticipate
reinforcing events in a way that makes it a useful
coordinator of another component, the actor, that
adjusts behavior in order to maximize the frequency or
magnitude, or both, of reinforcing events (Barto,
1995). In this model the matrix of the striatum would
be the actor, and the striasomes the critics. The first
appearance of the stimulus preceding the reward will
be followed by a slight activation of striosomal
medium spiny neurons (small SPs response peak in
Figure 15). This in turn results in a raise of intracellular
Ca and involvement of CaM followed by CaM-PKII
activation (Figure 14 and Figure 15). This process will
be slow and retarded given the low affinity of CaM for
PKII. The activity of adenylyl cyclase will also be
slightly increased by a calcium-dependent mechanism.
Later on, the reward (primary reinforcement) will be
de ected by the DAergic system, as can be measured by
 increasing concentration of DA in the striatum or
other output structures, and electrophysiological
me surements of phasic discharge of DAergic neurons.
DA will activate the adenylyl cyclase through D1
ec ptors. The maximum activity of adenylyl cyclase is
achieved through activation of both calcium- and D1
receptor-dependent pathways (Ahlijanian and Cooper,
1988). The resulting PKA activation will raise cAMP
concentration which, in turn, increases the amount of
phosphorylated DARPP (Walaas et al., 1983), which is
a potent inhibitor of protein phosphatase 1 (Hemmings
et al., 1984). This results in DARPP-mediated
disinhibition of CaM-PKII autophosphorylation which
prolongs the activated state of the complex by
drastically increasing the affinity of PKII for CaM. The
CaM-PKII complex will then be able to potentiate Glu
receptors, a process leading to LTP (dashed trace
labeled LTP in Figure 15).
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Figure 14. Cellular model of interactions for
learning of earlier predictors of reinforcement.
See description in text. Open arrowheads signify
excitation or activation, black arrowheads signify
inhibition or deactivation, and the triangular
arrowhead signifies a possible potentiation or
depression of receptors. Ca2+, free calcium ions;
(Ca2+)kCaM, calcium-activated calmodulin with k
(up to four) bound calcium ions; CaMmPK IIn,
activated -calmodulin-dependent protein kinase
II with m pockets occupied by activated
calmodulin molecules and n sites
phosphorylated; PO4, phosphate group; cAMP,
the second messenger cyclic adenosine
monophosphate; DARPP-32, DA- and cAMP-
regulated phosphoprotein. (The Figures 14-17
are adapted from (Houk et al., 1995)).
Figure 15 The interplay of intra- and
extracellular events in creating long-term
potentiation of a predictor of reinforcement. See
text for details. Ca, reinforcement-preceding
context (motor act); SPs, spiny neurons in
striosomal compartments of the striatum; LTP,
long-term potentiation. For other abbreviations
see Figure 14.
Given the fact that the DA signal is pulsatile in nature,
the synaptic modification mechanism probably has
strict temporal requirements, which is consistent with
behavioral observations. Moreover, DA release must
occur while the calcium concentration is elevated,
which means shortly after activation of a corticostriatal
synapse, thus also providing the specificity of the
reinforcement signal (Wickens and Kötter, 1995). The
next appearance of a predicting reward stimulus (now a
conditioned stimulus) will highly activate the
striosomal neuron because of its potentiated state
(dashed peak of SPs activation in Figure 15), which
will, in turn, act on the DAergic neuron through both
the direct and the indirect pathways. Given the
particular kinetics of this action, known from
electrophysiological studies (fast activation by indirect
input, slow inhibition by direct pathway), DAergic
neurons will be activated at the time of the conditioned
stimulus and then inhibited during the primary
reinforcer itself (Figure 16 and Figure 17). This
DAergic  signal, “corrected” by adaptive critics
(striosome), will be transmitted to matrix neurons,
reinforcing the corticostriatal inputs active first during
the primary reinforcement, then during the secondary
reinforcement (conditioned stimulus). This will result
in the effective reinforcement produced by the
s imulus.
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Figure 16. Modular organization of the basal ganglia,
including both striosomal (critic) and matrix (actor)
modules. SPs-to-DA represents the direct pathway.
DA-to-SPm signal is the output of striosomal module
and will account for an effective reinforcement
produced by a particular stimulus. The signals in F
neurons function as the ascending outputs of matrix
modules. Open arrowheads signify excitation, black
arrowheads signify inhibition, and triangular
arrowheads signify neuromodulation. C, cerebral
cortical columns; F, columns in frontal cortex; SPs,
spiny neurons in the striosomal compartment of the
striatum; SPm, spiny neurons in the matrix
compartment of the striatum; ST, subthalamic
sideloop; DA, DA neurons of the SN, pars compacta;
PD, pallidal neurons; T, thalamic neurons.
Figure 17. Hypothetical time course of signals
generating DA neuron firing patterns. A pattern of
excitatory signals which predicts reinforcement is
delivered via projections from the cerebral cortical
columns. The sideloop excitatory, direct inhibitory, and
primary reinforcement signals converge on DA
neurons, as shown in Figure 16. The bottom trace
shows the combination of these three signals. The
dashed curve shows the DA signal in presence of
cocaine.
From this model, the appearance of a new predictive
stimulus will further shift all sequence of events,
always correlating the effective reinforcement
(DAergic neuron discharge) to the very first
conditioned stimulus or reinforcement predictor (Houk
et al., 1995).
In view of the distinct functional role of striatal matrix
vs striosomes it is interesting that the level of CREB
phosphorylation is also different in these two
subregions. It is of short duration in the matrix
compartment and it is very persistent in striosomes as
well as in other limbic striatal regions. This persistent
phosphorylation can also support the neuroplasticity
mediated by DA (Liu and Graybiel, 1998).
The adaptive critics-actor model, however, does not
explain the response of DAergic neurons to any novel
stimuli. An alternative theory explains such short-
latency DA response as being associated with the
reallocation of limited behavioral and cognitive
processing capacity towards any unexpected event of
behavioral significance, including reward (Redgrave et
al., 1999). The caveat of this theory is, however, the
absence of proved response of DAergic neurons to
aversive stimuli. Finally, another group proposed the
“spectral timing” model, in contrast to the temporal
difference model, described before. According to this
model, there are two distinct pathways for initial
excitatory reward prediction (ventral striatum and
PPTN) and for timed, inhibitory reward prediction (the
striosomal cells) (Brown et al., 1999).
The adaptive critics-actor theory is particularly
interesting and relevant for the present study because it
allows us to explain the nature of compulsive drug use.
Addictive drugs, for example psychostimulants, will
directly activate the DAergic pathway, bypassing the
routes taken by natural positive reinforcers (Figure 17).
It will, therefore, escape the inhibitory regulation by
"critics" unit, and thus any control of consumption will
be lost. In addition, DA release will be extremely high,
again compared to the natural situation.
In summary, striatum compartmentalization has three
important functional consequences. First, its separation
into striosome and matrix compartments has an
important impact on striatal regulation of reward and
motivation. Second, the two types of projections,
striatonigral and striatopallidal, allow for differential
processing of information in the BG, and for
differential regulation of these two parallel ways by
DAergic system. Finally, its compartmentalization into
dorsal and ventral striatum, as a landmark for its motor
and limbic division, is very relevant in terms of drug
addiction. Drug reinforcing effects, caused by DAergic
stimulation, will be additionally increased by the
implication of limbic, emotional and motivational
centers of the brain.
3. Neurochemistry and genetics of drug addiction
with special attention to  psychostimulants
Drug addiction is usually defined as compulsion to take
a drug with loss of control over apparently voluntary
acts of drug seeking and drug taking. The major task of
the neuroscience of addiction is to understand the
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mechanisms of transition which occurs between
controlled and compulsive drug use. At the behavioral
level the prolonged drug use is characterized by the
phenomena of tolerance or habituation and
sensitization which is described as an increment in
response occurring upon repeated presentation of a
stimulus. At the neuronal level drugs elicit two
different types of responses: neuronal adaptations, i.e.
homeostatic responses to excessive stimulation, and
synaptic plasticity. These processes occur both on the
cellular and system level and are paralleled by
molecular changes residing on modified gene
expression. Therefore, changes in gene expression
correlate with the transition to an addictive state at the
molecular level. Clearly the neuroanatomical substrate
for this transition is the BG circuit supplied by
midbrain DAergic inputs (Figure 18). All abused drugs
ultimately react, directly or indirectly, with the
mesolimbic DAergic pathway.
Figure 18. Major brain structures affected by drugs of
abuse. The mesolimbic DA system originates in the
ventral tegmental area (VTA) of the midbrain, and
projects to the NAcc (NA). The amygdala (A),
hippocampus (HC) and medial prefrontal cortex (PFC)
sends excitatory projections to the NAcc. C, caudate
nucleus (striatum) (adapted from (Robbins and Everitt,
1999)).
3.1. General overview of cocaine addiction
3.1.1. History of cocaine use
Cocaine is isolated from the plant called Erythroxylon
coca (Figure 19). Probably the first users of cocaine
were the native people of South America who used it by
chewing coca leaves. A medical account of the coca
plant was published in 1569. In 1860, Albert Neiman
isolated cocaine from the coca leaf and described the
anesthetic action of the drug when it was put on his
tongue. Angelo Mariani, in the early 1880's produced a
"healing" wine, called Vin Mariani, that contained 11%
alcohol and 6.5 mg of cocaine in every ounce. Sigmund
Freud, in 1884, recommended cocaine for a variety of
illnesses and for alcohol and morphine addictions! Not
surprisingly, many of his patients went on to become
addicted to cocaine. In addition, the cases of fatal
cocaine poisoning and alarming mental disturbances
were reported. In 1886, John Pemberton developed
Coca-Cola, a drink that originally contained cocaine and
caffeine. Cocaine was removed from Coca-Cola in
1906. The Harrison Narcotic Act in 1914 made cocaine
illegal in the US. Finally, in 1985, crack cocaine was
introduced and rapidly became a major drug problem.
Figure 19. Erythroxylon coca plant.
3.1.2. Cocaine effects
Cocaine is a powerful psychostimulant that heightens
alertness, especially to the sensations of sight, sound,
and touch. It inhibits appetite and the need for sleep and
provides intense feelings of pleasure. Paradoxically, it
can make people feel contemplative, anxious, or even
panic-stricken. In general, as for any other drug of
abuse, the effects of cocaine depend on several factors,
including the amount and the route of administration,
the previous drug experience and the circumstances
under which the drug is taken. Physical symptoms
include accelerated heartbeat and breathing, and may
induce convulsions and coma with higher doses .
Compared to amphetamine, cocaine has a very short
duration of action that leads to a typical pattern of
administration: rats or humans given access to adequate
supplies of cocaine often binge, i.e., self-administer
multiple closely spaced doses over long periods of time
(Berke and Hyman, 2000).
With repeated administration over time, euphoria is
gradually replaced by restlessness, extreme excitability,
insomnia, and paranoia. Cocaine users usually do not
develop tolerance to cocaine stimulant effects, but
sometimes they report increased sensitivity to the drug's
convulsant effects. This phenomenon may explain some
deaths that occurred after apparently low doses.
Cocaine, as opposed to opioids and alcohol, does not
cause severe physical dependence. However, it is
perhaps the most powerful drug of all in producing
psychological dependence. The heavy cocaine user
suffers from severe depression upon drug withdrawal,
and the risk of relapse is very high. However,
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substantial variability is found in relation to individual’s
vulnerability to cocaine action, and the majority of
occasional cocaine users do not become addicted
(Addiction Research Foundation, 1995).
3.1.3. Neurochemistry of cocaine action on brain
circuits
Psychostimulants act at axonal terminals of
monoaminergic neurons as indirect monoamine agonists
(Figure 20). Cocaine blocks the reuptake of DA by
DAT, a member of the Na+/Cl--dependent twelve
transmembrane domain transporter family, that also
includes 5-HT and nor-adrenaline (NA) transporters.
Amphetamine releases DA and reverses its transport via
DAT (Hyman, 1996; Koob and Le Moal, 1997). The
blocking of DAT in the striatum was classically
considered the most important feature regarding the
development of addiction. The rate at which DAT is
blocked determines the perception of the “high” by a
human user as determined by PET studies, whereas the
level of blockade determines the intensity of this feeling
(Volkow et al., 1999). It should be mentioned here, that
other drugs of abuse also increase the DA concentration
in NAcc, but by different, less direct routes. They can
facilitate DA release by inhibition of GABAergic
neurotransmission via mu-opioid receptors in the VTA
in case of opioids and ethanol and via delta-opioid
receptors in the NAcc in case of ethanol (Cowen and
Lawrence, 1999).
The major DA receptors of the striatum are D1 and D2
receptors. D2 receptors are tonically stimulated by basal
levels of DA, and this tonic activity is important for
normal motor behavior, whereas D1 receptors are
activated by phasic release of DA and are particularly
relevant in terms of DA involvement in learning and
addiction. However both receptors act synergistically,
and moreover, the final effect of cocaine action depends
on the co-activation of several systems. For example,
the induction of IEG in the striatum requires both
functional D1 and NMDA receptors (Torres and Rivier,
1993) and is blunted by the selective denervation of 5-
HT projections under certain conditions (Bhat and
Baraban, 1993), whereas 5HT-1B receptor knockout
(KO) mice exhibit reduced expression of the IEG in the
striatum (Lucas et al., 1997). Cocaine also acts as a
local anaesthetic causing dose-dependent inhibitions of
most spontaneously active and glutamate-stimulated
neurons. These inhibitions which are not dependent on
DA receptors may involve direct interaction with
sodium channels (Kiyatkin and Rebec, 2000), but the
precise mechanism is unknown.
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Figure 20. The psychostimulants
action on DAergic neuron. In normal
state DAT reuptakes DA from the
synaptic cleft (1). Cocaine blocks
DA reuptake sites (2), whereas
amphetamine displaces DA from
vesicles (3) and reverses the
transport of DA by DAT (4). The net
output in case of both drugs is the
increase of DA concentration in the
synaptic cleft and over-stimulation
of DA receptors (DAR).
3.2. Experimental approaches for drug addiction study and their relative impact on our understanding of drug
action
3.2.1. Classical electrophysiological and
psychopharmacological methods
Several areas of the brain are known to be the targets of
intracranial self-stimulation. One of these regions is the
medial forebrain bundle, a collection of fibers, by which
the DAergic input reaches the forebrain targets (Figure
21). Acute administration of drugs that are abused in
humans increases the reward value of intracranial self-
stimulation, and drug withdrawal decreases this value
(Koob, 1998; Kreek and Koob, 1998; Leshner and
Koob, 1999), suggesting that continuous drug use
produces the state of reward deficit. Many studies have
implicated the NAcc in drug action. Rodents will self-
infuse a variety of drugs of abuse (e.g. amphetamine,
morphine, phencyclidine and cocaine) into the NAcc,
primarily in the shell region (McBride et al., 1999). The
shell of the NAcc is particularly sensitive to D1 receptor
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antagonists (Caine et al., 1995), suggesting a particular
way of cocaine action via the D1 receptors.
Extracellular DA is increased in the NAcc upon lever
pressing for food, upon self-stimulation of the lateral
hypothalamus, and upon injection of amphetamine or
cocaine into the NAcc, as measured by microdialysis
(Hernandez and Hoebel, 1988). Some NAcc neurons
exhibit changes of the firing rate synchronized to the
response-contingent delivery of water or cocaine.
Interestingly, the activity in response to cocaine is
influenced by the stimulus context in which the drug
was delivered (Carelli and Deadwyler, 1997). This
context-dependent drug action depends at least partially
on the stress state of the animal, i.e. on the state of
activation of the hypothalamic-pituitary-adrenal (HPA)
axis and is important not only for the establishment of
drug addiction, but also for the expression of
withdrawal syndromes. Intracerebroventricular
administration of a corticotropin-releasing factor (CRF)
antagonist reverses the anxiogenic-like responses
following withdrawal from chronic cocaine and ethanol
administration (Koob, 1999).
Psychopharmacological studies have pointed out the
role of the VTA in the development of sensitization.
Injection of opioids or psychostimulants directly into
the VTA leads to the development of sensitization
(Kalivas and Stewart, 1991). This mechanism may
involve protein kinase C (Steketee et al., 1998).
Injection of a D1 receptor antagonist into the VTA
blocks the development of neurochemical (DA release)
but not behavioral (motor-stimulant response)
sensitization to cocaine (Steketee, 1998).
Figure 21. Medial Forebrain Bundle
3.2.2. Genetic methods
The development of genetics and of molecular biology
techniques opened a new page in the study of drug
addiction. One direction of research aims at finding the
genetic factors responsible for the development of drug
abuse. A second line of experiments studies gene
expression in different animal models of drug intake in
order to dissect the role of different gene products in the
development of the distinct temporal and functional
phases of drug addiction. The conclusions drawn from
both types of studies are then tested in transgenic animal
models, including KO mice.
3.2.2.1. Classical genetic studies
It was clear for a long time that a genetic component is
implicated in drug addiction. Family, as well as twins or
adoption studies provided a lot of information clarifying
the relative impact of genetic and environmental factors
on drug abuse. However, human studies have obvious
limitations. Both ethical considerations and the unique
and highly complicated genetic background of every
single person make the search for genetic factors
extremely difficult. The first animal tools for dissecting
the particular genes and their chromosomal locations
important for drug action, appeared with the
development of inbred mouse strains. Inbred strains are
populations of animals produced by more than 20
generations of crossings within closely related animals,
usually sisters and brothers (Crabbe and Belknap,
1980). It is postulated that these animals are
homozygous at all gene loci. About 20 inbred strains of
mice exist, and many of them show clearly distinct
behavior in respect to various addictive drugs. The
inbred strains are useful for studying the effects of a
particular mutation on a specific trait, as well as for
correlation studies allowing the mapping of different
traits to a common genetic determinant. Inbred strains
maintain a stable genetic background during many
years, allowing for high reproducibility and contingency
in genetic studies.
One important application of inbred strain technology
has been the development of recombinant inbred strains.
In this technique different inbred strains are crossed,
and then various F2 generations are mated together to
result in an entire panel of new inbred strains, each with
different combination of parental genes. Then a
particular trait, e.g. reinforcing effects of cocaine, is
studied across these strains, followed by the localization
of this trait to a chromosomal locus (quantitative trait
locus) by means of traditional linkage analysis. Current
methods allow the determination of a narrow
chromosomal region. Subsequent database searches
result in the identification of candidate genes within that
subregion. The final phase of this positional cloning
approach will be the testing of candidate genes in
transgenic models. Searching for quantitative trait loci
linked to cocaine addiction resulted in at least three
putative loci, one of these containing the gene for the 5-
HT1B receptor (Crabbe et al., 1999).
3.2.2.2. Studies of gene expression
Studies of gene expression can be divided into two
groups:
1) “target-directed” studies by immunohistochemical
or RNA-based methods, such as Northern blot, in
situ hybridization etc., which require previous
identification of a gene product of interest;
2) random searching for new genes important for a
particular function. In this case the control and
experimental situations are compared (e.g. drug
treatment), and high throughput screening for
differentially expressed genes is performed.
Methods used include subtractive hybridization,
differential display, microarrays or DNA chips.
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The differential screening of cDNA libraries was a fuse
in a subsequent burst of methods allowing for
identifying differentially expressed genes (Rebagliati et
al., 1985; St John and Davis, 1979). In this technique,
two cDNA libraries, isolated from cells to be compared
(control and experiment), were immobilized on solid
support and hybridized with radioactively labeled
cDNA probe, representative of total mRNA population
of the cells of interest. The method was very time-
consuming and required a large amount of starting
material. It was substantially improved by the
introduction of subtractive cDNA libraries, where only
presumably differentially expressed sequences are
present. This method was especially useful when the
differentially expressed RNAs are of low to moderate
abundance in the cells in which they occur (Sargent and
Dawid, 1983). A great variety of protocols of
subtractive hybridization was developed and
successfully applied. However, the obvious
disadvantage of this technique lies in the fact that it is
impossible to compare more than two mRNA samples at
once.
Later on, two PCR-based methods for screening of
differential expression were developed. In the first
method, arbitrarily primed PCR fingerprinting of RNA,
the arbitrarily selected primer was used at low
stringency for first and second strand cDNA synthesis,
followed by PCR amplification of reaction products
(Welsh et al., 1992). The second method, discussed later
in more details was differential display (Liang and
Pardee, 1992). PCR-based methods have several
technical advantages, compared with hybridization-
based ones. They are much quicker, allow for
simultaneous detection of several groups of
differentially, both up- and downregulated genes, only
small amount of mRNA (less than 5 µg) is required, and
sensitivity is very high. They are also simple and easy in
use.
Finally, a third group of methods was developed, based
on comparison of restriction pattern between the
samples, such as serial analysis of gene expression
(Velculescu et al., 1995), restriction landmark cDNA
scanning (Suzuki et al., 1996) or restriction
endonuclease-based gene expression fingerprinting
(Ivanova and Belyavsky, 1995). However, the relevance
of these intellectual efforts in large part loose their merit
with the appearance of cDNA microarrays and similar
high throughput techniques, which will replace
completely other methods of differential gene
expression screening. This technology however is
introduced slowly in neuroscience research, given the
fact that the availability of arrays, representative of the
full palette of genes important for brain function,
especially for rat brain, is still low.
In this work, the method of differential display was
modified and used, therefore this procedure will be
described in details. The first step of the differential
display protocol is a reverse transcription with primers
consisting of a poly(T) stretch and one or two more
additional 3’ bases, which anchor the primers to the
poly(A) tail of mRNAs. The second step is a low
stringency PCR reaction with the same primer and also
with another short arbitrary primer which will anneal at
diff rent positions relative to the first primer. These
annealing positions are randomly distributed in distance
from the poly(A) tail. Therefore, the amplified products
from various mRNAs differ in size. These PCR
p o ucts are labeled with radioactive deoxyadenosine
triphosphate, and can then be displayed on an
acrylamide gel. The majority of expressed mRNAs will
be represented if twelve possible 3’ primers and twenty
5’ primers are used in all combinations for independent
amplifications and displays. A band of interest, such as
on  produced by one kind of cell versus another, can be
excised from the gel, its cDNA reamplified by PCR,
clon d and then sequenced. Its sequence can then be
compared with data banks and used to isolate longer
sequences from DNA libraries, and ultimately studied
for function. The method is very powerful, but it has
s me problems, including the number of false positives
generated during 40 rounds of low stringency PCR, the
need for cloning in order to analyse the differentially
expressed signal and sequence heterogeneity of the
bands excised from acrylamide gel. Therefore in the last
years many authors undertook attempts to improve and
facilitate the use of the method. Some of them
concerned the design of primers for PCR. These
included the addition of restriction sites to 5’ends of the
primers (Zhao et al., 1995), the design of gene family
specific primers ("targeted differential display")
(Donohue et al., 1995; Joshi et al., 1996) and the use of
non-radioactively labeled primers (Chen and Peck,
1996). Other modifications concerned new strategies for
the identification of true positive candidates, such as
restriction-enzyme fingerprinting approach (Shoham et
al., 1996), plasmid dot-blotting to screen cloned cDNA
fragments with cDNA PCR products as probes (Callard
et al., 1994), partial sequencing of cDNA inserts (Zhao
et al., 1996), single-strand conformation polymorphism
of cDNA inserts (Mathieu-Daude et al., 1996; Zhao et
al., 1996) and screening of multiple clones from
diff rential display by the technique of mRNA
hybridization using a slot blot (Liu and Raghothama,
1996). These modifications substantially facilitated the
use of the method. Differential display studies already
contributed to the progress of different areas of
euroscience's. For example, it provided some cues on
genes important for sleep-waking cycle (Cirelli and
Tononi, 1999), psychiatric illness related to cognition,
emory and mood (Flanigan and Leslie, 1997),
uditory plasticity (Lomax et al., 2000), long-term
potentiation (Matsuo et al., 1998; Matsuo et al., 2000)
and it will certainly gain more place in brain research in
the next years.
Ge es, whose expression has been found to be regulated
by cocaine, are summarized in Table 1 and some
examples are described below. Some of the changes
wer  found at the protein level (immunohistochemistry,
Western blot etc.) which very often correspond to
tran criptional regulation of a particular gene, but may
also reflect posttranscriptional, or even posttranslational
modifications (for example, the increase in TH
immunoreactivity upon chronic cocaine treatment, see
T ble 1 for details). Changes, occurring both at the
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mRNA and at the protein level, are often detected in
different cellular compartments, the mature protein
being transported away from the cell body. The protein-
containing compartment can be localized in very
different brain regions, at a long distance from the initial
site of mRNA synthesis.
3.2.2.2.1 Acute studies
A suitable marker of neuronal activity is the expression
of IEG, the first ones to be activated after a particular
treatment. Important IEG for brain function belong to
zinc finger (zif268, alternative names NGFI-A or egr1)
and to leucine zipper (fos/jun) transcription factor
families. Their expression following drug application
was extensively studied, in particular c-fos activation
upon increase in cAMP concentration brought about by
the binding at several neurotransmitter receptors.
Acute cocaine or amphetamine treatment results in an
increase in mRNA concentrations of c-fos and other
transcription factors, as well as Fos-like
immunoreactivity in the dorsal striatum and NAcc
(Graybiel et al., 1990; Hope et al., 1992). Fos
expression is immunocytochemically detectable after
1h, reaches its maximum after 2h, and is absent 48h
after treatment, thus showing a typical pattern of IEG
expression. c-fos induction in the striatum has different
patterns of expression in striosome-matrix
compartments and limbic subdivisions of the striatum
(Graybiel et al., 1990). These differences are drug-
specific. Cocaine induces IEG expression in cells
dis ributed broadly through the striatum, whereas
amphetamine-specific expression is highest in rostral
striosomes (Graybiel et al., 1990; Moratalla et al., 1996;
Moratalla et al., 1992). Interestingly, the same pattern of
induction was shown for another IEG, arc (activity-
regulated, cytoskeletal-associated gene), the
particularity of which is its expression in dendrites (Tan
et al., 2000). This drug-specific pattern may account for
different behavioral effects of the two drugs (Canales
and Graybiel, 2000). Cocaine-related c-fos induction is
limited to striatal neurons expressing SP (Kosofsky et
al., 1995) and the protein phosphatase inhibitor
DARPP-32, but not Enk (Berretta et al., 1992).
Concerning accumbal subdivisions, Fos-like
immunoreactivity upon acute cocaine is higher in the
shell than in the dorsolateral striatum, and lowest in the
core (Barrot et al., 1999). The effect is mediated by D1
receptor (Young et al., 1991), at least in part by NMDA-
sensitive receptors (Torres and Rivier, 1993) and by
5HT-3 receptor (Humblot et al., 1998). The intracellular
cascade leading to c-fos activation is shown in Figure
22.
Figure 22. Neural systems of addiction. A DA-releasing neuron from the ventral tegmental area (VTA) is shown
innervating a dendritic spine of a medium spiny neuron in the nucleus accumbens (NA). The DA transporter (DAT) is
the main site for cocaine action, which inhibits the re-uptake of DA by the VTA neuron, where it is initially produced.
DA acts at two types of DA receptors (D1 and D2), coupled to guanine-nucleotide-binding proteins (Gs and Gi
respectively), which modulate adenylyl cyclase (AC) and cAMP-dependent protein kinase (PKA). Possible substrates
for PKA include ion channels and the nuclear transcription factors CREB, Fos and Jun. Neurons in the NA in turn
receive glutamatergic inputs from the amygdala (A), the hippocampus (HC) or the prefrontal complex (PFC). EAAR,
excitatory amino-acid receptor; Glu, glutamate (adapted from (Robbins and Everitt, 1999)).
The expression of c-fos is not limited to BG, it has also
been found in many limbic areas, including the
cingulate cortex, the claustrum, the piriform cortex, the
lateral septal nucleus, the paraventricular nucleus of the
thalamus, the lateral habenula, and the amygdala
(Brown et al., 1992). In the thalamic paraventricular
nucleus the effect was mediated by the D3 DA receptor
(Deutch et al., 1998). The composition of the AP-1
complex and requirements for its activation may be
different in different regions, e.g. acute cocaine induces
both c-fos and jun-B mRNA expression in the striatum,
but only c-fos in the cerebellum (Couceyro et al., 1994).
Studi s of c-fos expression allowed dissecting out of
many effects of cocaine, with an aim to understand the
rel tive involvement of different brain regions and the
imp tance of particular neurotransmitter systems.
Studies of peptidergic identity of cocaine-responsive
neurons allowed for a model of DA-opioid peptide
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interaction. However, little is known about genes,
whose expression is regulated by c-fos, and their
relative impact in drug action. The development of c-fos
KO animals gave first insights in this subject.
Studies showed that zif268 expression often paralleled
that of c-fos. Both acute cocaine and amphetamine led
to zif268 induction in the striatum, both dorsal and
ventral (Bhat et al., 1992; Moratalla et al., 1992). Again,
the pattern of expression was different for striosomal
and matrix compartments in rostral striatum. The effect
is mediated by D1 receptor and by the 5-HT system
(Bhat and Baraban, 1993).
Although the expression of both c-fos and zif268A is
mediated by D1 DA receptor, the concomitant
activation of D1 and D2 receptors acts to intensify their
expression. High-affinity neurotensin receptors are
likely to be involved in this D1-like/D2-like cooperative
action. Pretreatment with neurotensin receptor
antagonists prevented the IEG expression induced by
both acute cocaine and D1/D2 receptors agonists
treatment in cells expressing Enk mRNA (Alonso et al.,
1999).
Data about acute c-jun expression are more
controversial. Some studies show its induction in the
NAcc (Hope et al., 1992), but other researchers could
not confirm this in the striatum (Moratalla et al., 1993).
The controversy is probably due to the variations of
expression in different striatal subregions.
c-fos expression is NMDA-receptor sensitive. This
finding led to extensive studies of changes in expression
of Glu receptors subunits upon cocaine treatment.
Various subunits were expressed in differential fashion
upon acute cocaine (Table 1 (Ghasemzadeh et al.,
1999). These changes could be important in terms of
cocaine action on a network level because they may
alter excitatory neurotransmission in the
mesocorticolimbic DA system, which could play a
significant role in the enduring biochemical and
behavioral effects of cocaine. This hypothesis is
strengthened by the fact that chronic cocaine also alters
the relative expression of different Glu receptor
subtypes (see Table 1).
Cocaine-induced IEG expression is different in three
mice strains (Table 1) (Kuzmin and Johansson, 2000),
yielding to robust, slight, or even complete absence of
expression. These differences in gene expression pattern
parallel the different cocaine reinforcing properties for
the three strains and show the importance of consistency
in drug studies if one aims at finding cause-effect
relationships in drug addiction, and especially the
importance of choosing the right strain for transgenic
studies.
Many genes are regulated by psychostimulants, but only
a small portion have been studied in terms of the
functional significance of such changes, and
consequently, of the role of a particular protein in drug
addiction. For example, acute cocaine or amphetamine
leads to rGb1 (rat G-protein b-subunit) up-regulation in
the striatum and the prefrontal cortex, in particular in
the shell of the NAcc (Wang et al., 1997) as identified
by subtracted differential display. The dose-response
curve for amphetamine in the striatum showed the
persistence of expression from 2 to 48 hrs. Antisense
oligonucleotide treatments that attenuate rGb1
exp ession in regions including the NAcc abolish the
establishment of behavioral sensitization. These
treatments do not alter acute behavioral responses to
cocaine, confirming the specific function of this protein
for sensitization phenomenon.
Another protein important for the development of
sensitization is neurotrophin-3 (NT-3). Acute cocaine
causes a transient increase of NT-3 mRNA in the VTA,
wh reas intra-VTA microinjections of NT-3 leads to a
ensitized behavioral response to a subsequent cocaine
challenge (Pierce et al., 1999). The effects of NT-3 on
the initiation of behavioral sensitization are mediated by
activation of the Ras/MAP kinase signal transduction
system.
Another example of a regulated protein found by
d ff rential display is CART (cocaine- and
amphetamine- regulated transcript). Acute cocaine or
amphetamine treatment increases CART expression in
the striatum in a region-specific manner (Douglass et
al., 1995). Subsequent studies showed that CART plays
a major role in the regulation of feeding behavior,
wh reas the function of CART in relation to drug
addiction is still unknown (Kuhar and Dall Vechia,
1999; Thim et al., 1998). The studies of cocaine-
induced CART expression, however, underlined the
importance of the experimental protocol used in drug
addiction studies, because other investigators could not
reproduce the up-regulation of CART in the striatum
(Fagergren and Hurd, 1999). The failure to reproduce
these findings probably comes from the slightly
different protocol used by subsequent authors (see Table
1). In general this problem of the protocol is not very
pronounced in the case of acute studies, the majority of
protocols consisting of a single injection with an
established dose of psychostimulant followed by 1 or 2
h before brain extraction. However, the protocol
problem is much more pronounced and critical in
chronic and sensitization studies.
Studies of gene expression also showed the interference
of cocaine with hormonal function. The majority of
studies concerned stress-related hormones. Drugs of
addiction and stress are mutually-interfering factors.
The stressors facilitate the acquisition of drug self-
administration, probably by increasing the reinforcing
efficacy of drugs of abuse (Piazza and Le Moal, 1998).
Drugs, in turn, modulate the release of stress hormones.
Cocaine, for example, alters hypothalamic and
extrahypothalamic/limbic CRF concentrations (Sarnyai,
1998). Acute cocaine treatment increases CRF
tra scription in the paraventricular hypothalamic
nucleus (Zhou et al., 1996). Similar reciprocal
interaction exists between cocaine and oxytocin /
vasopressin (VP) systems. For instance, oxytocin
facilitates, whereas VP inhibits the development of
behavioral sensitization to cocaine, while cocaine in
turn induces dose- and region-specific changes in
oxytocin and VP contents in the hypothalamus and
limbic structures (Sarnyai, 1998).
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3.2.2.2.2 Chronic and self-administration studies
c-fos induction by cocaine is highest in the dorsal
striatum, a region with lowest basal level of Dyn
expression. On subsequent treatment days the induction
of c-fos goes down, whereas Dyn expression in this
region gradually increases. Thus, both the regional and
temporal patterns of gene expression display an inverse
relationship between Dyn and c-fos expression. This
observation led to the hypothesis that Dyn may “blunt”
the cocaine induction of c-fos and that its expression in
BG serves to prevent the neurons of the direct striatal
pathway from excessive D1 stimulation. This
hypothesis is strengthened by the finding that c-fos
expression can be inhibited by an agonist of kappa-
receptor, on which dynorphin normally acts. The
activation of the Dyn system could also contribute to the
dysphoric syndrome associated with cocaine
dependence (Koob, 1996). The expression of both c-fos
and dynorphin may be regulated by CREB
phosphorylation upon the activation of D1 receptor
(Figure 22). CREB interacts with functional regulatory
elements in both the c-fos and prodynorphin genes, and
is phosphorylated in response to DA in a D1-dependent
manner (Hyman et al., 1995). The drug-induced
expression of Dyn is also specific for striosomes-matrix
compartments of the striatum. Following chronic
apomorphine treatment Dyn expression is increased
preferentially in striosomal neurons (Gerfen et al.,
1991). As opposed to Dyn, changes in SP parallel the
changes in c-fos activation (Gerfen et al., 1998; Steiner
and Gerfen, 1993) and are not specific for any
compartment.
Following chronic apomorphine treatment Enk
expression remains unchanged (Gerfen et al., 1991),
however cocaine self-administration causes a slight
increase in Enk expression in the NAcc (Hurd et al.,
1992).
Chronic cocaine administration leads to the
desensitization of both c-fos and zif268 induction in the
forebrain, caudate putamen, and NAcc (reviewed in
(Torres and Horowitz, 1999)). Interestingly, after the
return of mRNA and protein concentrations to basal
levels, an increase in AP-1 binding activity is observed
which persists upon chronic cocaine treatment (Hope et
al., 1992). The increase in AP-1 binding in the NAcc
and striatum develops gradually over several days and
remains at 50% of its maximal levels seven days after
the last cocaine exposure. The AP-1 complex contains
at least four “chronic” Fos-related antigens (FRAs),
some of which display delta FosB-like
immunoreactivity (Hope et al., 1994; Mumberg et al.,
1991). They are different from delta FosB, because they
respond to chronic cocaine, and heterodimerize
primarily with Jun-D and Jun-B, as opposed to c-Jun.
Some other chronic treatments may also induce chronic
Fras (Chen et al., 1995), which may therefore serve as a
marker for long-lasting synaptic activity, like c-fos for
acute neuron activation. Upon cocaine, chronic FRAs
are expressed preferentially in Dyn-expressing
projection neurons (Moratalla et al., 1996). Altogether,
FosB, along with c-fos, fra-1 and fra-2, comprise the fos
family of transcription factor proteins. FRAs are
differentially regulated by DA receptors and include
two types of proteins: those independent of D1 receptor
activation and those dependent on D1 receptors for
expression following drug challenge (Moratalla et al.,
1996). Studies in organotypic slice cultures of newborn
rat striatum have shown the induction of Fos-like and
Fra-like proteins upon D1 receptor stimulation. Fos-like
proteins were induced mainly in striosomes, and Fra-
like proteins in striatal matrix as well (Liu et al., 1995).
In summary, chronic cocaine exposure leads to time-
varying alterations in the inducibility of leucine-zipper
transcription factors in individual neurons and long-
lasting network changes in which groups of striatal
neurons express these proteins, suggesting that the
behavioral sensitization may reflect an enduring
functional reorganization of BG circuits (Moratalla et
al., 1996). It is not known if other IEG, such as zif268,
have several stable isoforms, similar to FRAs, or
whether their expression is definitively shut down upon
repeated exposure to a drug.
A small number of genes, regulated by cocaine, have
been studied in terms of their role in drug addiction
development, for example NAC-1, a transcription factor
named because of its selective up-regulation in the
NAcc three weeks after cocaine self-administration
(Cha et al., 1997). Further studies have shown that
NAC-1 induction may down-regulate postsynaptic DA
transmission, thus minimizing the behavioral impact of
cocaine administration (Kalivas et al., 1999). In
addition, adenoviral-mediated overexpression of NAC-1
in the rat NAcc prevented the development but not the
expression of behavioral sensitization to cocaine
(Mackler et al., 2000).
Table 1 summarizes other changes in gene expression
upon chronic cocaine under various protocols. In the
absence of a standard protocol, it is difficult to obtain
reproducible and reliable results, as shown in studies of
TH and DAT changes upon chronic cocaine. Different
groups undertook such an investigation, given the role
of both proteins in DA turnover, with diverse results
(Table 1). Besides the protocol of drug administration
itself, other factors need to be carefully evaluated, such
as animal strain, age, sex, etc. For example, Kuzmin and
coll. investigated self-administering cocaine mice and
used not saline-receiving animals, as usual, but yoked
controls, receiving cocaine passively, as controls for the
neurochemical effect of non-contingent cocaine
infusion. This showed differences in the expression of
several genes between cocaine- and saline-treated
animals, as well as between mice receiving contingent
and non-contingent regimens of cocaine treatment
(Table 1). This and other studies show the urgent need
for the elaboration of more standard and precisely
defined protocols of drug treatment in order to obtain
consistent and comparable data. However it is doubtful
to expect such a standardization in the nearest future.
The temporary solution is to use the same protocol in
frame of one or several groups (for example, acute
“binge” protocol in Table 1) throughout the years.
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e
 e
x
p
re
ss
io
n
 o
f 
a
 b
ra
in
 p
la
st
ic
it
y
-r
e
la
te
d
m
o
le
cu
le
, 
ti
ss
u
e
 p
la
sm
in
o
g
e
n
 a
ct
iv
a
to
r 
(t
P
A
) 
m
R
N
A
 w
it
h
 i
ts
 p
e
a
k 
a
t 
3
 h
 p
o
st
in
je
ct
io
n
in
 a
 g
ro
u
p
 o
f 
n
e
u
ro
n
s 
o
f 
th
e
 m
e
d
ia
l 
a
n
d
 i
n
su
la
r 
p
re
fr
o
n
ta
l 
co
rt
ic
e
s 
th
a
t 
p
ro
je
ct
 t
o
 t
h
e
m
e
d
ia
l 
st
ri
a
tu
m
, 
a
n
d
 t
h
e
 p
ir
if
o
rm
 c
o
rt
e
x
(H
a
sh
im
o
to
 e
t 
a
l.
, 
1
9
9
8
);
 t
h
e
 i
n
d
u
ct
io
n
 o
f 
tP
A
 m
R
N
A
co
u
ld
 b
e
 i
m
p
lic
a
te
d
 i
n
 a
n
 i
n
it
ia
l 
st
e
p
 i
n
 t
h
e
 p
la
st
ic
re
a
rr
a
n
g
e
m
e
n
ts
 i
n
 t
h
e
 n
e
u
ro
n
a
l 
ci
rc
u
it
s 
u
n
d
e
rl
y
in
g
 l
o
n
g
-
la
st
in
g
 c
h
a
n
g
e
s 
in
 b
e
h
a
v
io
ra
l 
e
x
p
re
ss
io
n
A
cu
te
 "
b
in
g
e
"
3
 c
o
n
se
cu
ti
v
e
 d
o
se
s 
o
f 
1
5
m
g
/k
g
 i
.p
.,
 a
t 
h
o
u
rl
y
 i
n
te
rv
a
ls
fo
r 
3
 d
a
y
s
In
cr
e
a
se
 i
n
 C
R
F 
m
R
N
A
 l
e
v
e
ls
 i
n
 t
h
e
 h
y
p
o
th
a
la
m
u
s 
a
n
d
 a
m
y
g
d
a
la
 o
n
 d
a
y
 1
, 
re
tu
rn
 t
o
b
a
se
-l
in
e
 l
e
v
e
ls
 o
n
 d
a
y
 2
, 
d
e
cr
e
a
se
 o
n
 d
a
y
 1
4
 b
u
t 
o
n
ly
 i
n
 h
y
p
o
th
a
la
m
u
s,
 r
e
tu
rn
 t
o
 b
a
se
-
lin
e
 l
e
v
e
l 
a
ft
e
r 
1
0
 d
a
y
s 
o
f 
w
it
h
d
ra
w
a
l
In
cr
e
a
se
 i
n
 p
re
p
ro
e
n
ke
p
h
a
lin
, 
p
re
p
ro
d
y
n
o
rp
h
in
 m
R
N
A
s 
in
 c
a
u
d
a
te
-p
u
ta
m
e
n
In
cr
e
a
se
 i
n
 p
re
p
ro
d
y
n
o
rp
h
in
 m
R
N
A
 i
n
 t
h
e
 c
a
u
d
a
te
-p
u
ta
m
e
n
, 
d
e
cr
e
a
se
 i
n
 k
a
p
p
a
-o
p
io
id
re
ce
p
to
r 
m
R
N
A
 i
n
 t
h
e
 S
N
 b
u
t 
n
o
t 
in
 c
a
u
d
a
te
-p
u
ta
m
e
n
N
o
 c
h
a
n
g
e
 i
n
 D
A
T
 m
R
N
A
 i
n
 S
N
 o
r 
V
T
A
In
cr
e
a
se
 i
n
 m
u
-o
p
io
id
 r
e
ce
p
to
r 
m
R
N
A
 i
n
 f
ro
n
ta
l 
co
rt
e
x
, 
N
A
cc
, 
a
n
d
 a
m
y
g
d
a
la
, 
b
u
t 
n
o
t
in
 t
h
e
 c
a
u
d
a
te
-p
u
ta
m
e
n
, 
th
a
la
m
u
s,
 h
ip
p
o
ca
m
p
u
s,
 a
n
d
 h
y
p
o
th
a
la
m
u
s 
(3
0
 m
in
 a
ft
e
r 
th
e
la
st
 i
n
je
ct
io
n
 o
f 
si
n
g
le
 d
a
y
 o
f 
tr
e
a
tm
e
n
t)
(Z
h
o
u
 e
t 
a
l.
, 
1
9
9
6
)
(S
p
a
n
g
le
r 
e
t 
a
l.
, 
1
9
9
6
)
(S
p
a
n
g
le
r 
e
t 
a
l.
, 
1
9
9
6
)
(M
a
g
g
o
s 
e
t 
a
l.
, 
1
9
9
7
)
(Y
u
fe
ro
v
 e
t 
a
l.
, 
1
9
9
9
);
 D
1
-r
e
ce
p
to
r 
d
e
p
e
n
d
e
n
t 
m
e
ch
a
n
is
m
3
 c
o
n
se
cu
ti
v
e
 d
o
se
s 
o
f 
1
5
m
g
/k
g
 i
.p
.,
 a
t 
h
o
u
rl
y
 i
n
te
rv
a
ls
fo
r 
2
 d
a
y
s
K
a
p
p
a
-o
p
io
id
 r
e
ce
p
to
r 
m
R
N
A
 d
o
w
n
-r
e
g
u
la
te
d
 i
n
 V
T
A
 a
n
d
 N
A
cc
 (
3
0
 m
in
 a
ft
e
r 
th
e
fi
n
a
l 
in
je
ct
io
n
)
(R
o
si
n
 e
t 
a
l.
, 
1
9
9
9
);
 I
n
 t
h
e
 V
T
A
, 
m
o
re
 p
ro
n
o
u
n
ce
d
d
e
cr
e
a
se
 i
n
 c
o
m
b
in
a
ti
o
n
 w
it
h
 e
th
a
n
o
l,
 i
n
 t
h
e
 N
A
cc
 w
it
h
o
n
ly
 c
o
ca
in
e
C
h
ro
n
ic
S
u
p
p
re
ss
io
n
 o
f 
Fo
s-
lik
e
 i
m
m
u
n
o
re
a
ct
iv
it
y
 a
cc
o
m
p
a
n
ie
d
 b
y
 l
o
n
g
-l
a
st
in
g
 i
n
cr
e
a
se
 i
n
 A
P
-
1
 b
in
d
in
g
 i
n
 N
A
cc
 a
n
d
 s
tr
ia
tu
m
. 
T
h
is
 A
P
-1
 c
o
m
p
le
x
 c
o
n
ta
in
s 
a
t 
le
a
st
 f
o
u
r 
FR
A
s,
 s
o
m
e
o
f 
w
h
ic
h
 d
is
p
la
y
 d
e
lt
a
 F
o
sB
-l
ik
e
 i
m
m
u
n
o
re
a
ct
iv
it
y
(H
o
p
e
 e
t 
a
l.
, 
1
9
9
4
)
T
w
ic
e
 d
a
ily
 w
it
h
 1
5
 m
g
/k
g
 f
o
r
a
 t
o
ta
l 
o
f 
1
0
 i
n
je
ct
io
n
s
W
id
e
sp
re
a
d
 s
u
p
p
re
ss
io
n
 o
f 
b
a
sa
l 
zi
f2
6
8
 m
R
N
A
 l
e
v
e
ls
 i
n
 r
a
t 
fo
re
b
ra
in
 b
e
tw
e
e
n
 8
 a
n
d
 2
4
h
r 
a
ft
e
r 
th
e
 l
a
st
 c
o
ca
in
e
 i
n
je
ct
io
n
(B
h
a
t 
e
t 
a
l.
, 
1
9
9
2
)
E
v
e
ry
 8
 m
in
 f
o
r 
6
 h
 p
e
r 
d
a
y
w
it
h
 0
.3
3
 m
g
/i
n
fu
si
o
n
 i
.v
. 
fo
r
7
 d
a
y
s 
(s
im
ila
r 
to
 s
e
lf
-
a
d
m
in
is
tr
a
ti
o
n
 p
a
tt
e
rn
)
In
cr
e
a
se
 i
n
 T
H
 m
R
N
A
 (
4
5
 a
n
d
 5
0
%
 i
n
 S
N
 a
n
d
 V
T
A
 r
e
sp
e
ct
iv
e
ly
)
(V
ra
n
a
 e
t 
a
l.
, 
1
9
9
3
)
In
cr
e
a
se
d
 T
H
 i
m
m
u
n
o
re
a
ct
iv
it
y
 b
y
 3
0
-4
0
%
 i
n
 V
T
A
 o
n
ly
(B
e
it
n
e
r-
Jo
h
n
so
n
 a
n
d
 N
e
st
le
r,
 1
9
9
1
)
T
w
o
 d
o
se
s 
(1
5
 o
r 
3
0
 m
g
/k
g
i.
p
.)
 f
o
r 
6
 d
a
y
s 
to
 p
ro
d
u
ce
b
e
h
a
v
io
ra
l 
se
n
si
ti
za
ti
o
n
 t
o
 a
ch
a
lle
n
g
e
 e
it
h
e
r 
2
4
 h
r 
(e
a
rl
y
w
it
h
d
ra
w
a
l)
 o
r 
3
 w
e
e
ks
 (
la
te
w
it
h
d
ra
w
a
l)
 l
a
te
r
A
t 
e
a
rl
y
 w
it
h
d
ra
w
a
l,
 a
ft
e
r 
b
o
th
 d
o
se
s,
 T
H
 i
m
m
u
n
o
re
a
ct
iv
it
y
 i
n
 t
h
e
 V
T
A
 i
n
cr
e
a
se
d
 t
o
1
2
5
%
 o
f 
sa
lin
e
 c
o
n
tr
o
ls
 b
y
 2
4
 h
r 
a
ft
e
r 
th
e
 c
o
ca
in
e
 c
h
a
lle
n
g
e
, 
w
it
h
 n
o
 c
h
a
n
g
e
s 
in
 T
H
m
R
N
A
 l
e
v
e
ls
. 
A
t 
th
e
 l
a
te
 w
it
h
d
ra
w
a
l,
 T
H
 i
m
m
u
n
o
re
a
ct
iv
it
y
 o
r 
m
R
N
A
 i
n
 t
h
e
 V
T
A
 w
e
re
n
o
t 
a
lt
e
re
d
 2
4
 h
r 
a
ft
e
r 
a
 s
a
lin
e
 o
r 
co
ca
in
e
 c
h
a
lle
n
g
e
(S
o
rg
 e
t 
a
l.
, 
1
9
9
3
);
 t
h
e
 t
im
e
 c
o
u
rs
e
 o
f 
T
H
 e
x
p
re
ss
io
n
 i
n
 t
h
e
V
T
A
 p
a
ra
lle
ls
 p
re
v
io
u
sl
y
 r
e
p
o
rt
e
d
 c
h
a
n
g
e
s 
in
so
m
a
to
d
e
n
d
ri
ti
c 
D
A
 r
e
le
a
se
 a
n
d
 a
u
to
re
ce
p
to
r
d
e
se
n
si
ti
za
ti
o
n
T
w
ic
e
 d
a
ily
 w
it
h
 1
5
 m
g
/k
g
 f
o
r
6
,5
 d
a
y
s
G
re
a
te
r 
th
a
n
 4
0
%
 d
e
cr
e
a
se
 i
n
 n
ig
ra
l 
D
A
T
 m
R
N
A
(X
ia
 e
t 
a
l.
, 
1
9
9
2
);
 n
o
t 
4
 h
rs
 a
ft
e
r 
a
cu
te
 i
n
je
ct
io
n
, 
n
o
r 
a
ft
e
r
re
p
e
a
te
d
 t
re
a
tm
e
n
t 
fo
llo
w
e
d
 b
y
 a
 7
2
-h
 w
it
h
d
ra
w
a
l 
p
e
ri
o
d
2
3
O
n
ce
 d
a
ily
 w
it
h
 1
0
, 
1
5
 o
r 
2
5
m
g
/k
g
 i
.p
. 
fo
r 
8
 d
a
y
s 
o
r 
tw
ic
e
d
a
ily
 w
it
h
 2
5
 m
g
/k
g
 i
.p
. 
fo
r 
8
d
a
y
s
D
A
T
 m
R
N
A
 d
e
cr
e
a
se
 i
n
 b
o
th
 S
N
c,
 a
n
d
 V
T
A
 (
1
 h
r 
a
ft
e
r 
th
e
 l
a
st
 i
n
je
ct
io
n
)(
Le
tc
h
w
o
rt
h
 e
t 
a
l.
, 
1
9
9
7
; 
Le
tc
h
w
o
rt
h
 e
t 
a
l.
, 
1
9
9
9
);
 n
o
d
if
fe
re
n
ce
 i
n
 D
A
T
 p
ro
te
in
 o
r 
b
in
d
in
g
 s
it
e
s 
w
it
h
in
 t
h
e
st
ri
a
tu
m
T
h
re
e
 d
o
se
s 
a
t 
1
 h
 i
n
te
rv
a
ls
e
a
ch
 d
a
y
 w
it
h
 1
5
 m
g
/k
g
 i
.p
.
fo
r 
1
4
 d
a
y
s 
(c
h
ro
n
ic
 "
b
in
g
e
"
p
a
tt
e
rn
) 
o
r 
1
0
 d
a
y
s 
w
it
h
d
ra
w
a
l
fr
o
m
 a
 c
h
ro
n
ic
 “
b
in
g
e
” 
p
a
tt
e
rn
N
o
 c
h
a
n
g
e
 i
n
 D
A
T
 m
R
N
A
 i
n
 S
N
 o
r 
V
T
A
(M
a
g
g
o
s 
e
t 
a
l.
, 
1
9
9
7
)
2
 w
e
e
ks
 o
f 
sc
h
e
d
u
le
 s
im
ila
r 
to
se
lf
-a
d
m
in
is
tr
a
ti
o
n
 p
a
tt
e
rn
fo
llo
w
e
d
 b
y
 t
e
n
 d
a
y
s 
o
f
w
it
h
d
ra
w
a
l
D
e
cr
e
a
se
 i
n
 D
A
T
 i
n
 t
h
e
 i
n
te
rf
a
sc
ic
u
la
r 
a
n
d
 c
a
u
d
a
l 
lin
e
a
r 
n
u
cl
e
i 
(p
ro
je
ct
 t
o
 t
h
e
 N
A
cc
),
b
u
t 
n
o
t 
in
 o
th
e
r 
D
A
e
rg
ic
 m
id
b
ra
in
 c
e
ll 
g
ro
u
p
s
(C
e
rr
u
ti
 e
t 
a
l.
, 
1
9
9
4
)
“B
in
g
e
” 
co
ca
in
e
S
e
ro
to
n
in
 t
ra
n
sp
o
rt
e
r 
d
e
cr
e
a
se
 w
it
h
in
 t
h
e
 d
o
rs
o
la
te
ra
l 
d
o
rs
a
l 
ra
p
h
e
, 
D
A
T
 d
e
cr
e
a
se
w
it
h
in
 t
h
e
 S
N
c 
a
n
d
 p
a
ra
b
ra
ch
ia
l 
p
ig
m
e
n
to
si
s,
 N
A
 t
ra
n
sp
o
rt
e
r 
in
cr
e
a
se
 w
it
h
in
 t
h
e
 l
o
cu
s
co
e
ru
le
u
s
(B
u
rc
h
e
tt
 a
n
d
 B
a
n
n
o
n
, 
1
9
9
7
);
 c
o
rr
e
la
ti
o
n
a
l 
a
n
a
ly
si
s
in
d
ic
a
te
d
 t
h
a
t 
p
o
st
-c
o
ca
in
e
 l
e
v
e
ls
 o
f 
D
A
T
, 
5
-H
T
 a
n
d
 N
A
tr
a
n
sp
o
rt
e
rs
 m
R
N
A
s 
w
e
re
 n
o
t 
a
ss
o
ci
a
te
d
 w
it
h
 c
o
ca
in
e
-
in
d
u
ce
d
 s
e
n
si
ti
za
ti
o
n
O
n
ce
 d
a
ily
 w
it
h
 2
0
 m
g
/k
g
 i
.p
.
fo
r 
1
0
 d
a
y
s 
fo
llo
w
e
d
 b
y
 1
4
 d
w
it
h
d
ra
w
a
l?
In
cr
e
a
se
 i
n
 D
1
 a
n
d
 D
2
 r
e
ce
p
to
r 
m
R
N
A
s 
in
 d
if
fe
re
n
t 
b
ra
in
 s
tr
u
ct
u
re
s
(S
ch
m
id
t-
M
u
tt
e
r 
e
t 
a
l.
, 
1
9
9
9
);
 s
im
ila
r 
to
 g
a
m
m
a
-
h
y
d
ro
x
y
b
u
ty
ra
te
 e
ff
e
ct
2
0
 m
g
/k
g
 i
.p
. 
fo
r 
1
5
 d
a
y
s
In
cr
e
a
se
 i
n
 D
2
 r
e
ce
p
to
r 
m
R
N
A
 i
n
 O
T
, 
b
u
t 
n
o
t 
in
 t
h
e
 s
tr
ia
tu
m
, 
2
4
 h
rs
 b
u
t 
n
o
t 
7
 d
a
y
s
a
ft
e
r 
w
it
h
d
ra
w
a
l.
(S
p
y
ra
ki
 a
n
d
 S
e
a
lf
o
n
, 
1
9
9
3
)
R
e
p
e
a
te
d
P
ro
e
n
ke
p
h
a
lin
 m
R
N
A
 i
n
cr
e
a
se
 a
ft
e
r 
3
h
rs
, 
d
e
p
le
ti
o
n
 a
ft
e
r 
2
4
 a
n
d
 4
8
h
rs
, 
D
2
 r
e
ce
p
to
r
m
R
N
A
: 
d
e
cr
e
a
se
 a
ft
e
r 
3
h
rs
, 
n
o
 c
h
a
n
g
e
s 
a
ft
e
r 
2
4
 o
r 
4
8
h
rs
(P
rz
e
w
lo
ck
a
 a
n
d
 L
a
so
n
, 
1
9
9
5
)
O
n
ce
 d
a
ily
 f
o
r 
1
0
 d
a
y
s
3
0
, 
b
u
t 
n
o
t 
1
0
 o
r 
2
0
 m
g
/k
g
 i
n
cr
e
a
se
d
 t
h
e
 e
x
p
re
ss
io
n
 o
f 
p
re
p
ro
d
y
n
o
rp
h
in
, 
b
u
t 
n
o
t
p
re
p
ro
e
n
ke
p
h
a
lin
 m
R
N
A
s
(D
a
u
n
a
is
 a
n
d
 M
cG
in
ty
, 
1
9
9
4
)
5
0
 m
g
/k
g
 p
e
r 
d
a
y
, 
fo
r 
p
e
ri
o
d
s
b
e
tw
e
e
n
 2
4
 a
n
d
 3
3
6
 h
rs
M
u
-o
p
io
id
 r
e
ce
p
to
r 
in
cr
e
a
se
 i
n
 N
A
cc
 (
d
e
v
e
lo
p
s 
2
 d
a
y
s 
a
ft
e
r 
e
x
p
o
su
re
, 
p
e
a
ki
n
g
 a
t 
3
d
a
y
s,
 r
e
tu
rn
e
d
 t
o
 b
a
se
lin
e
 a
ft
e
r 
4
 d
a
y
s)
(A
za
ry
a
n
 e
t 
a
l.
, 
1
9
9
8
)
R
e
p
e
a
te
d
 c
o
ca
in
e
Lo
n
g
-l
a
st
in
g
 b
u
t 
re
v
e
rs
ib
le
 r
e
d
u
ct
io
n
 i
n
 n
e
u
ro
p
e
p
ti
d
e
 Y
 p
ro
te
in
 a
n
d
 m
R
N
A
 l
e
v
e
ls
 i
n
ce
re
b
ra
l 
co
rt
e
x
 a
n
d
 N
A
cc
(W
a
h
le
st
e
d
t 
e
t 
a
l.
, 
1
9
9
1
);
 p
re
v
e
n
te
d
 b
y
 l
e
si
o
n
 o
f 
m
e
d
ia
l
p
re
fr
o
n
ta
l 
co
rt
e
x
3
 w
e
e
ks
 a
ft
e
r 
d
is
co
n
ti
n
u
in
g
 1
w
e
e
k 
o
f 
d
a
ily
 i
n
je
ct
io
n
s 
(1
5
-3
0
m
g
/k
g
 i
.p
.)
R
e
d
u
ct
io
n
 o
f 
th
e
 C
lu
R
3
 m
R
N
A
 l
e
v
e
l.
 I
n
cr
e
a
se
d
 l
e
v
e
l 
o
f 
G
lu
R
2
 m
R
N
A
 i
n
 p
re
fr
o
n
ta
l
co
rt
e
x
. 
In
cr
e
a
se
 o
f 
m
G
lu
R
5
 m
R
N
A
 l
e
v
e
ls
 i
n
 n
u
cl
e
u
s 
a
cc
u
m
b
e
n
s 
sh
e
ll 
a
n
d
 d
o
rs
o
la
te
ra
l
st
ri
a
tu
m
(G
h
a
se
m
za
d
e
h
 e
t 
a
l.
, 
1
9
9
9
);
 t
h
e
 G
lu
R
2
 m
R
N
A
 l
e
v
e
l 
w
a
s
n
o
t 
ch
a
n
g
e
d
 i
n
 a
n
y
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3.2.2.3. Transgenic animals
The development of transgenic and, in particular, KO
mice models allowed for a more precise understanding
of the function of different proteins in drug addiction.
A lot of attention was paid to KO of genes directly
involved in DA transmission, i.e. genes coding for
DAT, DA receptors and DARPP-32.
DAT KO mice display spontaneous hyperlocomotion
despite major adaptive changes. DA persists at least
100 x longer in the extracellular space, and the
psychostimulants had no effect on locomotor activity
(Giros et al., 1996). Even if they do not express DAT,
the primary target for cocaine, mice still acquire
cocaine self-administration, although this takes longer
than in wild-type animals (Miller et al., 1999). This
could be attributed to a role of the serotonin transporter
in cocaine addiction, but it is not clear whether such a
role exists in normal animals or if this is part of an
adaptation processes in KO mice. It is likely, however,
that serotonin plays a role in normal effects of cocaine,
because 5-HT1B KO mice display a markedly reduced
effect of cocaine on c-fos induction in different brain
structures, mostly in the striatum (Lucas et al., 1997).
Individual differences in DAT expression may
underline differences in human substance abuse
vulnerability. Interestingly, mice with 20-30% striatal
DAT overexpression display enhanced reward
conferred by cocaine (Donovan et al., 1999).
D1-receptor deficient mice have proven the critical role
of this receptor in psychostimulant action. The cocaine-
induced hyperactivity was abolished in these animals,
as well as cocaine-induced inhibition of action
potential generation in the NAcc (Xu et al., 1994).
Cocaine or amphetamine were not able to induce c-fos,
JunB and zif 268, or to regulate Dyn expression.
Cocaine however caused the abnormal increase of SP
expression in the striatum (Drago et al., 1996). Only
D1-mediated effects were abolished, because
haloperidol, a neuroleptic acting preferentially on D2
receptors, remained effective in inducing catalepsy and
striatal Fos/Jun expression. This psychostimulant
action, therefore, does not implicate receptor synergy
(Moratalla et al., 1996). KO animals did not exhibit
sensitization to cocaine (Xu et al., 1994).
Mice lacking DA D4 receptors were hypersensitive to
ethanol, cocaine, and metamphetamine (Rubinstein et
al., 1997).
DARPP-32 KO mice showed heightened SP-like
immunoreactivity in the striatum, but no increase of
DeltaFosB by chronic cocaine was observed. The
mutants showed a higher rate of locomotor
sensitization to repeated cocaine exposures, but the
effect of acute cocaine on locomotor activity was
unchanged (Hiroi et al., 1999). KO mice failed to show
a significant elevation of either plasma ACTH or
corticosterone levels following ‘binge’ cocaine,
suggesting that DARPP-32 could mediate the
stimulatory effect of cocaine on the HPA axis (Zhou et
al., 1999).
Other models have been developed, over-expressing
intracellular proteins implicated in cocaine action.
Over-expression of CREB in NAcc decreased the
rewarding effects of cocaine and made low doses of the
drug aversive whereas Dyn expression was increased.
Overexpression of dominant-negative mutant CREB
increased the rewarding effects of cocaine and
decreased the expression of Dyn. Blockade of kappa
opioid receptors antagonized the negative effect of
CREB on cocaine reward (Carlezon et al., 1998). This
points out the role of Dyn in the development of
cocaine tolerance.
Mice lacking the fosB gene show abnormal
biochemical and behavioral responses to chronic
administration of drugs of abuse or antidepressant
treatments (Nestler et al., 1999). In contrast, transgenic
mice with inducible deltaFosB expression in the subset
of NAcc neurons in which cocaine induces the protein
display increased responsiveness to the rewarding and
locomotor-activating effects of cocaine. These effects
of deltaFosB are mediated partly by induction of the
AMPA glutamate receptor subunit GluR2 in the NAcc.
These results support a model in which deltaFosB, by
altering gene expression, enhances sensitivity to
cocaine and may contribute to cocaine addiction (Kelz
et al., 1999).
However the evaluation of data from transgenic, in
particular KO animals, must be done carefully. First, in
mutant animals, substantial compensation occurs
during development . The more necessary the deleted
gene, the more profound compensations will occur in
the case of viable mutants, so more errors will be
possible during evaluation of experimental results. The
use of conditional KO provides more relevant results.
Second, the strategy of producing KO should be
carefully considered, especially when performing
behavioral tests. KO animals in most cases have a
mixed genotype between the strain at the origin of the
ES cell line and the second strain used for breeding the
chimeric animals. Very often these strains have
completely a different phenotype in behavior, for
example, in respect to memory tests or drug
dependence (Crawley et al., 1997; Deroche et al.,
1997). For example, two common strains for KO
production, C57BL/6J and 129/J mice, have significant
differences in relation to the effects of “binge” cocaine
administration on stereotypy and locomotor activity
(Schlussman et al., 1998). Therefore, care should be
taken to purify as much as possible such mixed strains
by consequent breeding and testing for the presence of
mutation. Finally, this situation is further complicated
by the fact that historically the great majority of
behavioral, lesions and electrophysiological tests were
performed in rats, where the protocols are well
established, and molecular biology is more studied in
mice. Even if these two rodents are highly similar in
terms of gene homology, this is not at all the case in
terms of behavior and even neurochemistry. One of the
most flagrant examples is a surprising insensitivity of
rats to MPTP, a neurotoxin specific for the DAergic
system, as opposed to mice, non-human primates or
humans. The reasons of such a resistance remain a
mystery (Miller et al., 1999).
26
3.3. Associative and non-associative mechanisms of
drug addiction
The acute reinforcing effects of cocaine and
amphetamine lead to patterns of drug use that, in
epigenetically vulnerable individuals, result eventually
into addiction, a state hypothesized to be the result of
plastic changes in multiple neural circuits. Many of
these changes are caused by the induction of IEG
following drug treatment (Figure 23). If the drug
treatment is repeated, these changes then enchain
downstream molecular events, accounting for long-
lasting neuroadaptations which could exert significant
behavioral consequences in the longer term.
Figure 23. Induction of IEG expression is under the joint control of calcium- and cAMP-dependent signal transduction
pathways. In the striatum these pathways appear to be mutually inhibitory at many stages (not shown), but their effects
inside the nucleus can be cooperative. Both PKA and CaMK-IV can phosphorylate CREB at serine 133. Calcium-
dependent CREB phosporylation may also occur as a result of activation of the ERK/MAPK in striatal cells.
ERK/MAPK also increase the transcription of striatal IEGs through phosphorylation of the transcription factor Elk-1. A
complex set of genes can be induced in striatal neurons. Some genes are part of a homeostatic response, reducing
sensitivity to subsequent stimulation; others may be involved in consolidating changes in the strength of specific
synaptic connections. Abbreviations: D1, DA D1 receptor; D2, DA D2 receptor; PKA, cAMP-dependent protein kinase;
CaM, calmodulin; CaMKIV, calcium/calmodulin-dependent protein kinase IV; MEK, MAP and ERK kinase; MAPK,
mitogen-activated protein kinase; SRF, serum response factor; AP-1, activator protein-1; CRE, cAMP response
element; CREB, CRE binding protein; TBP, TATA binding protein; RNA pol II, RNA polymerase II (adapted from
(Berke and Hyman, 2000)).
Plasticity changes that underlie addiction can be
divided conceptually into three groups:
1) compensatory adaptations in neural systems that
regulate autonomic and other somatic functions
leading to physical dependence and withdrawal;
2) adaptations in the mesoaccumbens brain reward
circuitry itself resulting in the emotional and
motivational aspects of dependence and
withdrawal;
3) synaptic plasticity, which allows for the
association of drug-related stimuli with specific
learned behaviors (Berke and Hyman, 2000;
Hyman, 1996).
The first mechanism is not very important for
psychostimulants, because, unlike the opiates and
ethanol, cocaine and amphetamine do not produce
physical dependence; they are, nonetheless, among the
most reinforcing and addictive drugs known,
underscoring the importance of plasticity in emotional
circuits (Hyman, 1996). Neuronal adaptations account
for both tolerance and some types of sensitization
whereas synaptic plasticity is important for specific
forms of sensitization related to associative learning.
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3.3.1. Tolerance
The development of tolerance is explained in Figure
24. Prolonged drug use produces profound adaptive
changes acting to maintain equilibrium by reducing
drug effects (tolerance), and acute withdrawal will
again disturb this novel homeostasis and produce
negative physical and emotional symptoms.
Manifestations in humans include dysphoria,
anhedonia, and drug craving with eventual
reinstatement of drug use. Anhedonia in humans may
be modeled in rats by transient decreases in DA
neurotransmission and elevations in electrical brain
self-stimulation reward thresholds observed after
cocaine administration (Markou and Koob, 1991).
Figure 24. The development of tolerance. Continuous exposure to a drug disturbs the homeostasis of the mesolimbic
DAergic system in its normal state. The system therefore undergoes substantial adaptations to restore its balance by
reducing drug effects (tolerance). Nevertheless, it is clear that the balance is only possible in the presence of the drug,
therefore abstinence will unmask neural adaptations that have occurred, and a subset of these may produce withdrawal
symptoms generally opposite to those of the drug (adapted from (Timmons and Hamilton, )).
Some cellular and molecular events leading to
tolerance development, are shown on Figure 25 and
represent compensatory adaptations to excess DA
stimulation which result in down-regulation of DA
transmission. First, acute cocaine treatment results in
the phosphorylation and internalization of D1
receptors, accounting for “acute tolerance”
phenomenon (Figure 25) (Dumartin et al., 1998;
Roseboom and Gnegy, 1989; Tiberi et al., 1996).
Second, cocaine and amphetamine induce expression
of prodynorphin mRNA and Dyn peptides in
striatonigral neurons (Jaber et al., 1995) which signal
back on presynaptic DA terminals within the striatum
via recurrent axon collaterals (Figure 25). Acting via
kappa receptors on DA terminals, Dyn decreases DA
release (Steiner and Gerfen, 1995). Indeed, kappa
receptor agonists produce an aversive dysphoric
syndrome in drug naive humans and rats, analogous to
the state induced by drug withdrawal in drug users.
Third, both cocaine and morphine increase levels of
TH, while decreasing the levels of neurofilament
proteins in the VTA (Beitner-Johnson et al., 1992).
Thus, despite the increased TH gene transcription, the
axonal transport of the mature protein will be slowed
down, leading to decreased DA synthesis in the
presynaptic space (Figure 25).
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Figure 25. Cellular mechanisms of
tolerance. Acute cocaine treatment yields
into the internalization of D1 receptors (1).
Chronic cocaine induces the expression of
Dyn which, by acting on presynaptic kappa
opioid receptors (KOR), inhibits DA
release (2). Chronic cocaine also decreases
the synthesis of neurofilament proteins
(NF), leading to decreased axonal transport
of tyrosine hydroxylase (TH) to the
presynaptic terminal (3). Tyr, tyrosine.
When drug administration ceases, the neural systems
which have undergone neuroadaptations, gradually
return to their normal sensitivity. This can take
anywhere from minutes to weeks depending on the
particular homeostatic response, but so far none
appears sufficiently long-lasting to be involved in the
persistent tendency of addicted individuals to relapse
(Berke and Hyman, 2000).
3.3.2. Sensitization
Sensitization is more likely to occur with intermittent
exposure to a drug, in contrast to tolerance, which is
more likely to occur with continuous exposure (Koob,
1996). Neural changes responsible for these apparently
opposite phenomena might however coexist in the
same system. By applying different protocols of drug
treatment, it is possible to induce first sensitization,
then tolerance, and vice versa (Dalia et al., 1998).
Tolerance, being a more pronounced and short-lasting
phenomenon, is masking the expression of
sensitization.
3.3.2.1. Context-independent sensitization
Context-independent sensitization relates to a
sensitized response to non-specific cues such as stress
or drug exposure, leading eventually to relapse to drug
use. This might be due to neuroadaptations, as in the
case of tolerance. For example, chronic cocaine is
known to induce profound modifications in the HPA
xis, which would explain the phenomenon of stress-
induced sensitization.
Other manifestations of context-dependent
sensitization are explained by changes in the
m soaccumbens circuitry that would increase the
effects of DA. These can be achieved, for example, by
a decreased sensitivity of presynaptic DA D2
autoreceptors and supersensitivity of postsynaptic D1
receptors. In fact, after a period of psychostimulant
administration, the ability of a subsequent dose to
evoke dopamine release in the striatum can be
increased (for reviews, see (Kalivas and Stewart, 1991;
Robinson and Becker, 1986)). This effect can persist
for at least several weeks (Hooks et al., 1994; Kalivas
and Duffy, 1993; Kalivas and Duffy, 1993; Robinson
et al., 1982). The enhancement of D1 receptor
responses in the NAcc was also reported in correlation
with locomotor sensitization to cocaine (Henry and
White, 1995). This effect can persist for one month
after withdrawal. These changes do not correlate with
an increase of the D1 receptor number or affinity, but
likely reflect modifications in post-receptor signal
transduction. In fact, chronic treatment of rats with
cocaine produced increases in cyclic AMP-dependent
protein kinase activity and decreases in Gi_ and Go_
levels in the VTA, NAcc, and locus coeruleus (Nestler
et al., 1990; Terwilliger et al., 1991). Changes in
transcription factors expression upon chronic cocaine
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could also explain some types of neuroadaptations, e.g.
the switch from c-fos to chronic FRAs, which leads to
a different composition of the AP-1 transcription
activation complex and therefore to a different set of
expressed genes. However, there is no evidence to date
for long-lasting up- or downregulation of mRNA or
protein which may account for the persistence of some
forms of sensitization—and, in humans, of addiction
(Berke and Hyman, 2000).
3.3.2.2. Context-dependent sensitization
Compensatory adaptations (changes in
neurotransmitter release, postsynaptic sensitivity, etc.)
are restored rapidly with discontinuation of drug
administration. The symptoms of withdrawal diminish,
but the relapse to drug use persists for years. In
addition to adaptations within the brain reward
circuitry itself, drugs induce a set of molecular
mechanisms leading to long-lasting changes in the
synaptic efficacy and structural synaptic change (Berke
and Hyman, 2000). At the behavioral level it is
expressed by production of long-lived, positively
biased, emotional memories that may be activated by
environmental or interoceptive cues. Relapse to drug
use in humans often occurs when addicts encounter
people, places, or other cues associated with their prior
drug use (Childress et al., 1986; Shiffman et al., 1996).
Context-dependent sensitization and cue-conditioned
human relapse suggest that the brain stores specific
patterns of drug-related information, resulting from
prior associative learning. Humans and animals can
readily learn to take addictive drugs; this process
requires the specific recognition of drug-associated
cues and the performance of specific actions. Drugs act
as very effective positive reinforcers (Woolverton,
1992). In addition, cues associated with drug
administration acquire motivational significance; for
example, rats will choose to spend more time in a
location in which they have passively received an
injection of psychostimulants than in another location
paired with saline injection (''conditioned place
preference''; (Tzschentke, 1998)).
DA plays a role as a reinforcement learning signal in
the striatum (Wickens and Kötter, 1995) which
involves the timely-organized coactivation of
corticostriatal (Glu-ergic) and DAergic circuits,
resulting in the reinforcement of particular synapses.
At a behavioral level this means an association
between a particular set of stimuli and a particular
behavioral response. The involvement of these striatal
''habit''-learning mechanisms by addictive drugs could
explain the tendency for drug-related cues and contexts
to provoke specific behaviors, such as drug self-
administration (Robbins and Everitt, 1999; White,
1996). The activity of cortical areas may also account
for the observation that giving an amphetamine
injection in a novel environment greatly enhances both
striatal IEG induction and behavioral sensitization,
without affecting striatal dopamine release (Badiani et
al., 1998).
The development of stimulus–response habits has been
attributed particularly to learning processes involving
dorsal parts of the striatum. Facilitation of synaptic
plasticity in the ventral striatum may also contribute to
drug use through enhanced learning related to the
m tivational significance of drug-related cues (Carr
and White, 1983). The changes in synaptic plasticity
first involve the activation of transcription factors, such
as CREB, arc, etc. Later phases may engage also
structural changes related to synaptic connections,
similar to the formation of new synaptic contacts in the
late phase of hippocampal LTP (Engert and
Bonhoeffer, 1999). In fact, chronic amphetamine
administration causes increased dendritic spine density
in the NAcc, as well as an increased number of
branched spines (Robinson and Kolb, 1997). DA can
stimulate neurite extension and growth cone formation
in embryonic striatal cultured neurons through a
pathway that involves D1 receptors, the cAMP/PKA
pathway, and protein synthesis (Schmidt et al., 1996;
Schmidt et al., 1998). Addictive drugs can induce
synaptic plasticity or associative learning in abnormal
fashion. Reinforcing events that are fully predicted do
not evoke DA release and hence do not provoke further
learning (see § II.2. C.3) (Schultz, 1998). However, the
direct pharmacological actions of psychostimulants and
other addictive drugs may override such normal
constraints on learning (Di Chiara, 1998). The
continuous DA release could lead to excessive
strengthening of synaptic patterns representing drug-
taking behavior, relative to other behaviors performed
by the animal, thus narrowing the behavioral repertoire
towards drug-related activities (Koob et al., 1998).
In addition, the manner of drug intake becomes
progressively more fixed—particular sequences of
actions become ''ritualized'' and automatic (Tiffany,
1990), consistent with the involvement of the dorsal
striatal ''habit''-learning system. In summary, these
learning-related actions of drugs are primarily
responsible for the compulsive nature of drug use.
Non-associative and associative mechanisms of
sensitization are not mutually exclusive. Molecular
events leading to both types of sensitization may occur
in the same cell. For example, two major
neuroadaptations caused by chronic cocaine are the
increased expression of the GluR2 subunit, following
FRAs induction and the decreased sensitivity of
calcium channels (Kelz et al., 1999; White et al.,
1998). Later on both modifications could contribute to
the changes in synaptic plasticity associated with LTP.
Thus, nonassociative changes in dopamine
neurotransmission may set the thresholds for the
effects of drugs on associative learning.
Neurotrophins also contribute to changes in the
mesoaccumbens system. There is a feedback loop,
whereby drugs of abuse decrease signaling through the
GDNF pathway in the VTA, which then increases the
behavioral sensitivity to subsequent drug exposure
(Messer et al., 2000). NT-3 contributes to the initiation
of behavioral sensitization to cocaine by activating the
Ras/MAP kinase signal transduction system (Pierce et
al., 1999). Data about BDNF are more controversial.
BDNF KO heterozygous mice show a delayed
development of locomotor cocaine sensitization
(Horger et al., 1999). BDNF enhances the initial
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stimulant effects of cocaine and facilitates the
development of sensitization to repeated cocaine doses
(Horger et al., 1999). However, BDNF also produces a
progressive augmentation in behavioral activation with
repeated drug administration with no changes upon
subsequent cocaine treatment (Pierce et al., 1999).
These results are in agreement with the observation
that BDNF elicits an increase in the phosphorylation of
extracellular signal regulated kinase (ERK) and thereby
prevents an additional increase in response to drug
exposure (Berhow et al., 1996).
The neurobiology of dependence is a highly complex
phenomenon, consisting of both single and repeated
exposure to drugs (where rewarding, discriminative
and aversive properties of a drug are important) under
environmental and genetic conditions that lead to or are
accompanied by drug-seeking behaviors (Stolerman,
1993). Environmental conditions include the hormonal
status of the organism. For example, glucocorticoids
may contribute to the state-dependent activation of
mesencephalic DAergic neurons and thus to the
individual vulnerability to the drugs of abuse (Piazza et
al., 1996). Gender differences in susceptibility to
addiction are also very important. In female rats the
gonadal hormones estrogen and progesterone modulate
DA activity in the striatum. Estrogen is able to enhance
DA release and DA-mediated behaviors (Becker,
1999).
3.4. Cocaine and neural axon remodeling
3.4.1.1.1 Cocaine and cytoskeletal proteins
Psychostimulants produce extensive biochemical
adaptations in brain monoamine, especially DA,
systems. They also may alter the morphology of
neurons in different brain regions, including that
receiving monoaminergic innervation. Treatment with
either amphetamine or cocaine (but not general motor
activity) increase the number of dendritic branches and
the density of dendritic spines on medium spiny
neurons in the shell of the NAcc, and on apical
dendrites of layer V pyramidal cells in the prefrontal
cortex. Cocaine also increases dendritic branching and
spine density on the basilar dendrites of pyramidal
cells. Changes in dendritic architecture may modify the
patterns of synaptic connectivity in the NAcc and
prefrontal cortex and account for some of the persistent
neurobehavioral consequences of repeated exposure to
psychostimulant or other addictive drugs (Robinson
and Kolb, 1999). In fact, experimental animal studies
showed a reduction in shape and size of mesolimbic
dopaminergic neurons after chronic morphine
administration (Pezawas et al., 1998).
Several reports show the interaction of
psychostimulants with cytoskeletal proteins. As was
mentioned before, cocaine administration induces
several IEG, which code for transcription factors. In
addition, it affects expression of a recently identified
"effector" IEG referred to as arc (activity-regulated,
cytoskeleton-associated). Arc is a protein with
homology to spectrin that is associated with the actin
cytoskeleton. Both striosome and matrix striatal
neurons show arc upregulation, which is mediated by
D1 dopamine receptor. Immunohistochemical studies
indicated that Arc induced by cocaine is expressed in
neuronal cell bodies and dendrites. Thus, Arc may be
involved in structural alterations underlying neuronal
lasticity triggered by cocaine (Fosnaugh et al., 1995;
Tan et al., 2000).
Cocaine also affects the metabolism of tau which
stabilizes microtubules and promotes microtubule
assembly. In fact, cocaine treatment decreases tau in
the cytoplasm as well as the membrane fraction of
cultured human neuroblastoma cells (Lew, 1992).
There is an increasing amount of data about the
importance of neurofilament proteins in drug addiction.
An initial observation showed that chronic
a ministration of either morphine or cocaine  decreases
levels of the three neurofilament proteins, NF-H, NF-
M, and NF-L, by between 15% and 50% in the VTA.
The regulation is selective and region-specific. No
detectable changes were observed in the levels of eight
other major cytoskeletal or cytoskeletal-associated
proteins analyzed and neurofilament levels were not
ltered in the SN, or other parts of the brain or spinal
c rd. Furthermore, the decline in neurofilament
expression was not observed following chronic
treatment with psychotropic drugs without reinforcing
properties, or chronic stress (Beitner-Johnson et al.,
1992). Later it was shown, that chronic ethanol and
nicotine exposure as well as "unpredictable" stress also
decreased levels of immunoreactivity of neurofilament
proteins in the VTA but not in the SN, in parallel with
increased levels of TH and glial fibrillary acidic protein
immunoreactivity (Bunnemann et al., 2000; Ortiz et al.,
1995; Ortiz et al., 1996). Finally, the strains of alcohol-
preferring versus nonpreferring rats display different
levels of neurofilaments in the VTA, strongly favoring
the hypothesis that neurofilaments expression may be
related to preference for different drugs of abuse
(Guitart et al., 1993).
In confluent endothelial monolayers, cocaine induced a
rapid increase in membrane permeability, a marked
disruption of F-actin and the formation of intercellular
gaps (Kolodgie et al., 1999).
In addition to its direct effects on cellular morphology,
psychostimulants interfere with the changes induced by
growth factors. Cocaine inhibits neuronal
differentiation in a dose- dependent fashion, in NGF-
stimulated PC12 cells, without affecting cell viability.
Dopamine and GBR 12909, a potent DAT inhibitor,
yield similar effect, which is mediated by D1 receptors
(Zachor et al., 2000). Interestingly, both stimulating
effects of NGF and inhibiting effects of cocaine are
mediated by the same intracellular message, c-fos.
NGF induces a transient peak of c-fos expression, and
induction of late genes expression, leading to the
neuronal phenotype. In the cocaine-treated cells, c-fos
level persisted up to several days (Zachor et al., 1998).
3.4.2. Cocaine and development
Drugs of abuse modify signaling of neurotransmitters
and intracellular messengers. These same
neurotransmitters regulate various aspects of cell
proliferation, survival, migration, circuit formation and
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establishment of topography during central nervous
system development (Levitt, 1998). Non-surprisingly,
the exposure to cocaine in utero leads to profound
alterations in brain development.
Rabbits exposed to cocaine in utero, show a marked
decrease in both dendritic bundling and typical long,
straight MAP2-stained profiles in the anterior cingulate
cortex. The organization of the apical dendrites is
modified. In cocaine-treated offspring, the dendrites
coursed in an irregular, wavy manner throughout the
layers, suggestive of dendrites that are longer than
normal, although cortical thickness is unchanged. The
drug-induced modification of cortical regions
development is not uniform, as suggested by lack of
dendritic changes in visual cortex (Jones et al., 1996).
In vitro results confirm the involvement of cocaine in
brain development. Both the number and length of
neurites were dramatically reduced by cocaine in
cocultures of neurons and glial cells from mouse
embryonic brain. These changes preceded extensive
neuronal death. Scanning electron microscopy
demonstrated a shift from a multipolar neuronal pattern
towards bi- and unipolarity prior to the rounding up
and eventual disappearance of the neurons. Selective
toxicity of cocaine on neurons was paralleled by a
concomitant decrease of the culture content in
microtubule-associated protein 2. In contrast, cocaine
did not affect astroglial cells and their glial fibrillary
acidic protein content (Nassogne et al., 1998; Nassogne
et al., 1995). Finally, in developing GABAergic
neurons cocaine produced cytotoxic effects that were
expressed in drastic decrease in the number of neurons
and in degeneration of their processes (Glezer et al.,
1999).
Recent studies show that cocaine is also able to modify
the expression of developmentally important molecules
in adult brain. EphB1 and ephrin-B2, a receptor and
ligand of the Eph family, are candidate guidance
molecules for the development of mesostriatal and
mesolimbic dopaminergic projections. EphB1 and
ephrin-B2 are expressed in complementary patterns in
the midbrain dopaminergic neurons and their targets,
and the ligand specifically inhibits the growth of
neurites and induces cell loss of SN, but not VTA,
dopaminergic neurons. In addition, ephrin-B2
expression is upregulated by cocaine and amphetamine
in adult mice, suggesting that ephrin-B2/EphB1
interaction may play a role in drug-induced plasticity in
adults as well (Yue et al., 1999).
Eph receptors and their ligands appear to guide axons
by repelling the growth cone, rather than attracting it
(Orioli and Klein, 1997). They are similar in this aspect
to another group of axon guidance molecules, the
semaphorins. Both Sema3A and ephrin A5 induce
physiologic growth cone collapse by actin filament
rearrangements and alterations in membrane dynamics
(enhanced endocytosis) (Fournier et al., 2000).
Interestingly, besides their role in axon guidance,
semaphorins are expected to have multiple functions in
morphogenesis and tissue remodeling by mediating
cell-repelling cues through plexin receptors (Artigiani
et al., 1999). This feature makes semaphorins an
attractive candidate as modulators of dopaminergic
neurons plasticity in adult brain, for example,
following cocaine treatment. Sympathetic neurons
undergoing dopamine-induced apoptosis, show up-
regulation of secreted collapsin-1 (Sema3A) and
collapsin response mediator protein. A synchronized
i duction of mRNA preceded commitment of neurons
to apoptosis. Dopamine-induced apoptosis was
prevented by blocking collapsin signaling. It has been
suggested, that, before their death, apoptosis-destined
neurons may produce and secrete destructive axon
guidance molecules that can affect their neighboring
cells and thus transfer a "death signal" across specific
and susceptible neuronal populations (Shirvan et al.,
1999). It is tentative to imagine, that these in vitro
apoptotic properties of semaphorins may be
represented in vivo by more subtle specific
m difications of neuronal morphology and synaptic
rearrangements.
3.4.2.1. Aims of this work
In summary, cocaine treatment results in substantial
neuroadaptations and synaptic plasticity in the
mesoaccumbal DAergic pathway (Berke and Hyman,
2000). Both phenomena require gene expression and
protein synthesis for their expression. A number of
neuroadaptations already known and the acquired
knowledge allows us to presume that this mechanism
plays a minor role in the long-lasting relapse to drug
taking, determining the addiction phenomenon.
Synaptic plasticity might instead be a crucial factor in
this respect. Some data exist about modified synaptic
efficiency and connections in the brain, repeatedly
exposed to a drug, however very little is known about
the factors responsible for such modifications. Recent
findings implicate Ephrin-B2, an axon guidance
molecule, in drug addiction. Ephrin-B2 is a guiding
molecule playing the major role in the establishment of
mesostriatal DAergic projections during development,
and it is also induced in the NAcc upon “binge”
cocaine treatment with a peak at 24 hrs after drug
wi hdrawal (Yue et al., 1999). This intriguing finding
suggests that the very same neurotrophic factors,
normally required for the development of the DAergic
system, might be involve in structural changes of
DAergic neurons in drug-induced plasticity. At the
same time this very protocol, resulting in Ephrin-B2
over-expression, may serve as model of a set-point for
induction of structural plasticity in the mesoaccumbens
pathway. However, it is important to have a
representative picture of gene expression changes at
this point in order to understand the nature and the
functional significance of such changes. We therefore
d cided to perform a screening for differentially-
expressed genes at this particular time-point by means
of differential display of mRNA. Two modifications of
the method were introduced allowing first for increased
r producibility and easy handling of the method, and
second for a gene-specific screening for the
semaphorins, members of another family of axon
guidance molecules. In addition, new rat semaphorins
were cloned by RT-PCR using degenerate family-
specific primers.
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II. METHODS
1. Differential Display of mRNA (according to (Brenz Verca et al., 1998))
This modified protocol (based on the original differential display procedure (Liang and Pardee, 1992)) uses longer
primers, designed to increase the specificity and to permit direct sequencing and ribonuclease protection assay with re-
amplified fragments.
1.1. Reverse transcription:
1) Denature and anneal 0.2-2 µg of total or polyA RNA with oligo dT set (Table 2), 2.5 µM, for 5 min at 75 ˚C, then
cool down to 0°C
2) Add the following components: RT Buffer, 1x; DTT, 10 mM; dNTPs, 625 µM; RNAsin, 40 U (optional!); MMLV-
RTase, 400 U). Total reaction volume 40 µl.
3) Incubate for 1 hr at 37 ˚C, then heat for 10 min at 75°C.
4) Precipitate with EtOH, resuspend in TE buffer.
Alternative (no need for precipitation):
1. Heat mix of primers, 1µM; and RNA, 0.2-3 µg; for 5 min at 65 ˚C, then put at 37 ˚C, let some minutes.
2. Add: RT Buffer, 1x; DTT, 10 mM; dNTPs, 20 µM; RTase, 200 U. Total reaction volume 20 µl. Incubate for 1 hr at
37 ˚C, then for 5 min at 80 ˚C.
1.2. PCR:
1. Mix the following components: PCR Buffer, 1x; MgCl2, 1 mM; dNTPs, 2 µM; {a-32P}-dATP, 2 µCi; Taq DNA
Pol, 1.5 U; oligo dT primer or pool, 1 µM; arbitrary primer (Table 2), 1 µM; RT-mix, 2 µl.
2. Run the following thermocycler profile:
94°C, 2 min initial
denaturation
(facultative)
94°C, 1 min
40°C, 2 min
72°C, 1 min ý 5 cycles
94°C, 45 sec
56°C, 1 min
72°C, 45-60 s ý 35 cycles
72°C, 5 min final extension
1.3. Electrophoresis:
1. Mix 7 µl of sample with 4 µl of loading dye, incubate for 2 min at 80 ˚C, chill on ice and load 4 µl on gel (6%).
Electrophoresis for about 3 Hr at 60 W constant power until the xylene canole dye runs to within 10 cm from the
bottom.
2. After electrophoresis, transfer the gel directly onto a piece of Whatman 3MM paper. Cover the gel with a sheet of
Saran wrap and dry under vacuum at 80°C for 1-2 hours. Take off Saran wrap and expose the X-ray film at room
temperature for 7 to 12 hours. Orient the film and dried gel with radioactive ink or needle punches or by piercing
the film with a needle at three defined labeled points on the dried gel.
1.4. Reamplification of bands:
1. Orient the film exposure and the dried gel with radioactive ink (some 32P + blue juice) previous to exposure.
2. Remove the Saran wrap, align the autoradiogram with the gel. Locate the bands of interest and cut through the film
with clean scalpel blades.
3. Rehydrate the dried gel slice in 100 µl 1x TE at 80 ˚C for 10 min, spin briefly.
4. Transfer the supernatant to clean tube, precipitate with EtOH.
5. Resuspend the pellet in up to 100 µl 1 x TE.
6. Mix the following components of the PCR reaction: PCR Buffer, 1x; MgCl2, 2.5 mM; dNTPs, 250 µM; XSP6, 1
µM; BT7, 1 µM; Taq DNA Pol, 1.5 U. Total reaction volume 40 µl. Use 5 µl of the extracted DNA for the PCR.
7. Run the following thermocycler profile:
94°C, 2 min initial denaturation
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94°C, 45 s
40°C, 1 min
72°C, 1 min ý 5 cycles
94°C, 1 min
62°C, 1 min
72°C, 1 min/kb ý 35 cycles
72°C, 15 min final extension
8. Check on 1.5-2 % agarose gel. Purify on low melting agarose for sequencing, clone if the band is not
homogeneous.
2. Reverse Transcription
1. Mix: 0.1-2 µg of total RNA; 2.5 µM of reverse primer (for ex., oligo(dT)). Final volume 18 µl. Heat for 5 min at 75
˚C, cool down to 0 ˚C.
2. Add the following components: RT Buffer, 1x; DTT, 10 µM; dNTPs, 625 µM each; RNAsin 40 U; MMLV-RTase,
400 U. Total reaction volume: 40 µl.
3. Incubate for 1 hr at 37 ˚C, then heat for 10 min at 75 ˚C.
4. Remove excess dNTPs and primers by EtOH precipitation or commercially available kits.
3. Cloning of new members of the rat semaphorin family and Semaphorin-Specific Enriched Differential Display
1) Total RNA is isolated from rat brain tissues using Ambion RNA isolation kit (RNAqueous, Cat. N°1912)
2) cDNA is synthetized from 1 µg of total RNA according to the Reverse Transcription protocol (§ II.2). Add water to
a final volume of 100µl.
3.1. Semaphorin-specific RT-PCR with two degenerate primers
This protocol is designed to clone the new members of the semaphorin gene family using RT-PCR with two
semaphorin-specific degenerate primers. PCR conditions are as previously described (Puschel et al., 1995).
1. Primers: forward: DDK; reverse: DPY or DPY/BamHI (see Table 2 for sequences).
2. Perform the PCR reaction with 10 or 20 µl of RT product in 100 µl final volume with the following reagents: PCR
buffer, 1x (20 mM Tris.HCl pH 8.4; 50 mM KCl); MgCl2, 3 mM; dNTPs, 0.25 mM, both primers, 1 µM; Taq
Polymerase, 5 U
3. PCR program:
1x denature template at 94°C for 4 min
5x denaturation at 94°C for 1 min
annealing at 60°C for 1.5 min
elongation at 72°C for 1.5 min
5x denaturation at 94°C for 1 min
annealing at 55°C for 1.5 min
elongation at 72°C for 1.5 min
5x denaturation at 94°C for 1 min
annealing at 50°C for 1.5 min
elongation at 72°C for 1.5 min
5x denaturation at 94°C for 1 min
annealing at 45°C for 1.5 min
elongation at 72°C for 1.5 min
20x denaturation at 94°C for 1 min
annealing at 55°C for 1.5 min
elongation at 72°C for 1.5 min
1x use a prolonged elongation time up to 10 min at 72°C
4. Analyze the samples on 2% agarose gel (estimated length of fragment: »900 bp).
For cloning new members of the semaphorin family a blunt-end ligation of the fragment into the appropriate vector (e.g.
pBluescript) is performed. A Semaphorin-Specific Enriched Differential Display is performed as below.
3.2. Enriched Differential Display
PCR conditions and program like in the first reamplification after Differential Display (§II.1.4)
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1. Primers: arbitrary or semaphorin-specific 25-mer primers (Table 2).
2. Perform the PCR reaction with 2 µl of the first PCR product in 100 µl final volume with the following reagents:
PCR buffer, 1x (20 mM Tris.HCl pH 8.4; 50 mM KCl); MgCl2, 2.5 mM; dNTPs, 0.25 mM, both primers, 1 µM;
Taq Polymerase, 5 U
3. PCR program:
1x denature template at 94°C for 2 min
5x denaturation at 94°C for 45 sec
annealing at 40°C for 1 min
elongation at 72°C for 1 min
35x denaturation at 94°C for 1 min
annealing at 62°C for 1 min
elongation at 72°C for 1 min
1x use a prolonged elongation time up to 15 min at 72°C
4. Riboprobe synthesis for non-radioactive in situ hybridization
Labeled RNA probes are synthesized by in vitro transcription of DNA, cloned downstream of T3, T7 or SP6 RNA
polymerases promoters, using digoxigenin- or fluorescein-labeled uridine-triphosphate as substrate. Alternatively,
the probes can be generated from PCR template, containing the same promoters. The probes are detected, after
hybridization to target nucleic acids, by enzyme-linked immunoassay using an antibody-conjugate (alkaline
phosphatase or horseradish peroxidase). The product is visualized by enzyme-catalyzed chromogenic, fluorescent
or chemiluminescent reaction.
1. Linearize 5 µg of insert-containing plasmid in 50 µl total volume reaction with 20U of corresponding enzymes and
reaction buffers (see REMARK 1), for sense and antisense probes respectively. Incubate for 4 hrs. Check
linearization efficiency on agarose gel.
2. Purify the template DNA on preparative agarose gel and purify the isolated band with an available Gel Extraction
method (for ex., JETquick Gel Extraction Spin kit). Check the purified DNA on analytical agarose gel with DNA
weight marker.
3. Label the RNA in a following reaction (if using the Kit for the first time, include controls; see REMARKS 2 & 3):
transcription buffer, 1x; NTP labeling mix, 2 µl; DNA, »1 µg; RNA polymerase, 40U; RNase inhibitor (optional),
20U. Total reaction volume 20 µl.
4. Incubate for 2 hrs at 37°C.
5. DNA template removal (optional): Add 2-20U DNase I, RNase free, and buffer if needed, incubate for 15-30 min
at 37°C. Add on ice 2 µl EDTA, 0.2 mol/l; pH 8.0 to stop the reaction.
Optional: Reduction of probe length (if needed, see remark 4): (adapted from (Angerer and Angerer, 1981; Brahic and
Haase, 1978)):
Add ddH2O up to 50 µl and 50 µl of 0.2M carbonate buffer, pH 10.2.
Incubate for the appropriate time at 60°C. Hydrolysis time is given by the following relationship (Cox et al., 1984):
t = (lo-lf) / (kLoLf)
where
t = time in minutes
Lo = initial length in kilobases
Lf = desired length in kilobases
k = approximately 0.11 strand scissions/kilobases/minute.
Neutralize by adding 3 µl 3M NaOAc, pH 6.0, and 5 µl 10% (volume/volume) glacial acetic acid. Precipitate with
2 Vol Ethanol (see REMARK 5). Continue with 7).
6. Precipitate the labeled RNA with 1/5 Vol NH4OAc, 10 M, and 3 Vol prechilled ethanol (see REMARK 5). Mix well.
Leave for at least 30 min at –70°C or 2 h at –20°C. Centrifuge for 30 min at 4°C, wash the pellet with 80%, then
with 100% Ethanol, dry with care.
7. Resuspend the probe in 100 µl ddH2O.
8. Check the integrity of the probe on agarose gel (fluorescein-labeled RNA can be visualized directly w/o EtBr
staining by UV transillumination). A better way is to check the probes on 2 to 2.5% agarose gel in MOPS buffer,
containing 6% formaldehyde (Bruskin et al., 1982).
The probes are stable for at least one year and can be stored in ddH2O, hybr dization solution, TE buffer or TE
containing 0.1% SDS at –20°C.
9. Estimate the yield in a spot test with a DIG-labeled control ( see separate protocol).
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4.1. Remarks
1. It is of advantage to use the restriction enzymes creating 5’-overhangs. One also can prefer to make an additional
cut in the middle of the vector in order to achieve better separation of DNA template for in vitro transcription from
the rest of the plasmid on agarose gel.
2. If desired, the kinetics of the labeling reaction can be followed and the amount of newly synthesized RNA
determined by the addition of a radioactively labeled tracer NTP (30 nm {a-32 }-UTP) and TCA or ethanol
precipitation.
3. In this reaction up to 20 µg of RNA per µg linearized template DNA are synthesized (approx. 100-fold
transcription of insert). Scaling up the reaction volume and components, while keeping the amount of template
DNA constant can improve the yield of DIG-labeled RNA.
4. Probes up to 1200 bp in length penetrate the tissue effectively.
5. The alternative to precipitation would be the purification with Boehringer Quick Spin columns.
5. Estimating the yield of DIG-labeled riboprobe in a spot test with a DIG-labeled control
The dilutions of newly prepared DIG-labeled riboprobe are spotted on a positive nylon membrane together with the
corresponding dilutions of DIG-labeled control RNA of known concentration in order to appreciate the efficiency of the
labeling reaction.
5.1. Membrane preparation
1) Make a predilution of the DIG-labeled Control RNA (Boehringer, Cat.No.1585746) in H2O to a final concentration
of 20 ng/µl.
2) Make serial dilutions of the prediluted control, according to the following dilution scheme. Mix thoroughly
between dilution steps.
DIG-labeled Control RNA,
Starting Concentration
Total dilution Final concentration
(dilution name)
20 ng/µl 1:20 1 ng/µl (A)
1 ng/µl (dilution A) 1:200 100 pg/µl (B)
100 pg/µl (dilution B) 1:2,000 10 pg/µl (C)
10 pg/µl (dilution C) 1:20,000 1 pg/µl (D)
1 pg/µl (dilution D) 1:200,000 0.1 pg/µl (E)
0.1 pg/µl (dilution E) 1:2,000,000 0.01 pg/µl (F)
Highly diluted solutions of RNA in H2O are not very stable. Spots must be made immediately after preparing the
dilutions. Alternatively the RNA can be diluted in RNA dilution buffer (DMPC-treated water, 20xSSC and
formaldehyde, mixed in a volume ratio of 5+3+2) for greater stability.
3) Estimate the expected yield of in vitro transcription reaction1. Predilute an aliquot of the newly synthesized
experimental RNA probe to an expected final concentration of approx. 20 ng/µl.
4) Make serial dilutions of the prediluted experimental probe2, according to the scheme (table).
5) Spot 1 µl of the diluted controls (C-F) on a piece of nylon membrane.
6) In a second row, spot 1 µl of the corresponding dilutions of the experimental probe.
7) Fix the nucleic acids to the membrane by cross-linking with UV-light or by baking for 30 min at 120°C
(Boehringer Mannheim Nylon Membrane). Proceed with standard detection procedure.
1 Good estimation for the in vitro transcription reaction is 1:40 template:product ratio (in fact it often gives 1:100 and
even higher ratios). It means that if 1 µg of 3000 bp plasmid with 300 bp insert was used for probe preparation, the
actual template was at 100 ng in the reaction, and the reaction will result in 4 µg of riboprobe.
2 It is actually more useful to titrate the control RNA with lower dilution factor (for example, 2x) to have a more
representative scale as a marker to compare with experimental dilutions.
5.2. Detection procedure for a 100 cm
2
 membrane:
1) Rinse the membrane briefly (1-5 min) in washing buffer (100 mM maleic acid, 150 mM NaCl; pH 7.5; 0.3% (v/v)
Tween® 20).
2) Incubate for 30 min in 100ml 1x Blocking solution (1% Blocking reagent (Boehringer) solution in 100 mM maleic
acid, 150 mM NaCl; pH 7.5).
3) Dilute anti-DIG-AP 1 to 5000 in 1x Blocking solution. Mix gently by inversion. This solution is stable for about 12
h at 4°C.
4) Incubate the membrane for 30 min in 20 ml antibody solution.
5) Wash 2 times for 15 min with 50 ml washing buffer.
6) Equilibrate for 2-5 min in 20 ml detection buffer (100 mM Tris-HCl, pH 9.5; 100 mM NaCl).
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7) Add 45 µl NBT solution and 35 µl BCIP solution in 10 ml of detection buffer. This color substrate must be
prepared freshly.
or
Dilute CSPD
Ò  
(vial 5) 1:100 in the detection buffer (this solution can be reused 1-2 times within a month. Store in
the dark at 4°C).
In case of chemiluminescent detection continue with step 11.
8) Pour off the detection buffer and add the color substrate solution. Allow the color development to occur in the dark.
The color precipitate starts to form within a few minutes and continues for approx. 16 h. Do not shake while the
color is developing.
9) When the spots appear in sufficient intensity, stop the reaction by washing the membrane with TE buffer or sterile
H2O for 5 min.
10) Compare spot intensities of the control and experimental dilutions to estimate the concentration of the experimental
probe.
11) Place the membrane between two sheets of Saran wrap. Gently lift the top sheet and, with a sterile pipette, add
approximately 0.5-1 ml (per 100 cm
2
) of the chemiluminescent substrate on top of the membrane, scattering the
drops over the surface of the membrane. Lower the top sheet of plastic. With a damp lab tissue gently wipe the top
sheet to remove any bubbles present under the sheet and to create a liquid seal around the membrane. Incubate
filter for 5 min.
12) Let excess liquid drip off and blot the membrane briefly (DNA side up) on Whatman 3MM paper. Do not let the
membrane dry completely!
13) Envelop the membrane into the sheet of Saran wrap and incubate for 5-15 min at 37°C to enhance the luminescent
reaction.
14) Expose for 15-20 min at room temperature to X-ray or Polaroid b/w film. Multiple exposures can be taken
(luminescence continues for at least 24 h and signal intensity increases during the first hours).
6. In situ hybridization
6.1. Brain isolation and cutting:
1) Remove the brains.
2) Freeze rapidly in cold isopentane (methylbutane) on dry ice. After 5-10 min transfer the brains to clean 50 ml
Falcon tube.
3) Store dry at –70 to -80°C. Continue with 4).
alternatively (Tanimura et al., 1998)
1') Remove the brains.
2') Keep in ice-cold 4% paraformaldehyde for 2-4 days.
3') Freeze in dry ice-cold hexane (5-10 min). Store dry at -80°C.
4) Cut the brains on sections of 25 µm of desired orientation.
5) Dry out the slides with sections for at least 1 hr at RT and then store in tightly closed plastic boxes (Parafilm) with
Silicagel at –20°C. For in situ studies remove the slides from the boxes at –20°C (be aware of evaporation) or take
the boxes out of the freezer and keep them for 1 hr at RT prior to opening.
alternatively
6) Fix cut sections in freshly prepared 4% paraformaldehyde, ice-cold, for 10 min, wash in 1xPBS for 15 min, and
store in 70% EtOH at 4°C.
It may be important to proceed to the next steps of protocol immediately after cutting to keep rare transcripts intact in
cryosections.
6.2. Tissue treatment and hybridization (adapted from (Braissant and Wahli, 1998)):
6.2.1. Post -fixation:
1) Incubate the slides for 10 min in 4% paraformaldehyde.
2) Incubate twice for 15 min in 1xPBS with 0.1% active DEPC.
3) Wash for 10-15 min in 5xSSC.
6.2.2. Pre-hybridization:
Both pre- and hybridization are carried out in plastic boxes saturated with a 5xSSC / 50% formamide solution to avoid
evaporation.
1) Add 250 µl of hybridization buffer (50% formamide, 5XSSC) with 40µg/mL salmon sperm DNA (GibcoBRL,
Cat.No. 15632-011) per section.
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2) Grease covers to hybridization boxes, close firmly with parafilm (drying of sections during this step can lead to
substantial background!).
3) Incubate for 1-2hrs at 55-61°C (the same temperature as for hybridization) in hybridization oven.
6.2.3. Hybridization:
1) Prepare riboprobe working solutions at conc. 40-400 ng/ml. Heat probe mix to 80°C for 5 min.
2) Add 20µl of probe per section, cover with a square of parafilm. Again close the box firmly with parafilm and put in
oven at 55-61°C (depending on the particular probe) for O/N (4-40 hrs depending on transcript abundance).
6.2.4. Washings and detection:
1) 30min in 2XSSC at RT.
2) 1hr in 2XSSC at 65°C.
3) 1hr in 0.1XSSC at 65°C.
4) If needed (should be tested for each probe):
20min RNase treatment, 30µg/ml, at 30°C
wash 2x for 15min in 2XSSC at RT.
5) Equilibrate for 5min in Buffer 1 (Tris-HCl, 100 mM; NaCl, 150mM; pH 7.5).
6) Incubate for 2hrs at RT with 150µl/section of Buffer 2 (Buffer 1 + 0.5% Boehringer blocking reagent) with 5000x
dilution of antibodies (DIG or fluorescein).
7) Wash 2x for 15min in Buffer 1.
8) Equilibrate for 5 min in Buffer 3 (Tris-HCl, 100mM; NaCl, 100mM; MgCl, 50m ; pH 9.5).
9) Incubate with Buffer 3 along with 4.5µl/mL NBT, 3.5µl/mL BCIP (150µl/slide) in dark overnight up to several
days at RT.
10) Wash for 15min in 1XTE.
11) Wash for 1hr (up to O/N) in 95%EtOH (with gentle agitation).
12) Rinse for 15min in ddH2O.
13) Let air dry and use xylene (xylol) and Eukitt resin to place coverslips.
6.2.5. Useful tips
a) If nuclear staining is required, slides can be counterstained with DAPE.
b) Following steps must be normalized for each probe:
hybridization T° (55-62°C)
hybridization time (4-40 hrs)
probe concentration (40-1000 ng/ml)
coloration time (1 hr – several days)
RNase treatment (20-40 µg/ml, RT – 37°C).
c) The following controls are useful: no probe, RNase treatment prior to hybridization (after first DEPC incubation:
5x SSC, 5 min; RNase 50 µg/ml, 30 min at 37°C; continue with second DEPC incubation), probes to different parts
of the mRNA.
7. Quantitative RT-PCR
This protocol has been developed to perform quantitative RT-PCR on iCycler (Biorad). It is based on Perkin-Elmer
recommendations and protocols. The quantification of a target is calculated relative to an internal standard (28s rRNA)
to account for variability in the initial concentration and quality of the total RNA and in the conversion efficiency of the
reverse transcription reaction. The measure of SYBR Green fluorescence at the threshold cycle is used for
quantification of PCR products.
All cDNAs are prepared from 100 ng of total RNA, according to the Reverse Transcription protocol (§II.2).
Terms used:
Standard: cDNA prepared from total brain RNA (actually this can be any RNA of good quality, containing the sequence
of interest). It is used in the PCR at different dilutions, allowing for regression curve construction.
NTC: no template control. One can use water, or better cDNA prepared in the same conditions as standard, but without
the RTase.
Unknown: cDNA prepared from brain regions of interest at different experimental conditions.
Protocol:
1) Design primers using PrimerExpress software according to program instructions.
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2) Optimize primer concentrations: run PCR on any cDNA template with all combinations of forward and reverse
primers at 50, 300 and 900 nM, respectively. Choose the concentration giving the lowest threshold cycle and
highest end-product concentration.
3) Prepare cDNAs.
4) Prepare the plate configuration: e.g. use five standard dilutions, each 5x, starting from 4x dilution of initial RT. All
standards are run in triplicate. The unknown cDNA are diluted 10x, and are run in quintuplicate. These parameters
can be adapted depending on particular experimental needs.
One half of the plate is normally devoted to 28s rRNA, the second half to the primers specific for the gene of
interest. However, if rRNA values remain stable when the experiment is repeated, it may be not necessary to
include these reactions in each plate.
5) Prepare the dilutions of the standard.
6) Prepare 10x dilutions of NTC and of all unknown cDNAs.
7) Prepare MasterMix 2x, containing: PCR buffer, 2x; MgCl2, 6 mM; dNTPs each, 400µM; HotStarTaq, 2U/25 µl.
The HotStarTaq Polymerase as well as PCR buffer and MgCl2 solutions are from Qiagen (1000U, Cat.No.203205).
The mix can be stored at 4°C.
8) Prepare standard pool, containing: 2x MasterMix, 1x; SYBR 5x, 0.2x (SYBR Green I, 10000x in DMSO,
Molecular Probes, Cat.No.S-7563); forward and reverse primers, 50, 300 or 900 nM respectively. Final volume 45
µl.
9) Pipette 45 µl of mix into the plate wells, add 5 µl of corresponding cDNAs.
10) Adjust the mask (normally to be performed once during the iCycler installation) and calibrate the machine.
11) Program the iCycler. The quantities for the standards are chosen arbitrarily (e.g. Start with 100 ng, and then
continue according to dilution factor).
12) Run the following thermocycler profile:
Times and Temperatures
Each of 40 cyclesHotStarTaq
Activation Melt Anneal / Extend
HOLD CYCLE
10 min
95°C
15 sec
95°C
30-60 sec
60°C
13) Save and analyze the data. The analysis includes the standard curve calculation and the determination of unknowns.
The following parameters may be modified to obtain the best correlation coefficient:
a) Baseline cycles
b) Threshold
c) Number of data points used in the analysis
d) Wells included in the analysis.
14) Once the optimal values are obtained, transfer them to Excel to continue the calculations (normalization relative to
the internal standard, statistics, and graphical representation).
8. Ligation in Low Melting Agarose
If blunt-end ligation with PCR fragments is performed, it is necessary first to treat them with T4 DNA Polymerase in
order to remove the adenine, added during the PCR reaction. It is also advised to phosphorylate the PCR fragments
further with T4 polynucleotide kinase with parallel dephosphorylation of the linearized vector with calf intestine
phosphatase to increase the efficiency of ligation.
1) Separate the DNA restriction fragments on a "low melting" agarose gel with 1xTAE buffer and 0.5 µg/ml ethidium
bromide both in the gel and in the running buffer. Load ca 1µg of total DNA per lane (for a plasmid of 3 kb such as
an empty cloning vector, e.g. pUC, Bluescript) or proportionally more or less DNA for bigger or smaller DNAs. If
the concentration of the PCR fragments is not precisely known, it can be estimated by comparison to vector bands
on a preparative gel picture.
The important parameters in a ligation are:
the equimolarity of each DNA fragment
a concentration < 0.5 fmol/µl of each fragment
Assuming the presence of 1µg of a fragment of 3 kb (e.g. corresponding to 0.5 pmol of linearized cloning vector)
in an excised band of 100 µl volume, the contribution of 5 µl of melted agarose of this fragment into 50 µl end
ligation volume leads to a final concentration of 0.5 fmol/µl, so much as required; higher concentrations lead to the
formation of multimers, too low concentrations preferentially lead to intramolecular reaction (e.g. the vector
closing itself).
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2) Take a picture of the gel. Cut out the bands with a clean scalpel blade with the aid of a UV hand lamp or on the UV
transilluminator (don't expose too long to UV light) and transfer them into sterile ED tubes. Adjust the volume to
100 µl if needed.
3) Melt the excised DNA bands in the heating block at 65 ˚C (for higher percentage gels, e.g. 2%, it may be necessary
to increase the temperature by some degrees to completely melt the agarose), mix well with vortexer, quick spin
and keep in the heating block. Put the tubes with the prepipetted ligation buffer (5x T4 DNA Ligase Buffer,
GibcoBRL) and ddH2O in the heating block at 37 ˚C.
4) Prewarm each pipette tip in the water-containing ED tube at 65 ˚C aspirating up and down, pipette DNA fragments
where required into the tubes at 37 ˚C. The melted agarose will remain liquid until kept at this temperature.
5) While keeping the tubes at 37 ˚C, add 1-2 µl of T4 DNA Ligase (Gibco BRL, Cat.No.15224-017) at 0.2 U/µl or 1
µl of ligase at 1 U/µl (keep the enzyme in a cooling block (-20˚C)). Mix well, quick spin, incubate at 4 ˚C or RT for
few hours to O/N.
General rules:
Ligations with overhangs: 0-4 ˚C; 0.4 U ligase/ tube; 3-4 hours is enough. Ligations with only blunt ends:
temperature irrelevant for "hybridization"; 0.4 - 1 U ligase/tube; 3-4 hours at least. Ligations with mixed ends:
temperature gradient (put the tubes on ice in beaker and let them until the ice is completely melted); 0.4- 1 U
ligase/tube; O/N. If more than 5 fragments must be ligated simultaneously, higher concentration of ligase is
required (1 U/tube).
6) For transformation of bacteria: melt ligation again at 65 ˚C before pipetting 10 µl to an aliquot of CaCl2 competent
bacteria on ice (for transformation prot. see §II.9).
9. Transformation of bacteria:
1) For each DNA to be transfected into the bacteria prepare a ED-tube on ice. Prepare an additional ED-tube for the
transformation control (any vector, at 0.04 ng/µl).
2) Resuspend well the competent bacteria using a micropipette, distribute 100 µl (» 108 bacteria) in the precooled,
appropriately labeled ED-tubes, keep tubes on ice.
3) Add 10 µl of the corresponding plasmid DNA (ca 1 ng) or one third of the ligation mix (liquefy at 65°C if low-
melting agar) to the bacteria, mix well with the pipette (never use vortexer).
4) Incubate on ice for 5 min.
5) Put the tubes  for 3 min into a water bath at 37˚C ; let stand for ca 5 min on ice.
6) Pipette ca 1 ml of L-Broth medium prewarmed to 45˚C to the bacteria tubes. Close the tube and mix well (invert ,
don't vortex).
7) Incubate for 5 min in the water bath at 37 ˚C (mix occasionally). During this time bacteria will recover and start
synthesizing resistance genes. There should be no more than one duplication.
8) Spin down the bacteria in a ED-centrifuge (ca 30 seconds is necessary), aspirate all supernatant but ca 100 µl.
9) Resuspend the bacteria well. Plate them onto an appropriate agar plate.
10) Put the dishes turned upside down into a 37 ˚C incubator and incubate overnight.
10. SCOP (Single Colony Prep)-Assay
The aim of this protocol is to quickly analyze the size of plasmid DNA from a large number of transformed bacterial
colonies or streaks. This allows to identify the colonies carrying the recombinant plasmid DNA of the desired length.
The alternative method is analytical PCR on colonies with the primers flanking the insert.
1) Gently aspirate an entire colony or 0.5 cm length of a streak with 20 ml pipet e and resuspend in the LETR
(lysozyme, 2 mg/ml; EDTA pH 8, 100 mM; Tris pH 8, 50 mM; RNaseA, 0.1 mg/ml). Incubate for 20-30 min at
RT.
2) Add one drop of phenol to each tube, mix, centrifuge for about 3 min.
3) Take 5 ml supernatant and load onto gel together with comparative markers.
11. Minipreparation of DNA
This protocol allows to purify plasmid DNA from transformed small bacterial cultures.
11.1. Growth:
1) Inoculate with one bacterial colony or streak 5 ml LB medium supplemented with 100µg ampicillin (or other
antibiotic).
2) Grow the culture at 37°C in the shaker for 18-24 h (up to 36 h).
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11.2. Lysis & extraction:
1) Centrifuge the bacteria, resuspend the pellet in 400 µl of ice cold LETR (lysozyme, 2 mg/ml; EDTA pH 8, 100
mM; Tris pH 8, 50 mM; DNase-free RNaseA, 0.1 mg/ml). Mix well. Transfer into Eppendorf tube, Incubate for
20-30 min at RT.
2) Add 1 drop of 10% Triton X-100, mix gently. Incubate for further 5 min at RT (optional). Centrifuge for 10-15 min
at 13 kRPM.
3) Remove the pellet.
4) Extract 1x with phenol, 1x with phenol:chloroform 1:1, 1x with chloroform (400 µl each, transfer the aqueous
phase onto a fresh tube each time)
5) Adjust the volume to 400 µl with water, add 40 µl 3M NaCl and 240 µl isopropanol. Incubate for 10 min at RT.
6) Centrifuge for 10 min at RT at 13 kRPM.
7) Discard the supernatant, wash the pellet 1x 80% EtOH and 1x 100% EtOH. Let dry, resuspend the DNA in 100 µl
TE.
12. Plasmid Preparation
This protocol allows to purify plasmid DNA from transformed bacterial cultures of 100 ml. The amount of DNA
recovered should be 500-1000µg.
12.1. Growth:
1) Inoculate with one big bacterial colony or streak 100 ml LB medium supplemented with 10 mg ampicillin (or other
antibiotic).
2) Grow the culture at 37°C in the shaker for 18-24 h (better 36-48 h). Optional: to improve the yield let stand the
grown culture at 4°C for 24-72 hr.
12.2. Lysis:
1) Centrifuge the bacteria in a 100 ml tube at 3000-4000 RPM for 15-20 min at 4°C. The pellet can be stored at -20°C
in Falcon 50 ml tubes.
2) Resuspend the pellet in 6-7 ml of ice cold LETR (if frozen pellet is used, do not allow to thaw prior to LETR
addition): lysozyme, 2 mg/ml; EDTA pH 8, 100 mM; Tris pH 8, 50 mM; DNase free RNaseA, 0.1 mg/ml. Mix
well. Transfer into an Oak Ridge tube. Incubate for ~ 30 min at RT (the suspension should get slightly viscous).
3) Add 100 µl 10% Triton X-100, mix (2-3 strong strokes, rotate). The suspension should get very viscous. Incubate
for further 10-30 min.
4) Centrifuge at 10’000-15’000 RPM for 30-40 min at 4°C. Transfer the clear supernatant to a fresh corex tube or
another suitable tube for organic extractions.
12.3. Purification:
1) Extract 1x1 vol. phenol, 1x1 vol. phenol/chloroform and 1x1 vol. chloroform.
2) Adjust the volume to 7 ml. Add 0.7 ml 3M NaCl (3M NaOAc can also be used), add 4.2 ml isopropanol. Mix well,
incubate for ~10 min at RT and spin at 10’000 RPM for 15-20 min.
3) Discard the supernatant and rinse the pellet carefully with 80% ethanol and with 100% ethanol. Let dry.
4) Resuspend the pellet in 0.5-1 ml TE.
Note: For bigger cultures, scale up the volume of lysis, extractions and precipitation.
Table 2. Primers used in the present study
Name of primer Sequence
Oligo-dT Primers
DLPGG 5'-C ACT ATA GGG AAG CTT TTT TTT TTT GG-3'
DLPGA 5'-C ACT ATA GGG AAG CTT TTT TTT TTT GA-3'
DLPGT 5'-C ACT ATA GGG AAG CTT TTT TTT TTT GT-3'
DLPGC 5'-C ACT ATA GGG AAG CTT TTT TTT TTT GC-3'
DLPAG 5'-C ACT ATA GGG AAG CTT TTT TTT TTT AG-3'
DLPAA 5'-C ACT ATA GGG AAG CTT TTT TTT TTT AA-3'
DLPAT 5'-C ACT ATA GGG AAG CTT TTT TTT TTT AT-3'
DLPAC 5'-C ACT ATA GGG AAG CTT TTT TTT TTT AC-3'
DLPCG 5'-C ACT ATA GGG AAG CTT TTT TTT TTT CG-3'
DLPCA 5'-C ACT ATA GGG AAG CTT TTT TTT TTT CA-3'
DLPCT 5'-C ACT ATA GGG AAG CTT TTT TTT TTT CT-3'
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DLPCC 5'-C ACT ATA GGG AAG CTT TTT TTT TTT CC-3'
Oligo-dT Primer Sets
DLP1 5'-C ACT ATA GGG AAG CTT TTT TTT TTT VG-3'
DLP2 5'-C ACT ATA GGG AAG CTT TTT TTT TTT VC-3'
DLP3 5'-C ACT ATA GGG AAG CTT TTT TTT TTT VA-3'
DLP4 5'-C ACT ATA GGG AAG CTT TTT TTT TTT VT-3'
DLPG 5'-C ACT ATA GGG AAG CTT TTT TTT TTT GN-3'
DLPA 5'-C ACT ATA GGG AAG CTT TTT TTT TTT AN-3'
DLPC 5'-C ACT ATA GGG AAG CTT TTT TTT TTT CN-3'
Arbitrary Primers (last 10 nucleotides are arbitrary and vary in each primer)
XAp1 5'-ACA CTA TAG CTC GAG AGG TGA CCG T-3'
XAp2 5'-ACA CTA TAG CTC GAG TGG ATT GGT C-3'
XAp3 5'-ACA CTA TAG CTC GAG CTG ATC CAT G-3'
XAp4 5'-ACA CTA TAG CTC GAG TTT TGG CTC C-3'
XAp5 5'-ACA CTA TAG CTC GAG GGA ACC AAT C-3'
XAp6 5'-ACA CTA TAG CTC GAG AAA CTC CGT C-3'
XAp7 5'-ACA CTA TAG CTC GAG TCG ATA CAG G-3'
XAp8 5'-ACA CTA TAG CTC GAG TGG TAA AGG G-3'
XAp9 5'-ACA CTA TAG CTC GAG TCG GTC ATA G-3'
XAp10 5'-ACA CTA TAG CTC GAG GGT ACT AAG G-3'
XAp11 5'-ACA CTA TAG CTC GAG TAC CTA AGC G-3'
XAp12 5'-ACA CTA TAG CTC GAG CTG CTT GAT G-3'
XAp13 5'-ACA CTA TAG CTC GAG GTT TTC GCA G-3'
XAp14 5'-ACA CTA TAG CTC GAG GAT CAA GTC C-3'
XAp15 5'-ACA CTA TAG CTC GAG GAT CCA GTA C-3'
XAp16 5'-ACA CTA TAG CTC GAG GAT CAC GTA C-3'
XAp17 5'-ACA CTA TAG CTC GAG GAT CTG ACA C-3'
XAp18 5'-ACA CTA TAG CTC GAG GAT CTC AGA C-3'
XAp19 5'-ACA CTA TAG CTC GAG GAT CAT AGC C-3'
XAp20 5'-ACA CTA TAG CTC GAG GAT CAA TCG C-3'
Universal reamplification primers
XSP6 5'-GCT CTA GAT TTA GGT GAC ACT ATA GCT CG-3'
BT7 5'-GCG GAT CCT AAT ACG ACT CAC TAT AGG GAA-3'
Semaphorin-specific degenerate primers
DDK forward primer (Luo et al., 1995)
AA sequence
Nucleotide sequence
DDKYIFFF
5'-GAY GAY AAR ATH TAY TTY TTY TT-3'
DPY reverse primer (Luo et al., 1995)
AA sequence
Nucleotide sequence
DPYCAWD
5'-TCC CAN GCR CAR TAN GGR TC-3'
DPY/BamHI (DPY reverse primer + site BamHI)
Primer + BamHI site 5'-CG GGATCC CAN GCR CAR TAN-3'
Semaphorin-specific Display primers
Forward
XColl1 5'-ACA CTA TAG CTC GAG ACT TCT TCT T-3'
XColl2 5'-ACA CTA TAG CTC GAG TCC TGA AGG C-3'
Reverse
HColl3 5'-CAC TAT AGG GAA GCT TGT GGT GAA GA-3'
HColl4 5'-CAC TAT AGG GAA GCT TAT CTC CTC CA-3'
Primers used for differential display, semaphorin-specific RT-PCR and enriched differential display studies. For
particular use refer to METHODS section.
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III. RESULTS
1. Modification of primer design in differential
display (Annex I)
Numerous methods are currently available allowing for
simultaneous detection of gene expression changes in
several samples. The method of differential display
(DD) (Liang and Pardee, 1992) has gained a large
audience in past years. Its inherent simplicity makes it
preferable to older methods such as subtractive
hybridization. It has also a big advantage compared to
more recently developed microarrays, because it allows
for detection of differential expression of virtually all
mRNAs present in the cells independently of their
previous identification and cloning. Nevertheless, false
positives generated by the PCR step as well as
laborious identification of differentially expressed
genes remain a major drawback of the method.
Therefore we have decided to introduce two
modifications into the original DD protocol.
First, as proposed previously, we used longer primers
instead of the original 10-mers. This modification
integrates the principles of DD with those of arbitrarily
primed PCR (Welsh et al., 1992). Accordingly, PCR is
performed in two steps. Few initial low-stringency
cycles are followed by several high stringency cycles
favoring more specific hybridization in the PCR.
Second, we took advantage of increased primer length
to introduce additional elements into the primer
sequence aimed at facilitating reamplification, analysis
and cloning of the cDNA fragments. The 5' terminus of
the oligo(dT) primers and the arbitrary primers are
extended with about one half of the T7 and SP6 RNA
polymerase promoters, respectively. Universal re-
amplification primers harboring the complete cognate
promoter sequences will prime within these extended
constant regions. Thus, the final amplicon will contain
two functional RNA polymerase promoters allowing
for direct generation of sense and antisense riboprobes
for hybridization techniques such as Northern blot, in
situ hybridization or ribonuclease protection analysis.
This configuration allows us to vary the arbitrary and
the oligo(dT) portion in the initial PCR primers while
maintaining the same universal reamplification primer
pair. In addition, the same particular re-amplification
primer can be used for direct sequencing of all
reamplified cDNAs.
Finally, four restriction sites flanking the promoter
sequences are introduced into the final amplicon, thus
providing increased flexibility for cloning purposes.
The performance of the modified primers is illustrated
in the following paper (Brenz Verca et al., 1998) using
FTO-2B rat hepatoma cells. The induction of the
tyrosine aminotransferase gene expression by
glucocorticoids is used as a positive control to check
for the reliability of the new method.
2. Changes in gene expression upon cocaine
treatment
In order to examine the changes in gene expression in
the dopaminergic brain system upon acute cocaine
treatment, we used the modified DD protocol described
above (Section I, (Brenz Verca et al., 1998)). Rats
received four subcutaneous injections of 30 mg/kg
cocaine-HCl or saline every 2 hrs and were sacrificed
24 hrs after the last injection. The experiments were
performed in two sets. First, the RNA from three brain
regions, the nucleus accumbens (NAcc), the lateral
st iatum (LStr) and the hippocampus (Hipp) upon
saline- and cocaine- treatment respectively were
isolated and analyzed in parallel. This allowed us to
compare not only drug-induced changes, but also basic
differences between the regions. Then, a separate DD
was performed on the ventral tegmental area (VTA) of
saline versus cocaine-treated animals. Results, as well
as general observations about the types of genes found
in the screening, will be presented below.
2.1. Changes in gene expression in NAcc, LStr and
Hipp
Twenty arbitrary primers were used in combination
with twelve oligo(dT) primers. In order to reduce the
complexity of the DD pattern, the oligo(dT) primers
were combined into 3 sets of 4 primers, each set with
the penultimate 3’ nucleotide constant. Such sets
contain the primers which are more compatible in
terms of annealing temperature than sets with the last
3’ nucleotide constant, normally used in the majority of
DD protocols. The sets were called DLPG (DLP for dT
lower primer), DLPA, and DLPC, for respectively, G,
A or C as the penultimate 3’ nucleotide.
All PCRs were performed in triplicate starting from
independent reverse transcription (RT) reactions. The
initial PCR amplifications were run always with two
controls, by omitting either cDNA in the PCR reaction
or the RTase in the RT step. In both control reactions
no bands were visible (not shown), so the DD pattern
was determined by the primers and the cDNA
template, and not by autoannealing of the primers nor
by the amplification of remaining genomic DNA or
any other contaminating templates. Patterns of
expression were compared for RNAs isolated from the
NAcc, the LStr, and the Hipp of saline- or cocaine-
treated rats. The fragments found in DD did not exceed
600 bp, and those smaller than 100 bp were not
proceeded for further analysis in order to exclude all
possible degradation products from the screening
results.
2.1.1. Two sets of signals found in differential
display
The overall pattern of gene expression in the three
brain regions investigated can be assigned to two
distinct sets of signals (Figure 26):
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1) The predominant pattern (about 95%) displayed
gene expression at similar intensities in all three
regions in saline-treated brains. These signals were
often found at the same level on gels with several
primer combinations. In this case each band,
probably consisting mostly of house-keeping
genes, remained unchanged upon cocaine
treatment, except for one signal.
2) The second type of pattern displayed a different
basal level of expression for three or at least two
of the investigated regions, and there about half of
the candidates displayed changes in expression
upon cocaine treatment.
2
3
4
1
Hipp Acc LStr
s c s c s c
Hipp Acc LStr
s c s c s c
Primer combination 1 Primer combination 2 Figure 26. Examples of differential display patterns
found by comparing the three regions upon cocaine
treatment. Numbers at left are related to corresponding
bands on the gel. N 2 and 4 are the typical examples of
the first set of signals (see text for explanations): their
expression level is the same in all regions under basal
conditions, and remains unchanged upon cocaine
treatment. In addition, N2 is present with two different
primer combinations. N 1 and 3 are examples of the
second set of signals: their expression is detected by
one particular primer combination, the basal expression
level is different depending upon the region examined,
and their expression changes upon cocaine. s: saline, c:
cocaine.
This second set of signals, with a region-specific
pattern, was found with only 12 out of the 20 arbitrary
primers. Three particular arbitrary primers among these
12 were especially efficient in this respect, giving rise
to one half of such signals. This means that each
arbitrary primer has a different capacity to detect the
variations in expression, both region- and drug-
dependent. Eight out of the 20 arbitrary primers did not
reveal any differences in expression between the
various genes. Maybe for these 8 arbitrary primers the
experimental conditions were sub-optimal or their
structure less suitable for PCR in general, and thus they
amplified only highly abundant messages, e.g. house-
keeping genes present in all regions and hardly
modified by drug treatment. It is also conceivable
however that these 8 primers were highly efficient PCR
primers, allowing for the DD reach the saturation point,
when the detection of specific differences is
impossible.
Whatever the explanation, it is necessary to vary the
PCR parameters in order that all primers work
efficiently.
2.1.2. Analysis of differentially expressed signals in
the three brain regions
We analyzed in more detail 40 signals which display
differential expression in the three brain regions at least
in duplicate experiments. This analysis was performed
prior to the sequencing of particular candidates, and
was aimed at drawing general conclusions about the
patterns of gene expression in the different regions
prior and following the drug treatment. One of the
questions we addressed was whether the pattern of
gene expression may serve as a useful criterion for
d fining the morphological and functional identity of a
particular brain region. If it were the case, the two
regions of the striatum (NAcc and LStr) must possess
higher similarities in gene expression pattern compared
to an anatomically and functionally distinct region such
as Hipp. We found some general pattern in gene
expression among the different brain regions:
1. 19 signals were expressed in every region
examined (Figure 27A), but at different levels
depending upon the region. 20% of the signals
were expressed only in the Hipp. Conversely, no
signal was found exclusively in the NAcc.
2. The level of expression in the Hipp was different
from the NAcc and the LStr in about 80% of the
cases, whereas the level of expression in the last
two regions was the same in about half of the
cases (Figure 27B). In fact this observation
confirms our presumption that the gene expression
pattern may be a useful marker of a functional and
neuroanatomical identity of a particular brain
region.
3. The majority of signals were stronger in the Hipp
(60%) and weaker in the NAcc (80%) than in one
or both of the other regions (Figure 27C). The
latter was especially striking compared to LStr. In
all cases where differences between the NAcc and
the LStr were observed, only once was it stronger
in the NAcc.
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Figure 27. General features of region-specific gene
expression pattern in DD. A. Expression of 40
sequences with different levels of expression in three
brain regions. Each circle represents a particular brain
region. Overlaps between the circles contain the
sequences present in several regions at the same time.
The abundance of signals in each group is represented
by the intensity of the colors and numbers inside the
sections. Note that the largest group of candidates is
expressed in all three regions, and that the NAcc does
not contain a specific signal. B. Distribution of
candidates with similar level of expression between
regions. Each circle represents a particular brain region.
Overlaps between the circles show the number of
candidates with similar level of expression between two
or all three regions. Colors and numbers as in A. Note
that the total number is not 40, because in this case not
every sequence was analyzed, but every individual
difference between regions. C. Distribution of signals
regulated among two different regions. Each circle is
divided into two hemispheres where the number inside
the left half corresponds to the number of signals up-
regulated in the left-side region compared to the right-
side one. So, e.g. numbers in the upper circle indicate
that 25 signals were up-regulated in the Hipp compared
to the NAcc, and 7 signals were up-regulated in the
NAcc compared to the Hipp. Note that the majority of
signals is up-regulated in the Hipp and down-regulated
in the NAcc compared to other regions. Colors and
numbers as in A. Acc: nucleus accumbens.
Signals not modified by drug treatment are presented in
Table 3. The majority of differences were found with
DLPA set of oligo(dT) primers. The differential
expression of 12 candidates was confirmed in triplicate
DD experiments. Some of the candidates have been
sequenced. Only one fragment (No11 in the Table 3)
was homogeneous enough to be sequenced directly
without cloning. Highest homology was found to the
murine protein HP1-BP74. This protein is the mouse
homologue of the Drosophila heterochromatinic protein
1 (Le Douarin et al., 1996). It interacts with TIF1, a
mediator of ligand-inducible activation of the nuclear
receptor. The NAcc-specific expression of this factor
may reflect the region-specific control of transcription,
exerted at the level of the structure of the chromatin
template.
The remaining bands were cloned into pBSKS+, and at
least ten monoclonal plasmid preparations were
analyzed for each separate fragment. Restriction
analysis was then performed to assess the level of
sequence heterogeneity in each particular band.
Normally this analysis resulted in defining several
sequences present in one signal; however one, or rarely
two sequences were predominant, and these particular
clones were sequenced.
The analysis of sequences allowed also for evaluation of
the possible redundancy of signals, a major drawback
inherent to DD experiment. Sometimes the PCR product
may be generated by only one of the primers from the
oligo(dT)-arbitrary pair working on both sides of the
amplicon. We suspected this to happen in our DD,
because some of the bands appeared at the same level
on the gel and showed the same pattern of expression
ind pendently of the arbitrary primers used. However,
in all fragments analyzed upon sequencing we found
both primers present.
Five sequences (No12,clone44; 14,clone59; 15,clone52;
18,clone11 and 20 in Table 3) showed no homology to
any known sequences and seven other sequences (No7;
2,clone45; 13; 14,clone4; 15,clone60 and 18,clone6)
displayed faint homology to several bacterial, plant,
Dr sophila, or mammalian genes. The very low
homology does not allow a reliable identification of
these candidates. One candidate (No12, clone47) has
high homology with a rat EST clone, and another
(No17, clone65) displayed significant homology with
murine RON receptor tyrosine kinase, a member of the
hepatocyte growth factor receptor family. RON receptor
tyrosine kinase plays an important role in early mouse
development and mediates the activation of
macrophages, as well as apoptotic and growth signals
(Iwama et al., 1996; Muraoka et al., 1999). The
d fferential expression of RON receptor tyrosine kinase
in three brain regions examined may reflect their
differential susceptibility to apoptotic signals, leading to
region-specific neurodegeneration, a well-known and
largely unexplained feature of numerous brain
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pathologies. This, however, deserves additional
experiments.
An additional signal was expressed at higher level in the
NAcc compared with two other brain regions. This
pattern was not reproduced in triplicate experiments
convincingly enough, and for this reason the signal is
not mentioned in the table. However, it has been
sequenced and strong homology was found to cysteine
sulfinate decarboxylase, the key enzyme in taurine
biosynthesis (Eppler et al., 1999). Taurine is a sulfur-
containing amino acid that is found in abundance in
mammalian tissues, including the brain. Many
biological roles have been proposed for this amino acid,
including in oxidative stress and cytotoxicity, and its
differential expression in three brain regions could again
account for differential susceptibility to
neurodegenerative processes.
Table 3. Differential display 2nd set signals with only regional differences (not modified by cocaine treatment)
No XAp Size s-H s-Acc s-Str I II III Identification Homology%
DLPC
1 1 320 + - - - + + -
2 1 70 - - +++ + + + -
3 2 130 + ++ ++ + + + -
4 2 125 + ++ ++ + + + -
5 10 220 ++ - - + ? + -
DLPA
6 2 240 +++ + ++ - + + -
7 2 400 +++ + ++ + + + Mouse IgE-binding lectin gene exons 1-
4 (35)
Human DNA sequence from cosmid
L21F12, Huntington’s disease region
(42)
82 % (29/35)
77 % (34/44)
8 2 320 + - + ? + + -
9 6 320 ++ - ++ + + + -
10 6 550 ++ + + + + + -
11 6 260 - - + + + + M.musculus HP1-BP74 protein 77-86 %
(41/53-
105/122)
12 8 320 + - + + + + None (44)
E.coli xylose-proton symport gene,
complete cds and maltose transport
gene, 3’ end (45)
R.norvegicus cDNAclone UI-R-AO-aj-
b-07-0-UI 3’ (47)
70 % (39/55)
100 %
(292/292)
13 8 160 + - - + + + C.elegans cosmid Y51A2D (8) 88 % (31/35)
14 10 160 - ++ ++ + + + D.melanogaster DNA sequence (4)
None (59)
75 % (34/45)
15 12 460 + ++ ++ - + + None (52)
A.thaliana transcribed sequence (60)4 % (54/84)
16 12 110 - ++ ++ + + + -
DLPG
17 1 230 ++ - + - + + M.musculus mRNA for RON receptor
tyrosine kinase (65)
95 %
(182/191)
18 1 190 ++ - - ? + + C.acetobutylicum sigE and sigG genes
for sigma factor E and sigma factor G
(6)
None (11)
66 % (38/57)
19 6 120 ++ + ++ + - + -
20 13 280 + - - + + + None (40)
XAp is the arbitrary primer used in combination with particular DLP; s: saline, c: cocaine; H: hippocampus, Acc:
nucleus accumbens, Str: lateral striatum; I, II and III correspond to triplicate DD experiments; the number in parenthesis
in the column “Identification” corresponds to a particular clone or clones sequenced for each fragment (see text for
details)
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2.1.3. Analysis of signals modified upon cocaine treatment
We further focused on signals differentially expressed
upon cocaine treatment. We found 20 candidates with
expression modified upon cocaine, up-regulated in
60% of the cases in a region-specific fashion (Table 4).
The majority of the signals were identified with DLPA
set of oligo(dT) primers. Some representative DD gels
from these candidates are presented on Figure 28 and
Figure 29. In most cases the differential expression was
reproduced in triplicate experiments. One example of
reproduction of results is shown in Figure 28. It can be
clearly seen that both the overall pattern of expression
as well as the differential expression of three particular
fragments (No16-18 in Table 4) remained almost
identical in the two independent experiments. No1
(No16 in Table 4) is present only in the cAcc; No2
(No17 in Table 4) is up-regulated in both NAcc and
LStr upon cocaine treatment; No3 (No18 in Table 4) is
down-regulated in cHipp. Figure 29 shows the DD
experiment made with arbitrary primers XAp1,2,4 and
15 and DLPA set. No4 and 5 (No13 and 14 in Table 4)
are up-regulated in the Hipp upon cocaine treatment;
No6 (No11 in Table 4) is up-regulated in both cNAcc
and cLStr, No7 (No12 in Table 4) is over-expressed in
all three brain regions upon cocaine treatment and No8
(No19 in Table 4) is down-regulated in the cHipp and
the cNAcc.
sH cH cA sL cLsA
XAp10
sH cH cA sL cLsA
XAp10
1
2 2
3
3
A B
1
Figure 28. A and B: duplicate differential display experiments performed on cDNAs from three brain regions with
DLPA oligo(dT) primer set in combination with arbitrary primer XAp10. Differentially expressed band are indicated by
numbers. 1,2 and 3 correspond to N16,17 and 18 in Table 2, respectively. s: saline, c: cocaine, H: hippocampus, A:
nucleus accumbens, L: lateral striatum.
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XAp4
sHcH cA sL cLsA
XAp2XAp1
sHcH cA sLcLsA sHcH cA sLcLsAM
XAp15
sHcH cAsL cLsA
6
7
150
100
200
250
300
350
4
5
8
A B
Figure 29. Differential display experiments performed on cDNAs from three brain regions with DLPA oligo(dT)
primer set in combination with arbitrary primers XAp1,2,4 (A) and XAp15 (B). Differentially expressed band are
indicated by numbers. 4,5,6,7 and 8 correspond to N13,14,11,12 and 19 in Table 2, respectively. s: saline, c: cocaine, H:
hippocampus, A: nucleus accumbens, L: lateral striatum.
Seven fragments (No2,3,9,13,14,15 and 18 in Table 4)
showed changes in expression only in one region, five
of them (No2,3,13,14 and 18) in the Hipp. The
expression of thirteen other fragments was modified
upon cocaine treatment in several regions
simultaneously. Nine out of these 13 fragments
displayed a unidirectional (either up- or down-
regulation) change in all regions, for example No1 was
up-regulated in both NAcc and LStr. Four other
fragments (No5,7,10 and 16 in Table 4) display changes
in the Hipp which were opposite to the changes found in
one or both striatal subregions. For 7 fragments
(No1,4,6,10,11,12 and 17 in Table 4), i.e. one third of
the signals, the changes were simultaneous and
unidirectional in the entire striatum (NAcc and LStr).
We found 14 signals with a level of expression
modulated in the Hipp, even more than for the LStr or
the NAcc (No11 and 12 respectively).
From the analysis of gene expression patterns, as
described prior to sequencing in the Hipp and the
striatum, we could conclude that both the basal level of
gene expression and the type of changes in response to
cocaine treatment are similar in the striatum subregions
and distinct in the Hipp, suggesting that the gene
expression pattern is a valuable marker of a particular
brain nucleus.
One half of the band excised from DD gel could be
ef iciently reamplified and further processed for direct
sequencing or cloning. Only 3 fragments excised from
the gel (No11,14 and 16 in Table 4) were homogeneous
e ough and could be sequenced directly after
reamplification without cloning. The other fragments
were cloned and the clones were further classified
ccording to restriction analysis as described before for
region-specific fragments. Sequences were submitted to
Genbank for homology search and these results are
summarized in Table 4. The majority of differentially
expressed signals were identified with DLPC and DLPA
sets of oligo(dT) primers. Five fragments
(No10;11;13,clone30; 14;16 in Table 4) have strong
homology to known mRNA sequences, whereas five
clones (No12; 13,clone27; 15; 18 and 20) are
homologous to mammalian ESTs. One of the known
proteins, CD81, will be discussed in more detail later in
th  RESULTS, whereas the other known candidates and
their possible relevance in terms of drug action, will be
treated in the DISCUSSION section.
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2.2. Changes in gene expression upon cocaine
treatment in the tegmentum
A DD was performed with untreated and cocaine-
treated tegmentum according to our protocol with some
minor modifications. Poly(A) RNA was used instead of
total RNA for the reverse transcription reaction. DD
was performed in duplicate starting from two
independent reverse transcription reactions. Again
some arbitrary primers did not detect expression
differences. In both DD experiments no differential
expression was found with the arbitrary primers XAp
3,11,13,16 and 18.
We found 23 candidates whose expression was
modified upon cocaine, up-regulated in 7 cases (Table
5). The fragment size was in the range of 105-460bp.
All differences have been confirmed in duplicate
experiments except for No20. High heterogeneity was
found in each band isolated from the DD gel, however,
but one sequence was predominant for each signal (for
example, type I for fragment No1 or type II for
fragment No5). 15 fragments were sequenced, and
homology search was performed in Genbank. Results
are summarized in Table 5. Fragments No4/II,10,12,13
and 21 have strong homology to known sequences, and
will be discussed in more detail in the DISCUSSION
section. Fragments No2,4/I,8,9,14,16,17 and 19 are
homologous to ESTs or genomic sequences. In this
display we found a number of mitochondrial sequences
(No9,12,21 in Table 5). One of them (No12),
corresponding to NADH dehydrogenase subunit 6, has
already been described previously to be up-regulated
by cocaine self-administration in the same brain region
(Couceyro et al., 1997).
In some cases not only the up-regulated band but also
the corresponding piece of gel from the lane of
comparison were excised from the DD gel for the
reamplification. Both were subsequently cloned and
analyzed. This type of analysis however did not help,
as we expected, to distinguish between truly
differential signal and contaminating sequences present
at equal amounts in both conditions. In four cases
chosen for such analysis (pairs N1/2,4/5,7/8 and 21/22
in Table 5) we could not detect any clone absent in the
control lane which would be then considered for
sequencing. This is probably due to the reamplification
PCR reaction, which is made under conditions
permissive to achieve the saturation, so that even if the
differences were initially present in two bands, they are
not detectable anymore after this PCR.
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2.3. Identified genes regulated by cocaine treatment
Identified candidates, whose expression was modified
by cocaine treatment are summarized in Table 6. Five
fragments (No2,3,4,7 and 8) were up-regulated, two
fragments (No6 and 9) were down-regulated and two
fragments (No1 and 5) were either up- or down-
regulated depending upon particular brain region, by
cocaine treatment. Three candidates are transmembrane
proteins (No1,5 and 7), three others are mitochondrial
(N 3,8 and 9), two candidates are intracellular
molecules (No4 and 6) and for one protein (No2) the
localization has not been established so far.
Table 6. Identified genes regulated by cocaine treatment
N° Protein Changes in mRNA expression upon cocaine
treatment
1 Sodium bicarbonate cotransporter (NBC) Up-regulation in the Hipp, down-regulation in the
striatum
2 Neuronal olfactomedin-related protein or pancortinUp-regulation in the striatum
3 Cytochrome c oxidase subunit VIIc (Cox7c) Up-regulation in the Hipp
4 Guanine nucleotide-releasing protein or mss4 Up-regulation in the Hipp
5 Target of the antiproliferative antibody (TAPA-1) or
CD81
Down- egulation in the Hipp, up-regulation in the
NAcc
6 Pyruvate dehydrogenase E1 alpha form 1 subunitDown-regulation in the tegmentum
7 Ecto-apyrase Up-regulation in the tegmentum
8 NADH dehydrogenase subunit 6 Up-regulation in the tegmentum
9 Sensory neuron or g-synuclein Up-regulation in the tegmentum
10 Cytochrome c oxidase subunit III (Cox3) Down-regulation in the tegmentum
Some of the sequences were proceeded to further
analysis, e.g. quantitative RT-PCR and in situ
hybridization. Experiments with CD81 and g-synuclein
are described in the next chapters. In addition,
behavioral and neurochemical experiments with CD81-
KO mice have been performed. The possible relation
of other candidates to cocaine function are discussed in
the DISCUSSION section.
3. Confirmation of differential display findings
The steps between initial DD screening and subsequent
functional analysis of interesting candidates include the
necessary confirmation of results. The first step in any
case is the band reamplification. This can be followed
by cloning, restriction analysis and sequencing of the
fragments. It is not strictly indispensable at this point,
but facilitates substantially the subsequent analysis by
eliminating the irrelevant candidates. There are a
number of methods of confirmation of DD, which
corresponds to the general methods of RNA
quantification. Probably, the best method in terms of
sensitivity and reliability is Northern blot, however it
requires large amounts of RNA, an important limitation
for investigating gene expression in the brain. Other
methods include reverse Northern blot (dot blot,
microarray or plaque assay), RNase protection assay, in
situ hybridization and quantitative RT-PCR. All these
methods were tested in the present study with variable
success and will be discussed now.
3.1. Reverse Northern blot
Reverse Northern consists in applying the cDNA
fragments of interest (reamplification products or cloned
fragments in this case) on a solid support, in most cases
nylo  membrane or glass, followed by hybridization
with labeled total cDNAs pool of the examined tissue.
Clo es may be applied on the solid support by manual
pipetting on the nylon membrane (dot blot), transfer of
growing colonies from transformed clones onto the
nylon or nitrocellulose membrane (plaque assay) or
machine application of a tiny amount of cDNA on, for
example, glass membrane (microarray). In our work we
used both dot blot and plaque assay, with probes labeled
by incorporation of either radioactively or DIG-labeled
nucleotide in the reverse transcription reaction. In the
latter case chemiluminescent detection was performed
up  hybridization.
Sev ral problems were noted with this method, making
the interpretation of the results unreliable. First, and
major problem, a persistent and strong signal appeared
with the negative control (empty vector) in
hybridization. Very often the signal was virtually
indistinguishable from positive controls used for
normalization (beta-actin, GAPDH etc.). Clearly the
presence of such a signal casts doubt on any other data
from the same experiment. The second problem
concerned the high variability of signal intensities, with
no correlation to the known level of expression of a
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particular gene in the cell. This is an inherent problem
of the method, due to the fact that all experiments are
performed under a standard hybridization protocol,
independently of particular sequence requirement.
Finally, the method is not very sensitive. Therefore, the
method of choice in our study could be glass
microarrays, containing genes of interest, including all
signals found by DD as well as other candidates
potentially interesting in respect to drug addiction.
Membranes have been prepared in this way and will be
soon subjected to hybridization with fluorescent probes.
3.2. Ribonuclease protection assay
Ribonuclease protection assay (RPA) consists in the
hybridization of RNAs with a radioactively labeled
riboprobe prepared from the clone of interest. The
riboprobe contains an additional fragment, not related to
the sequence of interest (a fragment of the cloning
vector, for example). The hybridization is followed by
treatment with single-strand specific RNase which will
leave the hybrid undigested, resulting in the formation
of a protected fragment. The mixture is then separated
on polyacrylamide gel. The intensity of the protected
fragment band is analyzed by autoradiography and
corresponds to the relative concentration of the
fragment of interest in a particular tissue sample. The
method is highly specific, but very tedious, requires
high amounts of radioactive material, and a limited
number of samples may be processed simultaneously.
Probably the major problem that we faced with this
method, is its extreme sensitivity towards the quality of
the RNA used. The isolation of RNA from brain or
other tissue is more tricky compared to cultured cells,
because the RNA is instantaneously exposed to tissue
RNases and some degradation always occurs. So far, we
were not able to adapt RPA for confirmation of DD
results in brain samples.
3.3. In situ hybridization
In situ hybridization consists in hybridization of tissue
sections with radioactively or non-radioactively labeled
oligo- or riboprobes, followed by evaluation by light
microscopy. In our study we used DIG-labeled
riboprobe. This method has been particularly useful for
the description of the distribution of a particular signal,
but it is not suitable for quantification of the level of
expression. An additional step (compared to
radioactivity) includes incubation with antibody, which
must also be normalized. Radioactive in situ
hybridization is a suitable method among other methods
for RNA quantification, allowing for exact spatial
resolution of the signal, which is not accessible by other
methods. However, it is certainly not a method of
choice when screening of multiple candidates from a
DD, because it is laborious, requests a large amount of
animals for reliable statistical analysis of the results, and
requires careful interpretation of the data, including the
precise neuroanatomical identification of the brain
regions examined.
3.4. Quantitative RT-PCR
The quantitative RT-PCR is a method allowing for very
sensitive and reproducible quantification of a particular
probe. It consists in amplifying of fragment of interest
with sequence-specific primers in parallel with
amplification of a house-keeping gene as positive
control for the normalization of the results.
Quantification is performed either on the final amount
of the amplified product, or on the time-point when the
amplification passes a certain threshold (real-time
PCR). The first method is not very reliable for
quantification, whereas the second procedure was
virtually inaccessible for a long time for many
laboratories, given the high cost of fluorescent probes
used in the reaction. An adaptation of the method, using
the SYBR Green dye which specifically incorporates
into he double-stranded DNA sequences has been used
in our study to confirm the CD81 up-regulation in the
NAcc of cocaine-treated brain (see Section III.4).
4. Cocaine-induced expression of the CD81 in the
NAcc (Annexes II & III)
As mentioned before, CD81 was found by DD to be up-
regulated in the NAcc of rats following acute treatment
with cocaine and drug withdrawal. The message was
present neither in the NAcc of saline-treated animals nor
in lateral striatum at any condition. CD81 is a
tetraspanin transmembrane protein, known to be
expressed in astrocytes and involved in cell adhesion. In
the following paper we confirm our data by quantitative
real-time RT-PCR and describe the expression of CD81
in the adult rat brain (Annex II). Quantitative PCR was
performed with 28S rRNA as a positive control for
normalization. CD81 was up-regulated after cocaine
treatment with a 4.6 fold raise in the expression in the
NAcc.
By means of in situ hybridization, we showed CD81
expression in many glial structures (choroid plexus,
ependyma, glia limitans) in accordance to previously
p blished data (Sullivan et al., 1998). However we
coul  not confirm the exclusivity of such glial-specific
pat erns. Many groups of CD81-positive cells
(paraventricular hypothalamic nucleus (PVH),
supraoptic nucleus (SO) or diagonal band of Broca)
showed a pattern of staining that cannot be attributed to
g ial cells.
We also show the expression of CD81 in brain regions
functionally related to the regulation of cardiovascular
function and fluid homeostasis. The brain systems
regulating these functions include a sensory part
composed of the choroid plexus, the subfornical organ,
the vascular organ of lamina terminalis as well as the
median preoptic nucleus and a motor or effector part,
represented by the magnocellular, vasopressin- and
oxyt cin-secreting, cells of PVH and SO in the
hypothalamus. All these regions, as well as other
regions projecting to PVH and SO, including the bed
nucleus of the stria terminalis (BST), DB and medial
preoptic nucleus, were also positive for CD81.
In addition, CD81 showed similar brain distribution to
galanin, and, to a lesser extent, to vasopressin. The co-
distribution was especially striking in the magnocellular
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cells of the PVH and in the anterodorsal thalamic
nucleus. Interaction of CD81 with the Gal pathway
could alter dopaminergic responses and influence the
reward pathway. These findings, added to previous data,
suggest a connection between the brain reward
pathways and centers regulating endocrine and
autonomic functions, and may show a relation of the
neurochemical, behavioral and somatic consequences of
drug abuse.
The CD81 is known to form complexes with integrins,
which mediate probably all CD81 cellular effects. By
comparing our data with published results on brain
integrin subunits, we could conclude that CD81 could
interact with both a3b1 and a6b1 heterodimers, at least
in magnocellular neurons of the hypothalamus and in
the SO.
The second paper presents behavioral and
neurochemical data on CD81-knockout mice (Annex
III). The behavioral paradigms employed for the first
objective were locomotor activity (used to assess the
stimulant properties of the drug) and place preference
conditioning (used to assess the reinforcing efficacy of
the drug). The C57BL6 mice were used as controls in
all experiments.
In place preference experiments the animals received
the saline in the lined and the cocaine in the bare
chamber, respectively. Both before and after
conditioning their preference for the particular chamber
type was tested by measuring the relative time spent in
each chamber. Both male and female control mice spent
more time in the bare, cocaine-paired chamber, after
conditioning. This was not the case for CD81-deficient
males. However this difference was at least partially
smoothed by the fact that male mutant mice showed the
higher preference for the lined chamber before
conditioning as compared to wild-type littermates.
Female CD81-deficient mice did not display the
preference for the bare, cocaine-paired chamber, after
the conditioning, except for the first day of trials.
Male C57BL6 mice were more active than male CD81-
deficient mice following low doses of cocaine. When
the dose was increased, this difference in the locomotor
activity was no more evident. The results with female
mice are more difficult to interpret. Whereas the activity
curve of wild-type animals is very similar with the one
for male controls, CD81-deficient mice show a
decreased activity at 0.1 and 3 mg/kg of cocaine, highly
increased response upon the injection of 1mg/kg
cocaine and no changes upon the highest dose
administrated, 10 mg/kg.
Finally, neurochemical changes in CD81-deficient mice
brain were observed. In the NAcc of male knockouts, a
significant increase in the concentration of dopamine, as
well as dopamine metabolite DOPAC, was detected.
These changes were region-specific (no differences in
the LStr), neurotransmitter-specific (no changes in the
level of serotonin and its metabolites), and sex-specific
(no changes detected in female CD81-deficient mice for
any of parameters measured in the study).
These data demonstrate the importance of the CD81 for
cocaine action, and more precisely, its sex-specific
function in drug addiction. These observations are
consistent with previously discussed involvement of
CD81 in hypothalamic function, a brain structure mostly
responsible for the hormonal, sex-specific differences in
neuroendocrine regulation.
In ddition, very recently a series of experiments also
demonstrated the altered response of CD81-deficient
mice to amphetamine, both in regard to dopamine and
serotonin metabolism. These effects were again sex-
specific.
5. Cocaine-modulated expression of -synuclein in
the tegmentum (Annex IV)
Another candidate, rat sensory neuron synuclein, persyn
or g-synuclein, was also found by DD to be up-regulated
in the tegmentum of rats following acute treatment with
cocaine and drug withdrawal. This candidate displayed
a pattern of “all-or-none” regulation in the tegmental
area. The homology was found in the 3’ region of the
mRNA sequence, which is not included in the high
homology region defining the synuclein family, thus the
un-equivocal identification of the signal was possible.
Synucleins are small (120-140 aa) proteins sharing
structural resemblance with apolipoproteins (Clayton
and George, 1999). They belong to a family of four
members, a-, b-, g-synucleins and synoretin, from
which the g-synuclein is the most distinct member. It
lacks a conserved C terminal domain of a- andb-
synucleins and displays different spatial and temporal
expression, being distributed diffusely throughout the
cell body and axons, at least in peripheral neurons, and
not in the presynaptic terminal. g-synuclein stimulates
breast cancer invasion and metastasis (Jia et al., 1999)
and accumulates in axons of patients with Parkinson’s
disease or Lewy body dementia (Galvin et al., 1999).
This last feature makes g-synuclein a close relative to a-
synuclein, a protein involved in the pathogenesis of
several neurodegenerative diseases. For this reason we
investigated in more details the distribution of a-and g-
synucleins in the adult rat brain, with a view of better
understanding their respective functions.
In general a-synuclein displayed a very characteristic
pattern of expression, confined to specific nuclei,
whereas g-synuclein was more widely expressed
throughout the brain. The two proteins displayed a
complementary pattern of expression all over the cortex.
Both ependymal ventricular lining cells and the choroid
plexus were positive for g-, but not for a-synuclein. a-
synuclein was expressed mostly in olfactory areas,
whereas g-synuclein was more present in the basal
ganglia. Both mRNAs were present in the hippocampus
at a relatively high level. In both thalamus and
hypothalamus, very specific nuclei were positive for a-
synuclein, whereas g-synuclein was largely presented in
both regions. The signal in the paraventricular nucleus
was mostly confined to subsets of neurons involved in
the control of the autonomic nervous system. a-
synu lein expression is highly correlated with TH
expression, whereas the correlation was poor for g-
synuclein.
In conclusion, the two members of the synuclein family
showed a distinct distribution pattern, suggesting
distinct functions for these highly related proteins. In
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addition, g-synuclein modulation by cocaine opens new
insights on the correlation between the
neurodegenerative disorders such as Parkinson’s and
drug addiction, both related to the dopaminergic system.
However, very recent experiments with quantitative RT-
PCR did not confirm the original DD finding.
Therefore, the precise function of synucleins in cocaine
action needs to be further determined.
6. Changes in CART expression upon cocaine
treatment
We were interested to check whether other molecules,
known to be induced by acute cocaine, also display an
altered expression in our conditions. In our protocol
gene expression is measured 24 hrs after the last
injection, therefore we do not expect to find changes in
the expression of immediate early genes or related
molecules, which display a high, but transient, burst of
induction. On the other hand CART, a molecule related
to uroplasticity events in the DAergic system might
be regulated under our conditions. As a matter of fact in
situ hybridization revealed CART up-regulation in the
NAcc upon cocaine treatment (Figure 30). The signal is
particularly strong in the shell of NAcc.
saline cocaine Figure 30. Up-regulation of
CART in the NAcc of
cocaine-treated rats
7. Semaphorin cloning and targeted display
7.1. The identification of new members of rat
semaphorin family.
Nine identified candidates display changes in expression
after cocaine treatment (Table 6). In addition, two axon
guidance molecules, ephrin-B2 and Eph-A5, have been
described to be up-regulated by cocaine using the same
protocol of animal treatment as used in this study.
Therefore we became interested at investigating the
expression of other families of axon guidance molecules
in cocaine-treated brains, e.g. the semaphorins.
Semaphorins are a group of axon guidance molecules
(for reviews see: (Artigiani et al., 1999; Raper, 2000;
Yu and Kolodkin, 1999)) found in different organisms,
including drosophila, grasshopper, chicken and mice.
About 20 members of the family have been identified.
Despite the intensive efforts in cloning new members of
the semaphorin gene family, very little orthologues are
known for the rat. From 19 potential semaphorins (one
for each subclass) only four were identified in the rat at
the time of development of a semaphorin nomenclature
(1999). Therefore, we decided to clone new rat
semaphorins, using the method of targeted RT-PCR.
This method takes advantage of the presence of a highly
conserved Sema domain of 500 amino acids in each
family member (Figure 31).
1 2319
Sema domain
DDK
DPY
142 718
1613 17025’ 3’
Figure 31. The relative position of
Sema domain and semaphorin-specific
degenerate primers DDK and DPY
within the semaphorin sequence (this
example is for rat Sema3A (R-
SemaIII))
Briefly, two degenerate primers are designed within the
most conserved part of the Sema domain, based on
amino acid sequence. The degeneracy of a given
primer is determined by multiplying the number of
possible nucleotides at each position. Degeneracy at
the 3’ terminus are avoided, because single-base
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mismatches may obviate extension, and the last base of
the terminal codon is omitted. We have chosen the pair
of degenerate primers DDK and DPY previously used
for the cloning of avian semaphorins (Luo et al., 1995)
(Figure 31 and Figure 32). DDK and DPY primers
code for 8 and 7 amino acids respectively, and their
design matches all requested criteria. They were
initially designed based on conserved protein
sequences from two avian semaphorins. We performed
the amino acid alignment of the Sema domain of
different rodent semaphorins and we could establish
that DDK and DPY primers should be specific enough
for cloning of new rat semaphorins. The alignment as
well as primers nucleotide sequence are shown on
Figure 32.
mSema-A            -QNPSLRTEPHDSRWLN-EPKFVKVFWIPESENP---D DDKIYFFFRESAVEAAP 254
mSema-B            -SHPVLKTDIFLR-WLHADASFVAAIPS----------TQVV YFFFEETASEFD- 255
mSema-C            -SSRPTKTESSLN-WLQ-DPAFVASATSPESLGSPIGD DDKIYFFFSETGQEFE- 218
mSema-D            -DHHPIRTEQHDSRWLN-DPRFISAHLIPESDNP---E DDKVYFFFRENAIGGE- 255
mSema-E            -KRMQLRTDQHNSKWLS-EPMFVDAHVIPDGTDP---N DAKVYFFFKERLTDNN- 252
mSema-F            -TLPPLRTAQYNSKWLN-EPNFVSSYDIG----------NFT YFFFRENAVEHD- 241
mSema-F-like       -THHSIKTEYLAF-WLN-EPHFVGSAFVPESVGSFTGD DDKIYFFFSERAVEYD- 247
mSema-G            -SHSPLRTEYAIP-WLN-EPSFVFADVIQKSPDGPEGE DDKVYFFFTEVSVEYE- 243
mSema-H            -KLGHIRTEHDDERLLK-EPKFVGSYMIPDNEDR---D DNKMYFFFTEKALEAE- 256
mSema-VIa          -DSPTLRTVKHDSKWLK-EPYFVQAVDY--G-------- DYIYFFF REIAVEYN- 244
mSema-VIb          -DRPTLRTVKHDSKWFK-EPYFVHAVEW--G--------SHV YFFFREIAMEFN- 254
mCollapsin-1       -HHHPIRTEQHDSRWLN-DPRFISAHLIPESDNP---E DDKVYFFFRENAIDGE- 255
rCollapsin-III/1   -HHHPIRTEQHDSRWLN-DPRFISAHLIPESDNP---E DDKVYFFFRENAIDGE- 255
hSema-I            -HHHPIRTEQHDSRWLN-DPKFISAHLISESDNP---E DDKVYFFFRENAIDGE- 255
hSemaphorin-E      -KRNAVRTDQHNSKWLS-EPMFVDAHVIPDGTDP---NDAKVYFFFKEKLTDNN- 252
hSemaphorin-III    -KQTAMRTDQYNSRWLN-DPSFIHAELIPDSAE----N DDKLYFFFRERSAEAP- 255
hSemaphorin-CD100  -SHSPLRTEYAIP-WLN-EPSFVFADVIRKSPDSPDGEDDRVYFFFTEVSVEYE- 243
hSemaphorin-V      -QRPSLRTEPHDSRWLN-EPKFVKVFWIPESENP---D DDKIYFFFRETAVEAAP 255
gCollapsin-1       -HHHPIRTEQHDSRWLN-DPRFISAHLIPESDNP---E DDKIYFFFRENAIDGE- 255
gCollapsin-2       -DHHYIRTDISEHYWLT-GAKFIATFPIPDTYNP---D DDKIYFFFREISQDSS- 260
gCollapsin-3       -KRNAVRTDQHNSKWLS-EPIFVDAHVIPDGTDP---N DAKIYFFF KERLTDNS- 252
gCollapsin-5       -RMAHLRTEPDSEHLLK-EPKFVGSYMIPDNEDH---D DNKVYLFFTEKALEAE- 260
gCollapsin-3part   -------------------------------------- DDKIYFFFKERLTDNS- 16
gCollapsin-4part   -------------------------------------- DDKIYFFFTEVSVEYE- 16
dSema-I            ---EPLQTEQYDSLSLN-APNFVSSFTQG---------- DFVYFFFRETAVEFI- 225
dSema-II           LEYKFKRTLKYDSKWLD-KPNFVGSFDIG----------EYV YFFFRETAVEYI- 259
tSema-I            ---EPQRTELSDLKQLN-APNFVNSVAYG---------- DYI FFFYRETAVEYM- 228
CeSema             KSAANIRTQSYDARVLN-APNFVATFAY-----K-----EHVY FWFREIASEAID 248
mSema-A            ALGR-ACAECCLA-R DPYCAWDGS------ACTRFQPT---AK---------RRF 551
mSema-B            VYE--SCVDCVLA-R DPHCAWDPESR----LCSLLSGS--------------TKP 532
mSema-C            LYP--TCGDCLLA-R DPYCAWTGS------ACRLASLYQPDLA---------SRP 510
mSema-D            IYGK-ACAECCLA-R DPYCAWDGS------SCSRYFPT---AK---------RRT 553
mSema-E            IYGT-ACADCCLA-R DPYCAWDGH------SCSRFYPT---GK---------RRS 550
mSema-F            FHQ--TRSACIGA-Q DPYCGWDAVMK----KCTSLEESLSMTQWDQSIPTCPTRN 536
mSema-F-like       KYR--FCVDCVLA-R DPYCAWNVN------TSRCVATTSGRSG---------SFL 538
mSema-G            KHG--SCEDCVLA-R DPYCAWSPA------IKACVTLHQEEAS---------SRG 541
mSema-H            MYGS-ACADCCLA-R DPYCAWDGI------SCSRYYPTGAHEK---------RRF 559
mSema-VIa          RHG--KCKKTCIASR DPYCGWVRESG----SCAHLSPL---S----------RLT 552
mSema-VIb          LYS--GCMKNCIGSQ DPYCGWAPD-G----SCIFLRPG---T----------SAT 564
mCollapsin-1       IYGK-ACAECCLA-R DPYCAWDGS------SCSRYFPT---AK---------RRT 553
rCollapsin-III/1   IYGK-ACAECCLA-R DPYCAWDGS------SCSRYFPT---AK---------RRT 553
hSema-I            IYGK-ACAECCLA-R DPYCAWDGS------ACSRYFPT---AK---------RRT 553
hSemaphorin-E      IYGT-ACADCCLA-R DPYCAWDGH------SCSRFYPT---GK---------RRS 550
hSemaphorin-III    AYGA-ACADCCLA-R DPYCAWDGQ------ACSRYTAS---SK---------RRS 552
hSemaphorin-CD100  KHG--TCEDCVLA-RDPYCAWSPP------TATCVALHQTESP---------SRG 541
hSemaphorin-V      AHGR-VCTECCLA-R DPYCAWDGV------ACTRFQPS---AK---------RRF 552
gCollapsin-1       VYGK-ACAECCLA-R DPYCAWDGS------SCSRYFPT---AK---------RRT 553
gCollapsin-2       TYGK-ACADCCLA-R DPYCAWDGN------SCSRYAPT---SK---------RRA 558
gCollapsin-3       IYGT-ACADCCLA-R DPYCAWDGN------SCSRFYPT---GK---------RRS 550
gCollapsin-5       MYGT-ACADCCLA-R DPYCAWDGI------SCSRYYPTGMQAK---------RRF 562
gCollapsin-3part   IYGT-ACADCCLA-R DP-------------------------------------- 294
gCollapsin-4part   TYT--TCFDCVLA-R DPYCAW---------------------------------- 295
dSema-I            NDKITSCSECVAL-Q DPYCAWDKIAG----KCRSHGAPR-WLE---------ENY 538
dSema-II           RRYD-NCFRCVR--- DPYCGWDKEAN----TCRPYELD----------------- 538
tSema-I            SKT--RCKDCVEL-Q DPHCAWDAKQN----LCVSIDTV---TS---------YRF 523
CeSema             QQT--SCSKCVQL-Q DPHCDWDSSIARQVIVMSSLTPT---SL---------MWT 541
DDK amino acid sequence
    nucleotide sequence
  D   D   K   Y   I   F   F   F
5'-GAY GAY AAR ATH TAY TTY TTY TT-3'
DPY amino acid sequence
    nucleotide sequence
  D   W   A   C   Y   P   D
5'-TCC CAN GCR CAR TAN GGR TC-3'
Figure 32. Conservation of SEMA domain sequence for degenerate primers DDK and DPY. Highly conserved amino
acid sequences DDKIYFFF and DPYCAWD are shown in bold. The nucleotide sequences of the primers are given in
the table below the alignment.
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The cDNA was produced from total RNA extracted
from rat brain, and PCR resulted in a fragment of the
expected size of 900 bp. The specificity of the
amplification was assessed with negative controls,
where one of the primers was omitted (DDK). The
fragment was purified from preparative agarose gel,
treated with T4 DNA polymerase in order to remove
the adenosine nucleotide added during the PCR step,
p osphorylated with T4 polynucleotide kinase and
cloned into the pBSKS+ vector, restricted with EcoRV,
producing blunt ends. The transformation and plating
r sulted into 41 clones, which were proceeded for
further analysis. A first analytical restriction was
p rformed with BamHI and Eco0109I (Table 7).
Table 7. Restriction analysis of semaphorin clones 1-43
Clone number BamHI restriction, bp Eco0109I restriction, bp
1,8,12,14,30,32,33 600 and 100 300 and 150
2,4 250 and 150 400
3,38,40,43 - 400
5,13,15,17,19,25,26,31,34,41 - -
6 - about 10 fragments
7 - 1150, 700, 400 and 270
9,16,22,28 - 2100
18,23 500 and 300 550
20 - 3100,2000,1200 and 600
21 - 3000 and 700
24 1000 380, 250 and 100
27 260 550
29 900 380
35 - 400 and 250
36 600 and 100 330
37 - 650, 400 and 260
39 - 350
42 140 300
This primary analysis resulted in several patterns of
restriction. On this basis, a first potential group of
fragments, homologous in nucleotide composition, was
obtained (for example, No1,8,12,14,30,32 and 33 in
Table 7). A subsequent analysis with different
restriction enzymes gradually narrowed the number of
candidates to analyze and of resulting groups. Finally
14 different groups were identified. One or two clones
from each group were sequenced, and seven clones had
a significant homology with members of the
semaphorin family (groups I-VII in Table 8). Six
candidates were found with homologies to murine or
human members of the semaphorin family, whereas
one clone (group VII) had closest homology with the
avian semaphorin, G.gallus collapsin-2. No
mammalian orthologue of this semaphorin has been
identified so far. Seven other clones (groups II-XIV in
Table 8) did not carry any homology to semaphorins,
but in these cases only one primer (reverse
s maphorin-specific primer) participated in the PCR
reaction from both sides. Finally, a group-specific
restriction analysis was performed with each clone in
order to confirm the homogeneity of the putative
members of the same group.
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Table 8. Different sequences found by semaphorin-specific RT-PCR on rat brain tissue
Groups number Number of clones in one
group (based on
restriction analysis)
Identification
(new name in parenthesis),
Genbank Accession number
Score (bits) and
homology
I 8 (N°
1,8,12,14,30,32,33,36)
Mouse mRNA for M-sema F (Sema4C), S794631170: 790/857
(92%)
II 8 (N°
5,9,13,16,17,22,31,34)
M. musculus mRNA for semaphorin C
(Sema4B), X85992
1306: 802/847
(94%)
III 4 (N° 3,7,38,40) M. musculus mRNA for semaphorin IV, isoform
a (Sema3F), AF080091
1328: 816/864
(94%)
IV 1 (N°19) M, musculus mRNA for msemK1p (Sema7A),
AB017532
1279: 781/824
(94%)
V 5 (N° 2,4,18,23,27) M. musculus mRNA for semaphorin M-sema K
(Sema3E), Z80941
829: 564/612
(92%)
VI 3 (N° 29,35,37) M. musculus mRNA for semaphorin M-sema G
(Sema4D), U69535
1203: 783/845
(92%)
VII 1 (N° 26) G. gallus mRNA for collapsin-2 (Sema3D),
U28240
202: 315/386
(81%)
VIII 1 (N° 39) R. norvegicus mRNA for cytocentrin, U8262318: 110/110
(100%)
IX* 1 (N° 24) M. musculus mRNA for alpha glucosidase II
alpha subunit, U92793
868: 483/498
(96%)
X* 2 (N° 21,41) Genomic sequence from Mouse 4, AC002108331 (68-89%)
XI* 1 (N° 28) Human mRNA for adipsin/complement factor D,
M84526
154: 46/65 (70%)
XII* 2 (N° 42,43) M. musculus gene for Klotho and secreted
isoform of Klotho protein, exon 2, 3 and 4,
AB010090
237: 65/87 (74%)
XIII* 1 (N° 25) Drosophila melanogaster cytoplasmic dynein
intermediate chain gene
75 %
XIV* 1 (N° 15) Mouse BAC mbac20 from 14D1-D2 (T-cell
Receptor Alpha Locus)
96 %
*RT-PCR fragments with reverse semaphorin-specific primer from both sides
7.1.1. Classification of the cloned semaphorins
The semaphorin family comprises 7 classes. The first
two classes are found only in invertebrates, class 3
includes secreted semaphorins and classes 4-6
comprise the transmembrane family members. Class 4
contains an extracellular immunoglobulin domain and
a short cytoplasmic domain whereas the characteristic
feature of class 5 is the presence of seven
thrombospondin repeats. Class 6 contains the longest
cytoplasmic tail. Finally, class 7 also contains an
immunoglobulin domain as well as a GPI anchor.
Homology search served as a criteria to assign the
newly cloned semaphorins into a particular class. The
very high homology of groups I-VI (at least 92% at
nucleotide level) with murine semaphorins allowed for
unequivocal identification of the majority of the new
clones as rat orthologues of these classes. The highest
homology of group VII was with avian collapsin-2
(Sema3D), but it was not very pronounced (81%) and
did not allow for a more precise identification prior to
solation of complete cDNA. Human mRNA sequence
for SEMA3D was not identified so far, however, the
genomic sequence for Sema domain is known. On this
basis, we could reconstitute the putative human
SEMA3D Sema domain mRNA and amino acid
sequence and align it with group VII (not shown). 94%
homology at the amino acid level allowed us to
unmistakably identify the group VII as a true rat
Sema3D orthologue.
From this analysis we found that three novel rat
orthologues of class 3 semaphorins had been cloned,
on  of which is actually a new vertebrate Sema3D,
with a closest homology to avian SEMA3D or
C llapsin-2 (group VII in Table 9). This sequence has
been submitted to Genbank under Accession number
AF268594. We could also clone two new and one
previously identified rat orthologues of class 4 (group
II, partial cDNA sequence can be found in EST
sequences database) and one rat orthologue of class 7.
59
Table 9. Semaphorin family members
Class Chick Human Mouse Rat Zebrafish
Sema3A / SEMA3A1 C-Collapsin-1
(Coll-1)
H-Sema III (H-
Sema-D)
M-SemD
(M-Sema III)
R-SemaIII Sema-Z1a
Sema3B / SEMA3B H-Sema A, H-
Sema V
M-SemA
Sema3C / SEMA3C C-Coll-3 H-Sema E* M-SemE cDNA clone*
Sema3D / SEMA3D C-Coll-2* group VII* Sema-Z2
Sema3E / SEMA3E C-Coll-5 M-Sema H
(M-Sema K*)
group V*
Sema3F / SEMA3F H-Sema IV, H-
SEMA3F
M-Sema IVa* and bgroup III*
Sema4A / SEMA4A M-SemB
Sema4B / SEMA4B M-SemC cDNA clone;
group II
Sema4C / SEMA4C M-Sema F (Sem I,
M-Sema-F1)
group I
Sema4D / SEMA4D C-Coll-4 H-CD100 M-Sema G (Sem J,
M-Sema-G2)*
group VI*
Sema4E / SEMA4E Sema-Z7
Sema4F / SEMA4F H-Sema W M-Sema W R-Sema W
Sema4G / SEMA4G
Sema5A / SEMA5A M-SemF
(M-Sema-F2)
Sema5B / SEMA5B M-SemG
(M-Sema-G1)
Sema6A / SEMA6A M-Sema VIa
Sema6B / SEMA6B M-Sema VIb R-sema Z
Sema6C / SEMA6C M-Sema Y R-sema Y
Sema7A / SEMA7A H-Sema K1, H-
Sema L
M-Sema L,
M-Sema K1*
group IV*
The novel nomenclature is indicated in the left column, old names are given to facilitate the orientation in the literature
published before the unified nomenclature was adopted. 1 Rodent/Other vertebrates. Invertebrates as well as viral
semaphorins are not shown. Groups found in the present study are shown in bold. Asterisks mark the semaphorin
member with highest homology to a particular group. cDNA clone stands for partial cDNA sequence found in EST
sequence database.
7.2. Semaphorin-Specific Differential Display
7.2.1. The development of a new strategy
Current methods of targeted DD require the replacement
of arbitrary primers by targeted primers, specific for any
member of a gene family of interest. However, this
method is not suitable in all cases. One inherent feature
of DD is its bias towards fragments close to the 3’
region of mRNA. One of the primers (anchoring)
anneals to the polyA tail of mRNA, and the second one
should not be far from the first one in order to produce
short fragments (ca 200-600 bp) to be separated on a
sequencing gel. If the conserved domain of the given
gene family (like the Sema domain for semaphorins) is
situated far from 3’ mRNA end, this approach cannot be
used anymore. One possible solution is to replace the
oligo(dT) anchoring primer by the arbitrary or the
second targeted primer. The function of anchors in
oligo(dT) primers is achieved by one or two additional
nucleotides, present in 3’ end of the primers. This
design allows for separation of the total mRNA pool on
completely independent groups, according to the
anchoring nucleotides, and thus the possibility to cover
all possible mRNAs present in the cell is achieved.
When using two targeted primers in the display, this
feature is not maintained anymore. Therefore, based on
the previous method for DD, we developed an improved
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strategy for semaphorin-specific DD, designed in two
steps (Figure 33). The first step will be an RT-PCR
performed with semaphorin-specific degenerate primers
under the conditions used to find new semaphorin
family members (see §I.1.1). The resulting 900 bp band
will thereafter represent a mixture of various
semaphorins, and the ratio of each sequence in this
mixture will depend on particular experimental
conditions. The second step involves a second PCR, an
actual DD using sets of arbitrary or semaphorin-specific
primers, under conditions similar to those used for the
reamplification after DD ((Brenz Verca et al., 1998) and
METHODS section), i.e. few steps of amplification at
low-stringency conditions, followed by several cycles at
igh stringency. This strategy, designated “Enriched
Differential Display”, allows to enrich the template for
DD PCR reaction in sequences belonging to the gene
family of interest. In addition, it allows us to perform all
re ctions in agarose gel, thus facilitating the
manipulations, decreasing the time needed for the
xperiments and omitting radioactivity in the PCR.
N’V’AAAAAAAAAAAAn
N’V’AAAAAAAAAAAAn
N’V’TTTTTTTTTT
5’
5’
T12VN
dNTPs
Reverse Transcriptase
semaphorin-specific degenerate primers
dNTPs
Taq Polymerase
Purification of bands
arbitrary primers
Taq Polymerase
Semaphorin-specific
PCR amplification
Display by 2nd PCR
with arbitrary primers
control cocaine
900 bp
Agarose gel
Reverse
Transcription
control cocaine
900 bp
Agarose gel
Figure 33. Enriched semaphorin-specific differential display
7.2.2. The design of semaphorin-specific primers
The distribution of all semaphorin-specific primers within the Sema domain is depicted in Figure 34.
1 2319
Sema domain
DDK
XColl1 XColl2
HColl3 HColl4
DPY
142 718 731 857
1430 1613 17025’ 3’979
Figure 34. The relative position of Enriched Differential Display semaphorin-specific primers within the Sema domain
(this example is for rat Sema3A (R-SemaIII)).
To search for primers for semaphorin-specific Enriched
Differential Display, we aligned murine and rat
semaphorin sequences from Genbank database together
with our cloned new semaphorins from group III
(Figure 35). 10 nucleotides were chosen for two forward
and two reverse primers in regions of highest
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semaphorins homology and designated XColl1 & 2 and
HColl3 & 4 respectively. All four primers are located
within the part of the Sema domain, amplified by the
primers DDK and DPY (Figure 34). We were especially
concerned with the binding specificity at the 3’ terminus
of the primers. The highest specificity was achieved
with forward primers (XColl1 and XColl2) as compared
to reverse primers (HColl3 and HColl4). The non-
s maphorin “tail” of the primers was designed to
contain the restriction sites XhoI and HindIII and part of
SP6 and T7 promoters to enable the subsequent cloning
and reamplification with XSP6 and BT7 primers (Brenz
Verca et al., 1998). The sequences and structure of the
primers are shown in Table 10.
groupIII              - ACTTCTTCTTCCGA-GAG-CGC-CTGCAGA-------G 28
mSemaA                T ATTTCTTCTTCCGC-GAGTCCG-CTGTGGA-------A 962
mSemaB                T ATTTCTTCTTTGAG-GAGACAG-CCAGCGAG-----TT 826
mSemaC                T ACTTCTTCTTCAGC-GAGACGG-GCCAGGAG-----TT 650
mSemaD                T ATTTTTTCTTCCGA-GAAAATG-CAATAGG------CG 870
mSemaE                T ATTTCTTCTTCAAA-GAAAGAC-TGACTGACAACAATA 897
mSemaF                T ACTTCTTCTTCCGA-GAAAACG-CCGTGGAA-----CA 746
mSemaFlike            T ACTTCTTCTTCAGT-GAGCGGG-CAGTGGAG-----TA 836
mSemaG                T ACTTCTTTTTTACG-GAGGTAT-CCGTGGAG-----TA 785
mSemaH                T ACTTTTTCTTTACT-GAGAAGG-CGCTGGAGGCGGAGA 1378
mSemaVIa              T ACTTCTTCTTCAGA-GAAATTG-CAGTAGAA-----TA 801
mSemaVIb              T ATTTCTTCTTCCGG-GAGATCG-CCATGGAG-----TT 784
mCollapsin1           T ATTTTTTCTTCCGA-GAAAATG-CAATAGA------CG 797
rCollapsinIII/1       T ATTTTTTCTTCCGA-GAAAATG-CAATAGA------TG 760
XColl1 specific part   ACTTCTTCTT
groupIII              ACAAGTGGAGCGCAT TCCTGAAGGCACGGCT 138
mSemaA                ACAAATGGACCACAT TTCTGAAGGCGCGGCT 1078
mSemaB                AGAAGTGGACCACCT TCCTCAAAGCCCAGTT 937
mSemaC                AACGCTGGACCTCCT TTCTCAAGGCTCAGCT 761
mSemaD                ATAAATGGACAACAT TCCTAAAAGCACGCCT 982
mSemaE                ACAAGTGGACCACAT TCTTAAAGGCAAGACT 1003
mSemaF                ACACCTGGACTACCT TCATGAAGGCTCGCCT 854
mSemaFlike            AGAAATGGACGACGT TCCTGAAGGCTCGGTT 947
mSemaG                AAAAGTGGACCTCCT TCCTAAAGGCAGGCT 896
mSemaH                ACAAGTGGAGCACTT TCCTTAAAGCGCGGCT 1484
mSemaVIa              AGCAGTGGACATCTT TCCTGAAGGCTCGCCT 915
mSemaVIb              AGCAGTGGACTTCCT TCCTGAAGGCCCGGCT 898
mCollapsin1           ATAAATGGACAACAT TCCTAAAAGCACGCCT 909
rCollapsinIII/1       ATAAATGGACAACTT TCCTGAAGCACGCCT 872
XColl2 specific part                 TCCTGAAGGC
groupIII              T-GCTG TCTTCACCTCT-------TCA----GGCTC 264
mSemaA                T-GCTG TCTTCTCCACC-------TCC----AGTGG 1201
mSemaB                C-GCAG TCTTTACCTCCCAGTGG--CAGGTTGGCGG 1060
mSemaC                TCGGGG TCTTTACCTCCCAGTGGCAC-----AGAGG 890
mSemaD                T-GGAG TGTTCACAACA-------TCA----AGCAA 1108
mSemaE                T-GGCA TCTTCACCACA-------TCA----AGCTC 1129
mSemaF                T-GGTA TCTTCACCAC--------AATGTAAACAG 965
mSemaFlike            C-GGGG TTTTTCAAGCGCGATGGGGCG----ATATG 1071
mSemaG                T-GCGG TCTTCACCCACAGCTGAACA----ATGTG 1020
mSemaH                T-GGAC TGTTTAATACT-------ACC----AGCAA 1610
mSemaVIa              TGGCAAC CTTTTCCACA--------CCTTATAACAG 1035
mSemaVIb              TCGCTG TCTTCTCAACT--------CCTAGCAACAG 1018
mCollapsin1           T-GGAG TGTTCACAACA-------TCA----AGCAA 1035
rCollapsinIII/1       T-GGAG TGTTCACAACA-------TCA----AGCAA 998
HColl3 specific part        TCTTCACCAC
groupIII             ---GAAGAGCTCATG-------T TAGAGGAGTGGAGG-T 711
mSemaA               TCTGAAGGACTTCTC-------C TGGAAGAGCTGCAGG-T 1648
mSemaB               -----AGTGCTTATCTC-----G TGGAGGAGATTCAGC-T 1450
mSemaC               -----AGTCCACATC-------A TTGAGGAGCTGCAGA-T 1310
mSemaD               CTAGAAGAAGTTCTT-------C TGGAAGAAATGACCG-T 1555
mSemaE               AGTGGGGAACTCATC-------C TGGAGGAGCTGGAAG-T 1576
mSemaF               ----GGCAGCTGTTTG------C TGGAAGAGATGAGCTT 1377
mSemaFlike           -----GATCCACATG-------G TGGAGGACTGCAGG-T 1496
mSemaG               -----GGTGCATGTC-------A TCGAGGAGACCCAAC-T 1457
mSemaH               TG-GAGGAAGTCATT-------C TAGAGGACTTCAAA-T 2063
mSemaVIa             T--GGCAGCCTTTTC-------C TGGAGGAGATGAATG-T 1485
mSemaVIb             AGGGCCCAGCATCTTT------T TGGAGGAGTTTGAGA-C 1468
mCollapsin1          CTAGAAGAAGTTCTT-------C TGGAAGAAATGACCG-T 1482
rCollapsinIII/1      CTAGAAGAAGTTCTT-------C TGGAAGAAATGACAG-T 1445
HColl4 specific part                        TGGAGGAGAT
Figure 35. Alignment of 12 murine and 1 rat semaphorin sequences from the Genbank with the group III of our newly
cloned semaphorins . Only the fragments of entire alignment are shown containing the sequences chosen for the
Enriched Differential Display primers. Consensus sequences used for primer formulation are shown in bold below the
alignment.
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Table 10. Semaphorin-specific differential display primer sequences.
Forward primers (X stands for XhoI site):
XColl1: ACACTATAG CTCGAG ACTTCTTCTT
XColl2: ACACTATAG CTCGAG TCCTGAAGGC
Reverse primers (H stands for HindIII site):
HColl3: CACTATAGGG AAGCTT GTGGTGAAGA
HColl4: CACTATAGGG AAGCTT ATCTCCTCCA
Enriched Differential Display primer sequences chosen
based on the alignment of the nucleotide sequences of
14 rodent semaphorins. Semaphorin-specific sequences
are in bold, restriction enzyme XhoI and HindIII sites
are underlined, the rest of the sequences corresponds to
part of T7 or SP6 RNA polymerase promoters.
7.2.3. Preliminary results
Preliminary experiments of Enriched Differential
Display are shown on Figure 36. It can be observed
that the pattern of display is specific for a particular
primer pair, and some net differences can be seen
between saline- and cocaine- treated brains as well as
between different brain regions, as shown by arrows on
the figure. However the background varies in intensity
between several spots. This can be due to problems of
standardization (discussed later, §III.7.2.4). Only the
differences clearly distinct from the otherwise
homogeneous background should be chosen for further
analysis. Some differences are specific for only one
particular brain region (one candidate labeled in
XColl1-XAp1 was only obvious in the NAcc). Some
other fragments have shown parallel changes in two
regions simultaneously. For example, the XColl1-
XAp7 combinations yielded three fragments, down-
regulated in both the LStr and the Hipp (the two
brightest ones are indicated by arrows on Figure 36).
The combinations of two semaphorin-specific primers
yielded less differences than combinations of one
targeted and one arbitrary primer.
A very detailed analysis of semaphorin-specific
Enriched DD, based on these ideas and methodology
and on these preliminary data, has been the focus of
Dr. David AJ Widmer’s thesis, elaborated in our
laboratory and submitted and accepted at the Rutgers
University (August 2000). 58 fragments have been
found to be up- or down-regulated after acute cocaine
administration in eleven differential displays with
different combinations of primers. 46 of the
differentially displayed fragments were sequenced.
Several fragments represented different parts of the
same sequences. Of these, six were members of the
semaphorin axon guidance family, eleven had strong
homology to other molecules, and another thirteen
were novel gene sequences with no clear homology to
any Genbank records. All semaphorins were already
identified from the first experiment shown on Figure
36. However, not all changes could be reproduced in
duplicate/triplicate experiments and need to be
confirmed by other methods, such as quantitative RT-
PCR. The low reproducibility of the method as
compared to the standard DD, could be due to potential
problems discussed later (III.7.2.4. The more consistent
changes in semaphorin expression included Sema3D
and Sema4B up-regulation in the NAcc, Sema4D
down-regulation in the NAcc, and Sema5A over-
expression in the Hipp. The potential implications of
these findings in drug addiction studies is dealt with in
the DISCUSSION section.
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Figure 36. Enriched Differential Display on mRNAs prepared from different parts of cocaine- or saline-treated brains
with several combinations of arbitrary and semaphorin-specific primers
   XColl1-HColl3       XColl1-HColl4            XColl1-XAp1
 1 2  3  4 5  6  1 2  3  4  5  6 M 1 2  3 4  5  6
      XColl1-XAp2              XColl1-XAp4                  XColl1-XAp7
  1  2  3  4  5  6  1   2  3  4  5  6  M 1  2   3  4  5  6
1: sAcc
2: cAcc
3: sLStr
4: cLStr
5: sH
6: cH
s: saline
c: cocaine
Acc: Nucleus Accumbens
LStr: Lateral Striatum
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7.2.4. Potential drawbacks of the new method
Two potential problems can be stated in regard to this
method:
1. The identical starting amount of cDNA from the
sample and from the control, used for the first
PCR in the Enriched Differential Display, is an
absolute prerequisite for the success of the
method. Any variation in the initial cDNA
material will be exponentially amplified during the
2nd PCR reaction, i.e. the actual DD, and the risk
of false positives will substantially increase. All
reverse transcription reactions are performed with
the same amount of RNA, but the efficiency of
reaction as well as percent of cDNA recovered
after EtOH precipitation step may differ from tube
to tube and it is impossible to directly measure the
cDNA concentration by OD readings or
densitometric quantification on gel. Therefore, the
possible solution to this problem will be a careful
quantification of the cDNA template by
quantitative PCR technique with GAPDH or
another endogenous control.
2. The 1st PCR step should be as specific as possible.
In case of multiple PCR products at this step the
bands should be purified on gel, which again
implies variability in the starting material for the
2nd PCR reaction. The sources of such variability
are: products of variable sizes after the 1st PCR
(from 870 to 910 bp approx.) or variation in the
recovery during gel extraction or elution
procedures. Therefore an aliquot of the 1st PCR
reaction is used directly for the 2nd PCR. The
optimal dilution of this aliquot should be
determined in order to achieve the most
informative screening.
The required specificity of the 1st PCR could be
accomplished by a touch-down PCR program. The
annealing temperature is progressively diminished
at every 5 cycles of PCR. At the last cycles, when
the annealing temperature is low and thus
permissive for non-specific binding, the
concentration of primers available for annealing is
low, and a possible contamination remains
insignificant.
Another issue in the Enriched Differential Display
resides in choosing either arbitrary or semaphorin-
sp cific primers for the 2nd PCR. We have opted for the
second possibility, which may maintain semaphorin-
specificity allover the procedure, avoiding the
amplification of non-semaphorin sequences as
contaminants of the cDNA. Already during the RT-
PCR leading to new semaphorin members about 20%
of the sequences were non-semaphorins, due to the
limited specificity of the primers used in the reverse
transcription reaction. Semaphorin-specific primers in
the 2nd PCR from both sides will yield fragments of the
same length, so an ideal compromise resides in using
one semaphorin-specific primer and a second arbitrary
primer.
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IV. DISCUSSION
In this work the differential display study was
undertaken to find out the genes differentially
expressed in response to cocaine treatment in the
striatum, the hippocampus and the tegmentum of rats.
The screening resulted in 47 differentially expressed
fragments, ten of which have homology with mRNAs
of known proteins. In addition, CART up-regulation in
the nucleus accumbens (NAcc) was shown. These
observations add new data to previous knowledge
about gene expression upon cocaine treatment, in
particular in the protocol of early drug withdrawal
applied in this study, which previously resulted in
finding of ephrin-B2 up-regulation (Yue et al., 1999).
Two of the identified proteins, CD81 and g-synuclein,
up-regulated in the NAcc and tegmentum respectively,
have been studied in more detail, and two papers
extensively describe these studies. In this section we
will introduce the eight other candidates and discuss
their possible involvement in drug addiction.
1. Sodium bicarbonate transporter
We have found up-regulation in the hippocampus and
down-regulation in the entire striatum of the
electrogenic Na+/HCO3- cotransporter (NBC).
Bicarbonate transporters are the principal regulators of
pH in animal cells, and are expressed in the stomach,
pancreas, intestine, kidney, reproductive and central
nervous systems. The functional family of HCO3-
transporters includes Cl- -HCO3- exchangers, three
NBC isoforms, a K+/HCO3- cotransporter, and a Na+-
driven Cl- -HCO3- exchanger (Romero et al., 1997).
NBC is responsible for the transport of HCO3- across
the basolateral membrane in kidney, where
approximately 80% of the filtered load of HCO3- is
reabsorbed in the proximal tubule via a process of
active acid secretion. Cases of differential regulation of
NBC have been reported previously. For example,
NBC-1 is up-regulated in metabolic acidosis and K+
depletion and in response to glucocorticoid excess and
is down-regulated in response to HCO3- loading or
alkalosis (Soleimani and Burnham, 2000). NBC is
expressed in neurons, and especially in glial cells in the
brain and plays an important role in the regulation of
both intracellular and extracellular pH. NBC is
responsible for astrocyte vulnerability to acidic injury,
the factor contributing to stroke after cerebral ischemia.
The NBC expression profile in brains suggests that this
transporter is critical in later stages of brain
development, during the time of generation and
maturation of astrocytes (Giffard et al., 2000).
Interestingly, dopamine (DA) inhibits the NBC in renal
proximal tubules, the effect being mediated by D1
receptor signaling (Kunimi et al., 2000). Cocaine also
activates dopaminergic (DAergic) signaling via this
type of receptor, and thus may regulate the transporter
expression in this way. On the other hand, this could
also be a response of glial cells, the major cells
expressing the NBC, to cocaine action. In both cases
the modified NBC activity would necessarily influence
both the extracellular and intracellular pH of the
surrounding neurons, which in turn would affect their
excitability. This could be a new compensatory
mechanism involved in cellular response to drug
action.
2. Olfactomedin-related protein or pancortin
We have found increased expression in the striatum of
the olfactomedin-related protein, or pancortin, upon
cocaine treatment. Olfactomedin is a 57-kDa
glycosylated extracellular matrix (ECM) protein of
unknown function originally identified in the
amphibian olfactory neuroepithelium. The
olfactomedin homologues have been identified in fish,
frog, rat, mouse and human. The high evolutionary
conservation of its primary structure supports the
notion that olfactomedin has an important function in
the mammalian nervous system (Karavanich and
Anholt, 1998). Olfactomedin contains cysteines which
form disulfide-linked polymers that constitute the
primary architecture of the olfactory ECM. By analogy
to other ECM proteins of the nervous system,
olfactomedin may influence the maintenance, growth,
or differentiation of chemosensory cilia of olfactory
neurons (Yokoe and Anholt, 1993). The massive
production of olfactomedin and its striking deposition
at the chemosensory surface of the olfactory
neuroepithelium suggest a more specific role for this
protein in chemoreception (Snyder et al., 1991).
More recently, two independent groups have cloned
four olfactomedin-related proteins (in rat) or pancortins
(in mice, called pancortins for their massive expression
in the cerebral cortex) (Danielson et al., 1994; Nagano
et l., 1998). All members of this new family share a
common central region (Figure 37) and variable N- and
C-terminals.
Olfactomedin-related fragment
A
YB
Z
M
Figure 37. Schematic representation of
how the five pancortin cDNA blocks are
linked to generate the four transcripts
AMY, AMZ, BMY, and BMZ. Names
are given according to the nomenclature
proposed by the group who first
identified the proteins [Danielson, 1994
#161]
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The distinct mRNAs are generated from a single gene
by a tissue-specific and developmentally regulated
choice of two alternative 5’ ends (A or B). Alternative
splicing further generates RNAs with two different 3’
ends (Y or Z) of roughly equimolar concentrations.
The homology to olfactomedin is found in the Z region
of long forms, which also have the carboxy terminal
sequence KDEL, a functional endoplasmic reticulum
anchor sequence in Plasmodium falciparum (Danielson
et al., 1994; Munro and Pelham, 1987). However, the
homology to olfactomedin as well as the presence of
putative signal peptide sequences indicate that these
proteins are secreted. Later studies suggested the
possibility for A region-containing pancortins to be
extracellular proteins, conversely to B-pancortins
(Nagano et al., 2000). The pancortins are mainly
expressed in the olfactory bulb, the cerebral cortex and
the hippocampus. However, the distribution of
particular subunits in the brain, studied by in situ
hybridization in rat or mouse brain, remains a
controversial issue (Danielson et al., 1994; Nagano et
al., 1998).
It is difficult to propose a role for olfactomedin-related
proteins in cocaine action, because the function of
neither pancortins nor olfactomedin is clear. We know,
however, that the mRNAs of pancortins are unstable,
and therefore the level of protein should be regulated
transcriptionally. Pancortin has also been identified by
differential display, an RNA-biased method, as one of
the genes expressed in the pons during the neuronal
circuit formation period  (Nagano et al., 1998).
Different pancortins are differentially regulated during
development. This suggests a role in differentiation
and/or survival of neurons, probably by furnishing
them an appropriate extracellular environment.
Neuroplasticity changes in cocaine-treated brain need
also a specific extracellular environment, and the
expression of ECM proteins might be regulated
correspondingly. It is known that the migration of
DAergic cells in the embryonic mesencephalon
depends upon ECM cues like tenascin (Kawano et al.,
1995), and the secretion of DA is facilitated in cells
grown on ECM substrate (Bethea, 1987). Moreover,
tenascin-knockout mouse display a paradoxical
behavioral response to apomorphine (Fukamauchi et
al., 1997), favoring the idea of a role of ECM
molecules in DAergic system both in developing and
adult brain.
3. Metabolic enzymes
We have found four fragments, two of them encoded
by the mitochondrial genome, homologous to
metabolic enzymes:
1) Pyruvate dehydrogenase E1 alpha form 1 subunit,
down-regulated in the tegmentum;
2) NADH dehydrogenase subunit 6 (mitochondrial
genome), up-regulated in the tegmentum;
3) Cytochrome c oxidase (Cox), subunit III
(mitochondrial genome), down-regulated in the
tegmentum;
4) Cox, subunit VIIc, up-regulated in the
hippocampus.
The pyruvate dehydrogenase complex is an assembly
of three enzymes, catalyzing the oxidative
decarboxylation of pyruvate to acetyl CoA. The E1
component of the complex is the pyruvate
decarboxylase subunit itself. NADH dehydrogenase
and Cox belong to different mitochondrial membrane
complexes involved in oxidative phosphorylation
(Wallace, 1992). The electrons of NADH enter the
respiratory chain at NADH dehydrogenase, a large
enzyme consisting of about 25 polypeptide chains. Cox
is the terminal enzyme in the respiratory chain and is
l cated in the inner membrane of mitochondria. It
catalyses the reduction of dioxygen to water and pumps
an additional proton across the membrane. The
resulting electro-chemical gradient is used in the
synthesis of ATP (Hofacker, 1999). Cox of mammals
is found in a dimeric state, with each monomer
c ntaining thirteen subunits. Genes for subunits I, II,
and III, which represent the catalytic core of the
enzyme, are encoded by mitochondrial DNA. The
remaining ten, smaller regulatory subunits, are encoded
by nuclear DNA (Lenka et al., 1998). Some
Alzheimer’s patients have a missense mutation in the
mitochondrial genes for Cox. The mutation appears to
cause a decrease in the enzyme activity and a
corresponding increase of reactive oxygen species
(ROS) which leads to cell death. Cox also affects
a gregation of beta-amyloid peptide in Alzheimer's
disease’s associated plaques (Scott).
The regulation of NADH dehydrogenase subunit 6 in
 mesoaccumbal DAergic system by cocaine has
been reported previously (Couceyro et al., 1997).
These changes correlate with other known cocaine
effect on metabolism, i.e. alteration of 2-deoxyglucose
uptake (Table 11) (London et al., 1990). Both 2-
deoxyglucose uptake and NADH dehydrogenase
xpression are diminished by cocaine self-
administration in the NAcc. At the same time, enzyme
expression is up-regulated in the tegmentum, which
may account for the adaptive response of the DAergic
neurons.
Methamphetamine administration produces selective
damage to DAergic nerve terminals, which is due to
the release of DA from synaptic vesicles within the
terminals, allowing the generation of ROS via DA
metabolism (Wei et al., 1997). The possible
neurotoxicity of cocaine is still debated, but its
hepatotoxic effect is associated with increased
mitochondrial generation of ROS (Boess et al., 2000),
which preferentially damage the pyruvate
dehydrogenase and Cox complexes (Gibson et al.,
1998). This would account for their decreased
expression in the tegmentum following cocaine
treatment (Table 11). It is more difficult however to
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explain the over-expression of several Cox subunits in
the hippocampus and the striatum (Table 1). Again this
could be an adaptive, neuroprotective response to over-
stimulation of neurons. The down-regulation of Cox
subunit VIIc has been associated with apoptotic
processes in macrophages (Ragno et al., 1998).
Otherwise, the discrepancies in metabolic enzyme
responses on drug treatment can be explained by
differences in the protocols used in different studies
(Table 11). For example, both acute high dose and
chronic metamphetamine treatments resulted in
decrease in Cox in the striatum and substantia nigra
(Burrows et al., 2000; Prince et al., 1997), as opposed
to the data mentioned in the Table 11.
Table 11. Changes in brain metabolism induced by cocaine treatment
Enzyme / brain region Hipp NAcc LStr VTA5
Pyruvate dehydrogenase ß1
NADH dehydrogenase ß2 ß2 no changes2 Ý1,2
Cox subunit I
subunit III
subunit IV
subunit VII Ý1
Ý3
Ý3
Ý3
Ý3 no changes3
ß1, no changes3
no changes3
2-DG uptake ß4
Changes in brain metabolism induced by cocaine treatment are presented here as assessed by measures of metabolic
enzymes expression or 2-deoxyglucose (2-DG) uptake. Ý and ß indicate increase or decrease of corresponding
parameters, respectively. 1differential expression found in the present study; 2NADH dehydrogenase expression upon
cocaine self-administration (Couceyro et al., 1997); 3cytochrome c oxidase (Cox) expression upon 2 weeks passive
administration of cocaine (Walker and Sevarino, 1995); 42-DG uptake upon cocaine self-administration (Hammer et al.,
1993); 5in the present study the entire tegmentum was analyzed. Hipp: hippocampus, NAcc: nucleus accumbens, LStr:
lateral striatum, VTA: ventral tegmental area.
It is clear from previous as well as from the present
study that cocaine interferes with brain metabolism. It
is still unknown whether these changes represent a
general effect of drug treatment, or more specific
phenomenon related to drug reinforcing action. In
addition, the particular involvement of Cox in this
process may correlate with cocaine effects on increased
production of ROS, impairment of mitochondrial
function and apoptosis.
4. Mss4
A signal transduction molecule, which was found in
the present study to be over-expressed in the
hippocampus upon cocaine treatment, is the guanine-
nucleotide-releasing factor (GRF) mss4. The
involvement of the hippocampus in drug addiction has
not been discussed so far, however there is a
substantial amount of data illustrating this
phenomenon. For example, cocaine-exposed offspring
exhibit consistent hippocampal abnormalities as adults
(Baraban et al., 1999). Intrahippocampal injections of
morphine is rewarding. The most robust reward
appears to be in CA3 region, an area rich in opiate
receptors and endogenous opiate peptides. Mu-type
receptors, linked to postsynaptic Gi proteins, seem
particularly important for this effect (Bardo, 1998).
Chronic administration of cocaine was associated with
increases in nitric oxide synthase activity in the
hippocampus (Bhargava and Kumar, 1997). In
addition, repeated cocaine administration down-
regulated glucocorticoid receptors in the rat brain
cortex and in the hippocampus (Budziszewska et al.,
1996). Cocaine-induced activity increases in many
regions of the brain, including the striatum, the basal
forebrain, the hippocampus and the ventral tegmentum
a  measured by functional MRI (Breiter et al., 1997).
Th  effects of cocaine in the hippocampus may be
related either to general effects of the drug on brain
function or to more specific interference with
hippocampal activity. The hippocampus is a structure
which plays a major role in the processes of memory.
Cocaine also interferes with memory processing in the
brain by influencing both the reinforcement and
associative types of learning. Not surprisingly,
exposure to cocaine self-administration environment
enhanced Fos expression in the hippocampal CA1
region, dentate gyrus and NAcc, even without the
associated injection of cocaine (Neisewander et al.,
2000). The mechanism of cocaine action may be due to
the sustained enhancement of AMPA receptor- and
NMDA receptor-mediated currents induced by DA
D1/D5 receptor activation in the hippocampus (Yang,
2000). In addition, DA may facilitate the acetylcholine
release in the hippocampus, thus regulating
hippocampal cognitive processes (Imperato et al.,
1993). DA agonists have strain-specific action on
hippocampal acetylcholine release in mice and on
memory consolidation (Imperato et al., 1996). Cocaine
is also able to block the induction of LTP at the
excitatory synapses in the CA1 region of the
hippocampus independently of NMDA receptors or
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channels (Smith et al., 1993). Both repeated and acute
cocaine administration decreased the Goa mRNA level
in the CA3 region and increased it in the CA1 at
various time points. Furthermore, in all hippocampal
regions, acute, but not chronic, cocaine administration
increased the Gsa mRNA level at 24 h, whereas
chronic treatment significantly decreased that level 48
h after the last dose (Przewlocka et al., 1994). This last
finding is of particular relevance here, because changes
in synaptic plasticity, ultimately leading to changes in
long-term memory, involve the regulation of G-
proteins. The stimuli that evoke plasticity induce the
mRNA encoding for a member of the regulator of G-
protein signaling (RGS) family, RGS2, in neurons of
the hippocampus, the cortex, and the striatum (Ingi et
al., 1998). Ras subfamily of small G-proteins have
been implicated in synaptic function and region-
specific learning and memory functions (Kawasaki et
al., 1998). Mice that lack the Ras-GRF, have severely
impaired LTP in the amygdala and a corresponding
deficit in long-term memory for aversive events (Orban
et al., 1999). Mss4 is a GRF for the Sec4/Ypt1/Rab
family of small G-proteins involved in the regulation of
intracellular vesicular transport (Muller-Pillasch et al.,
1997). It interact with Rab3a, a small G-protein mainly
expressed in neural and endocrine cells which might
regulate exocytosis (Darchen et al., 1995).  The Rab3a
plays a role specifically in the recruitment of synaptic
vesicles for exocytosis during repetitive stimulation
(Geppert et al., 1994). Mss4 also regulates rab8 which
plays a role in membrane trafficking during neuronal
process outgrowth (Huber et al., 1995). Finally, mss4
binds to cytoplasmic domains of a-integrin, and may
therefore provide the link between ECM, integrins and
intracellular messenger cascades (Wixler et al., 1999).
The up-regulation of mss4 in the hippocampus might
therefore reflect the implication of cocaine in memory
processes. The multiple interaction pattern of mss4
with other proteins suggest different mechanisms for
this phenomenon, including the release of
neurotransmitter, neuronal process outgrowth and
integrin-dependent cellular events.
5. Ecto-apyrase
Nucleotides such as ATP, ADP, UTP or the
diadenosine polyphosphates are extracellular signaling
substances in the brain and in other tissues. Enzymes
located on the cell surface catalyze the hydrolysis of
these compounds and thus limit their spatio-temporal
activity. In nervous tissue nucleoside 5'-triphosphates
are hydrolyzed by ecto-ATP-diphosphohydrolase
(ecto-apyrase) and possibly also by ecto-nucleoside
triphosphatase and ecto-nucleoside diphosphatase
(Zimmermann, 1996). We have found the ecto-apyrase
expression to be increased in the tegmentum upon
cocaine treatment.
Cocaine exerts its action in the tegmentum, essentially
in the VTA, both directly and indirectly, through the
NAcc neurons. The increased synaptic levels of DA in
the NAcc activates a long-loop negative feedback
pathway to the VTA involving both D1 and D2
postsynaptic receptors (Rahman and McBride, 2000).
However the inhibitory effects of cocaine on VTA
neurons are relatively weak and may represent a poor
compensatory response to enhanced DA
neurotransmission within the NAcc. This may explain
the extremely potent rewarding effects of cocaine
(Einhorn et al., 1988). In addition, the D1 receptors of
the VTA are selectively involved in behavioral
sensitization induced by intra-VTA injections of D-
amphetamine (Bjijou et al., 1996). The direct effect of
cocaine in the VTA includes blocking the reuptake of
DA released from the dendrites of the A10 DA
neurons, thus prolonging the actions of DA at D2
autoreceptors (Cameron and Williams, 1994). The
uptake of DA as well as other catecholamines into
synaptosomes is potentiated by ATP in a dose-
d pendent manner (Cao et al., 1990). The similar effect
could happen i vivo as a compensatory reaction to
inhibited DA reuptake, and therefore explain the up-
regulation of ecto-apyrase, needed to metabolize the
excess of extracellular ATP. It was shown that
DAergic principal neurons of the VTA do not possess
somatic P2 purinoceptors present on peripheral and
central noradrenergic neurons (Poelchen et al., 1998).
However, the effect of ATP on DAergic neurons was
examined in the absence of the drug. Cocaine treatment
could therefore activate the ATP signaling in the VTA,
and our finding of all-or-none expression of ecto-
apyrase strongly favors this hypothesis.
6. Semaphorins
In the present study we found one new vertebrate
member of the semaphorin family, with a closest
homology to avian SEMA3D, and five novel rat
orthologues of class 3, 4 and 7 semaphorins. In
addition the method of Enriched Differential Display
was developed in order to perform the screening for
differentially expressed members of the semaphorin
family. The subsequent application of this method in
our group (Widmer, 2000) resulted in the finding of
semaphorin differential regulation in various brain
regions upon cocaine treatment. Namely, Sema3D and
Sema4B were up-regulated, whereas Sema4D was
down-regulated in the NAcc, and Sema5A was over-
expressed in the hippocampus. Sema3D is a guidance
cue for the midline crossing of axons and for the
elongation and synapsing of retinal axons in the avian
optic tectum (Luo et al., 1995). Sema4B and Sema4D
are both guiding molecules, one for the olfactory
neurons invading the olfactory bulb, and the other for
th  immature thymocytes to the medulla of the thymus
r spectively, during development (Tamagnone et al.,
1999; Williams-Hogarth et al., 2000). Finally, Sema5A
is a transmembrane protein, possibly acting as a
permissive cue for growing axons (Adams et al., 1996).
Its cytoplasmic location was mapped to the deletion
related to Cri-du-Chat syndrome (Simmons et al.,
1998). The involvement of multiple semaphorins in
cocaine action suggests the activation of a complex
program of synaptic rearrangements induced by the
drug, which may recapitulate the plastic changes
occurring during development in terms of mechanisms
and of the molecular players involved.
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In conclusion, we found several genes, differentially
regulated in several regions of the rat brain in response
to cocaine treatment. The proteins for which the
mRNAs found are coding, display a high range of
functional characteristics, illustrating the complexity
and the variability of neuroplastic changes induced in
the brain by psychostimulant treatment. The functional
significance of the proteins suggests that important
metabolic and neuroplastic changes occur in the
reward- and memory-related brain centers following
drug action. Four metabolic enzymes were found to be
differentially expressed, in line with previous findings
concerning brain metabolism in cocaine addiction.
Other proteins show an involvement of synaptic
plasticity. The putative ECM protein pancortin, as well
as mss4 and CD81, two integrin-binding proteins,
could affect the neuroplasticity by providing the
necessary extracellular environment. The
transmembrane proteins NBC and ecto-apyrase could
affect the neuronal excitability by changing the
conductance properties of neuronal membrane or more
directly, by regulating the level of extracellular
messengers. Finally, CART, synucleins and axon
guidance molecules of the Eph-ephrin or the
semaphorin families, could directly influence the
morphology and synaptic rearrangement of DAergic
cells. The additional search for other molecules
expressed in the same time point, as well as a detailed
study of the functional significance of already
identified molecules will further clear up the exact
picture of molecular and cellular events involved in
early stages of drug addiction.
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Annex I
Modification of Primer
Design Facilitates the Use
of Differential Display
BioTechniques 24:374-380 (March 1998)
The method of differential display
developed by Liang and Pardee (10)
has gained a large audience and is now
the method of choice to quickly identi-
fy and isolate differentially expressed
genes in several experimental systems.
The method is powerful because of its
inherent simplicity, and it allows the si-
multaneous comparison of up- and
down-regulated genes with small
amounts of raw material. Nevertheless,
several vulnerable spots have been
identified in recent years. Most criti-
cisms concerned false positives gener-
ated by the polymerase chain reaction
(PCR) step (9). In addition, the identifi-
cation of differentially expressed genes
remains tedious and limited by the fact
that the amplified cDNA fragment gen-
erally corresponds to the trailer region
of mRNA. Additional difficulties are:
(i) the contamination of bands recov-
ered from the display gel by heteroge-
neous sequences (1) and (ii) the strong
bias in favor of the abundant mRNAs
(2). For these reasons, many authors
have attempted to improve the method,
either through different primer designs
(19,20) or by adapting techniques for
faster confirmation of differential gene
expression (13,19) and developing
methodologies for easier identification
of true positives (3,11). The use of
longer primers instead of the original
10-mers has been proposed to increase
the specificity and reproducibility of
the method (4,10,20) by favoring more
specific hybridization in the PCR. This
technique integrates the principles of
differential display with those of RNA
fingerprinting by arbitrarily primed
PCR (18). PCR is performed in two
steps: (i) a few initial low-stringency
cycles allowing minor mispairing be-
tween the arbitrary primer and the
cDNA template, followed by (ii) sever-
al high-stringency PCR cycles favoring
perfect matches with the anchored
primers.
Inspired by these improvements, we
developed a novel primer strategy
aimed at facilitating re-amplification,
analysis and cloning of the cDNA frag-
ments (Figure 1A) in which the main
feature is the use of a universal re-am-
plification primer set. The primers are
modified with the addition of a constant
region at either end of the product; this
is obtained by extending the 5¢terminus
of the oligo(dT) primers (DLP) and the
arbitrary primer (XAp) (Life Technolo-
gies, Basel, Switzerland) with about
one half of the T7 promoter (Figure 1A,
f) and one half of the SP6 RNA poly-
merase promoter (Figure 1A, a),
respectively. Universal re-amplification
primers harboring the complete cognate
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Figure 1. Modified primers for differential display. (A) Modified primer strategy for differential dis-
play. Top: arbitrary primers (25-mers) consist of a constant portion composed of one half of the SP6 RNA
polymerase promoter (a) in the 5¢region, an XhoI restriction site (b) in the middle followed by an arbi-
trary decamer sequence (c) in the 3¢region. The 3¢anchor primers (27-mers) bear a constant portion com-
posed of a HindIII restriction site (e) and one half of the T7 RNA polymerase promoter (f), both located
upstream of the anchoring oligo(dT) sequence (d). Middle: universal re-amplification primers (29- and
30-mers) contain the entire phage polymerase promoter: SP6 for the 5¢re-amplification primer (A) and
T7 for the 3¢re-amplification primer (F), preceded by an additional restriction site: XbaI (g) and BamHI
(h), respectively. Re-amplification primers hybridize to the constant portion of the cognate anchor
primers. Bottom: the final flanking sequences after differential display and cDNA re-amplification con-
tain two RNA polymerase promoters for preparing sense and antisense riboprobes and four restriction
sites for further cloning. The sequences of the primers are the following. Oligo(dT) primer sets: DLP1,
5¢-CAC TAT AGG GAA GC(T)11VG-3¢; DLP1 to DLP4 primer sets have a wobble in the penultimate
position (V = G, C or A) and differ in their last nucleotide, which is G, C, A and T for DLP1, DLP2,
DLP3 and DLP4, respectively; arbitrary primers: XAp1, 5¢-ACA CTA TAG CTC GAG AGG TGA CCG
T-3¢; XAp1 to XAp20 differ in their ten last nucleotides (shown in italics), which correspond to the de-
camer arbitrary sequences described by Bauer et al. (1); re-amplification primers: BT7, 5¢-GCG GAT
CCT AAT ACG ACT CAC TAT AGG GAA-3¢and XSP6, 5¢-GCT CTA GAT TTA GGT GAC ACT ATA
GCT CG-3¢. Restriction sites are underlined. (B) TAT gene 3¢region with location of polyadenylation
signals and priming sites for targeted primers. The rat TAT gene has two polyadenylation signals (pA1,
pA2) (5). The arbitrary portion of primers XTAT1 and XTAT2 was chosen to specifically prime at the in-
dicated locations (XTAT1: 5¢-ACA CTA TAG CTC GAG CTC CCA CCC A-3¢; XTAT2: 5¢-ACA CTA
TAG CTC GAG AGG AGG ACA C-3¢). The approximative length of the expected cDNAs is indicated.
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promoter sequences (Figure 1A, A and
F) will prime within these constant re-
gions and hence add a functional RNA
polymerase promoter into the re-ampli-
fied cDNA. Thus, the terminal se-
quences of re-amplified cDNAs will
contain a T7 RNA polymerase promot-
er (Figure 1A, F) allowing direct gener-
ation of antisense riboprobes for hy-
bridization techniques such as Northern
blot, in situ hybridization or ribonucle-
ase protection analysis and an SP6 pro-
moter (Figure 1A, A) for sense RNA
synthesis (e.g., to be used as control).
This configuration allows variation of
the arbitrary and oligo(dT) portions in
the initial PCR primers while maintain-
ing the same universal re-amplification
primer pair. Direct sequencing of re-
amplified cDNAs without previous
cloning is possible, independently of
the initial primer combination, by using
the same particular primer (XSP6).
Whenever cloning is necessary, two
restriction sites are located within the
arbitrary and oligo(dT) primers (Figure
1A, b and e, respectively). Two addi-
tional restriction sites (Figure 1A, g and
h) are added by the universal re-ampli-
fication primers and provide increased
flexibility for cloning purposes.
We illustrate the performance of the
modified primers using FTO-2B rat he-
patoma cells (7). In this cell line, the ty-
rosine aminotransferase (TAT) gene ex-
pression is induced by glucocorticoids
(15,16), providing us with a valuable
positive control for mRNA display.
Therefore, in addition to the normal ar-
bitrary primers, we designed two others
(XTAT1 and XTAT2) with the arbitrary
portions substituted by sequences
specifically priming at defined loca-
tions in the TAT gene (Figure 1B). The
rat TAT gene has two polyadenylation
signals (pA1 and pA2, in which pA2 is
more frequently used) generating
RNAs of different lengths (Figure 1B).
Because the distance between the exact
polyadenylate tail addition point and
the polyadenylation signal may vary
(17), in a differential display reverse
transcription (DDRT)-PCR experiment
the TAT gene signal is not expected to
be found in any particular 3¢primer set.
The results of differential display
performed with XTAT1 and XTAT2
primers are shown in Figure 2A (exper-
imental conditions given in the legend).
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Fragment Effect
Size Arbitrary DLP Primer Exerted
Lane (in bp) Primer or Set Identification by Dex
6 600 XTAT1 DLP3 tyrosine aminotransferase +
8 600 XTAT1 DLP4 uncharacterized 0
10 280 XTAT1 DLPAG tyrosine aminotransferase +
10 580 XTAT1 DLPAG uncharacterized 0
10 900 XTAT1 DLPAG a2-macroglobulin +
12 270 XTAT1 DLPAT metallothionein I +
12 600 XTAT1 DLPAT tyrosine aminotransferase +
14 310 XTAT2 DLP1 tyrosine aminotransferase +
16 300 XTAT2 DLP2 tyrosine aminotransferase +
18 270 XTAT2 DLP3 uncharacterized +
18 290 XTAT2 DLP3 tyrosine aminotransferase +
18 300 XTAT2 DLP3 tyrosine aminotransferase +
20 300 XTAT2 DLP4 metallothionein I +
22 310 XTAT2 DLPAG tyrosine aminotransferase +
24 250 XTAT2 DLPAT metallothionein I +
24 300 XTAT2 DLPAT tyrosine aminotransferase +
Effect exerted by dexamethasone may be up-regulation (+), down-regulation (-) or no
change (0). Lane numbers given in the first column are according to Figure 2A. Non-
changing bands (0) were included as negative controls.
Table 1. cDNA Fragments Generated from Arbitrary Primers XTAT1 and XTAT2 and Corre-
sponding to mRNA Whose Expression was Modified after Dexamethasone (Dex) Treatment
Benchmarks
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Figure 2. Differential display of mRNA from FTO-2B rat hepatoma cells after dexamethasone treatment. Cells were cultured in Dulbecco’s modified Ea-
gle medium (DMEM) with 10% fetal calf serum and treated with 0.5 mM dexamethasone (Sigma Chemie, Buchs, Switzerland). Total RNA was extracted 48 h
after addition of dexamethasone. Control RNA was extracted from untreated cells grown under identical conditions. After DNase I treatment (Sigma Chemie),
2 mg total RNA were reverse-transcribed with the oligo(dT) primer sets DLP1–DLP4 according to Liang and Pardee (10). Subsequent PCR was performed with
the same sets of oligo(dT) primers in addition to arbitrary primers XAp1–XAp20 or targeted primers XTAT1 and XTAT2. In some cases, primer combinations
used DLPAG and DLPAT (particular components of the DLP1 and DLP4 sets, respectively) as oligo(dT) primers, as indicated. PCR was performed as follows:
five cycles at low stringency (94°C for 60 s, 40°C for 120 s, 72°C for 60 s) followed by 35 cycles at high stringency (94°C for 45 s, 56°C for 60 s, 72°C for 60 s)
on a Biometra TRIOÔ thermal cycler (Biolabo, Châtel-St.-Denis, Switzerland). A typical PCR was carried out in a 20-mL final volume with the following final
reagent concentrations: 2 mM dNTPs, 1 mM 3¢anchor primer, 1 mM arbitrary primer and 1 mM MgCl2. cDNA (1/50 of that obtained from an RT), 1–2 mCi [a-
32P]dATP at 3000 Ci/mmol (Hartmann Analytic, Braunschweig, Germany) and 1.5 U Taq DNA polymerase (Life Technologies, Gaithersburg, MD, USA) were
used for each PCR. Reaction products were resolved on 6% denaturing sequencing gels that were dried and exposed to Fuji X-ray film (Wahl ExImpo AG,
Gams, Switzerland) overnight. Excised gel slices were rehydrated in 100 mL 1´TE buffer (100 mM Tris, pH 7.5, 10 mM EDTA, pH 8.0) at 80°C for 10 min. Re-
amplifications were carried out in 40 mL total volume with the following final reagent concentrations: 250 mM dNTPs, 1 mM BT7, 1 mM XSP6, 2.5 mM MgCl2,
1.5 U/reaction Taq DNA polymerase and 5 mL eluate/reaction DNA. Cycling conditions were five cycles at 94°C for 45 s, 40°C for 60 s, 72°C for 60 s, followed
by 35 cycles at high stringency (94°C for 60 s, 62°C for 60 s, 72°C for 60 s) and a 15-min extension step at 72°C. Sequencing was done using the dsDNA Cycle
Sequencing System (Life Technologies). (A) DDRT-PCR using primers XTAT1 and XTAT2 in combination with DLP1–DLP4, DLPAT and DLPAG. cDNAs
corresponding to circled bands have been re-amplified and sequenced. (B) Duplicate experiments (from duplicate RT) with XTAT1 (lanes 1–8), XTAT2 (lanes
9–16) and XAp11 (lanes 17–24) in combination with DLP1–DLP4. Identical signals occurring in Panel A are circled. (C) DDRT-PCR using primers
XAp7–XAp12 in combination with DLP1–DLP4. “-”: samples from untreated cells; “D”: samples from dexamethasone-treated cells.
Two TAT-specific primers were used in
combination with either four sets of
DLP primers or with two separate
DLPs (DLPAG and DLPAT). From
whole display, bands corresponding to
14 up-regulated and 2 unchanged sig-
nals (Figure 2, A and B, circled, and
Table 1) were re-amplified with
primers XSP6 and BT7 and sequenced
directly using primer XSP6. Out of the
14 differentially regulated signals, nine
were found to correspond to TAT c-
DNAs with the approximative length
expected from the given primer combi-
nations (Figure 1B and Table 1). The
deviation of a few nucleotides from the
expected length and the number of sig-
nals generated from the same mRNA
indicate that poly(A) addition does not
happen at a precise distance from the
polyadenylation signal. Three other
bands were generated from metallo-
thionein I mRNA and another fragment
from a2-macroglobulin, both of which
are genes known to be regulated by
glucocorticoids (6,8,12,14). One band
corresponded to a novel gene whose
regulated expression was confirmed by
reverse Northern blot analysis (data not
shown). The reproducibility was tested
in a duplicate DDRT-PCR using the
same combinations of primers (Figure
2B). The differential signals found in
the first experiment were reconfirmed,
the same for overall display patterns,
although the intensity of corresponding
signals in the two experiments was not
always conserved. These results clearly
demonstrate the validity of our modi-
fied technique. In particular, the identi-
fication of other differentially ex-
pressed genes, even with TAT-specific
primers, shows that the increased
primer length and presence of constant
portions in the 5¢terminus do not im-
pair or limit the priming ability. Primer
specificity is determined by the last 3¢
nucleotides in the primer. Moreover,
the reliability of the method is greatly
improved by a small percentage of false
positives (13 out of 14 differential sig-
nals are shown to be true positives by
sequence analysis).
DDRT-PCR was also performed
with arbitrary primers XAp1–XAp20
in combination with DLP1–DLP4. Fig-
ure 2C displays examples of the
patterns generated with XAp7–XAp12.
XAp11 patterns are presented in dupli-
cate (Figure 2B, lanes 17–24, and 2C)
to emphasize again the reproducibility
of the method. In the patterns partially
shown in Figure 2C, 23 differential sig-
nals (12 up- and 11 down-regulated c-
DNAs) were found, and the identifica-
tion of these fragments is currently in
progress. Thus, differential display
done with these arbitrary primers gave
the usual patterns, including differen-
tially expressed bands, excluding that
our initial result with the primers
XTAT1 and XTAT2 would be condi-
tioned by the primer choice. This docu-
ments that our primer strategy does not
impair, but actually improves, the ini-
tial strategy by Liang and Pardee. First,
the use of universal re-amplification
primers greatly facilitates and speeds
up practical work. Second, the new
primer design allows direct preparation
of riboprobes for downstream analysis
of re-amplified cDNAs and permits
flexible cloning of fragments whenever
required and direct sequencing with a
unique primer.
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FIG. 1. (A) Map of CD81 and positions of fragments used in this study. MD3 and TAPA are the mouse and rat CD81 mRNA sequences,
respectively, as designated in GenBank. Fragments are presented as submitted to GenBank, but both are incomplete, although full-length
mRNAs from both species most probably have the same length and structure. Homology is shown between coding sequences of both mRNAs.
The fragment P51 was found in the differential display study, with the larger part homologous to rat and mouse 39-untranslated region (UTR)
and the smaller one homologous only to mouse 39-UTR, since the sequence for rat 39-UTR is not yet available in GenBank. U and L show
respectively the positions of the upper and lower primers used for end-point quantitative RT-PCR. F and R respectively indicate the positions
of forward and reverse primers used for real-time PCR. The in situ probe was made from a clone containing the coding sequence of mouse CD81.
ORF, open reading frame. (B) Differential display of mRNAs isolated from three brain regions of control or cocaine-treated rats (see text for
details). s, saline; c, cocaine; H, hippocampus; A, nucleus accumbens; LS, lateral striatum. The band corresponding to CD81 is indicated by an
arrow. (C) End-point quantitative RT-PCR with CD81-specific primers on cDNA produced from mRNA of saline- or cocaine-treated rat accumbal
tissue (sAcc and cAcc, respectively). Four serial dilutions of cDNA were used (from 13 to 10003), and the PCR products were loaded on gel
together with 100 bp ladder. The CD81 amplified band of 243 bp disappears when PCR is performed on 1003 sAcc dilution, while is still present
in cAcc, indicating upregulation of CD81 upon cocaine treatment in NAcc. (D) Real-time quantitative RT-PCR with CD81-specific primers on
cDNA produced from NAcc, tegmentum, or hippocampus. Total RNA was extracted, using an RNAqueous kit (Ambion), from the NAcc of
saline- or cocaine-treated rats. Two independent RT reactions were performed and the cDNA templates used for PCR. Real-time quantitative
PCR was carried out on an iCycler (Bio-Rad) using the SYBR green method, with appropriate primers for CD81 and for 28S rRNA (as a control),
as described under Experimental Methods. Up to five independent PCRs were performed for each condition. The threshold cycle was defined
as the fractional cycle number at which the fluorescence passed the fixed threshold. The measures of relative fluorescence were made during the
threshold cycle, determined for each PCR. The measures for CD81 were normalized using the numbers for 28S rRNA. The average with standard
deviation is presented. Although the comparison of absolute values between different regions is not possible, these results clearly demonstrate
the CD81 upregulation in the cocaine-treated NAcc, as opposed to tegmentum and hippocampus.
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human CD81 binds to hepatitis C virus via the envelope
protein E2 and is, therefore, a possible key molecule in
virus pathogenicity (Pileri et al., 1998). Anti-CD81
blocks T cell maturation (Boismenu et al., 1996); how-
ever, in CD81-deficient mice the thymocytes develop
normally (Tsitsikov et al., 1997). These mice show, in
FIG. 2. In situ hybridization of CD81 mRNA distribution throughout the adult rat brain. Photomicrographs are shown for coronal 25-mm
sections hybridized with DIG-labeled CD81 probe. (A–H) Sections are shown in rostral-to-caudal direction. Regions specifically labeled with
CD81 probe are marked on the right side. For orientation, some unstained regions are indicated on sections. AD, anterodorsal thalamic nucleus;
Arc, arcuate nucleus; BST, bed nucleus of the stria terminalis; CG, central gray; ChP, choroid plexus; DB, nucleus of the diagonal band of Broca;
DEn, dorsal endopiriform nucleus; DG, dentate gyrus; Ep, ependymal layer of the ventricles; IG, induseum griseum; IPR, interpeduncular
nucleus; Hipp, hippocampal formation; LOT, nucleus of the lateral olfactory tract; LS, lateral septum; MHb, medial habenular nucleus; MnPO,
median preoptic hypothalamic nucleus; MPO, medial preoptic hypothalamic nucleus; Pir, piriform cortex; PVA, paraventricular thalamic
nucleus, anterior part; PVH, paraventricular hypothalamic nucleus; PVP, paraventricular thalamic nucleus, posterior part; R, red nucleus; SCh,
suprachiasmatic nucleus; SFO, subfornical organ; SN, substantia nigra; SO, supraoptic nucleus; TT, tenia tecta; VMH, ventromedial hypothalamic
nucleus; ac, anterior commissure; cc, corpus callosum; CPu, caudate putamen; fmj, forceps major of the corpus callosum; gcc, genu of the corpus
callosum; sm, stria medullaris of the thalamus; vhc, ventral hippocampal commissure.
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general, a subtle phenotype, suggesting the extensive
compensatory processes that occur during develop-
ment (Levy et al., 1998).
CD81 is expressed in virtually all types of cells, with
the exception of red blood cells and platelets (Levy et al.,
1998), and has been thoroughly characterized in lym-
phocytes. In the brain CD81 is expressed by glial cells
(Sullivan and Geisert, 1998), anti-CD81 causing changes
in astrocyte morphology (Geisert et al., 1996). CD81 is
upregulated during early postnatal development, at the
time of glial birth and maturation, and in the case of
reactive gliosis (Irwin and Geisert, 1993; Sullivan and
Geisert, 1998). This upregulation is evidence for a role
of tetraspanins in brain plasticity.
In this study we have performed a differential dis-
play screening to identify molecular cues induced by
psychomotor stimulants that revealed CD81 upregula-
tion in the nucleus accumbens (NAcc) upon cocaine
treatment. We have confirmed this finding by quanti-
tative RT-PCR and undertaken a detailed description of
CD81 distribution in rat brain. This shows that CD81 is
not exclusively glial and is expressed in selective brain
nuclei, mainly confined to regions important for regu-
lation of cardiovascular function and fluid homeostasis.
The pattern of CD81 localization is consistent with a
putative role in relation to effects observed after drug
withdrawal. This adds to data linking together the neu-
rochemical, behavioral, and somatic consequences of
FIG. 3. CD81 in situ hybridization in the ependymal layer of the ventricles and choroid plexus. (A) The ependymal lining of the lateral ventricle.
Several layers of CD81-positive ependymal cells are indicated by an arrow. (B) The ependymal lining of the third ventricle at the level of anterior
hypothalamus. Inset magnified in (C): The ependymal lining of the third ventricle. The border between CD81-positive chain-like ependymal cells and
CD81-negative zones is indicated by arrow. (D) CD81 signal in choroid plexus. (E) Nissl staining in choroid plexus of section adjacent to D. Cells facing
the ventricular cavity are indicated by arrows, internal choroid plexus cells by dotted arrows. Scale bars, 50 mm (in A, D, E) and 25 mm (in C).
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drug abuse. It provides additional evidence for a rela-
tion between the primary targets of psychostimulants
in the brain reward circuits and centers regulating au-
tonomic or neuroendocrine functions.
RESULTS
CD81 Upregulation in Nucleus Accumbens
To examine the changes in gene expression in the
dopaminergic brain system upon acute cocaine treat-
ment, we used the method of differential display (Liang
and Pardee, 1992) according to the modifications de-
scribed recently (Brenz Verca et al., 1998). Patterns of
expression were compared for mRNAs isolated from
the NAcc, the lateral striatum, and the hippocampus
(Hipp) (as control) of saline- or cocaine-treated rats.
Among differentially expressed tags one cDNA was
found to be induced upon cocaine treatment in the
NAcc (Fig. 1B). The candidate was not detectable in
other parts, neither in the NAcc of control animals nor
in any other brain region examined. The result was
reproduced in triplicate differential display experi-
ments starting from three independent reverse tran-
scription (RT) reactions. The band was cut out and
reamplified with the set of universal reamplification
FIG. 4. CD81 in situ hybridization in the olfactory bulb (A) and the cortex (B) and the diagonal band of Broca. EPl, external plexiform layer;
IGr, internal granular layer; IPl, internal plexiform layer; Mi, mitral cell layer. The small densely packed cells of layer II are indicated by arrows;
the bigger diffusely distributed cells of layers IV–V are marked with dotted arrows. (C–E) CD81 in situ hybridization in the diagonal band of
Broca. (C) Low magnification; (D) high magnification. (E) A Nissl-stained adjacent section. Big cells positive for CD81 are indicated by arrows
in both stainings. Scale bars, 250 mm (in A–C) and 25 mm (in D, E).
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primers described in the protocol (Brenz Verca et al.,
1998) and the PCR product was sequenced directly,
yielding a sequence with 98% homology with the
TAPA-1 (Geisert et al., 1996), rat CD81-homologous se-
quence.
To further assess the induction of CD81, primers
were designed for quantitative PCR based on rat
(TAPA-1) and mouse (MD3) CD81 homologous se-
quences in GenBank (Fig. 1A). Serial 10-fold dilutions of
RT product from mRNA of saline- or cocaine-treated
rats were amplified with these CD81-specific primers.
As a control, the product of the RT reaction was used
but without RTase added. The expected band of 243 bp
was found in undiluted or 10-fold-diluted cDNAs from
both treated and untreated animals; however, the signal
from 100-fold-diluted cDNA was evident only for co-
caine-treated brain, suggesting an increased quantity of
CD81 mRNA in this region compared to control (Fig.
1C). At the 1000-fold dilution, the band was absent
under both conditions.
The quantification of RT-PCR end-product does not
allow for precise evaluation of concentration differ-
ences between the samples. Therefore the real-time
RT-PCR was used to confirm the upregulation of
CD81 mRNA in the NAcc, which allows for quanti-
fication of PCR product during the exponential phase
of reaction. Primers were chosen based on the rat
(TAPA-1) CD81-homologous sequence in GenBank
(Fig. 1A). Quantitative PCR was performed in quin-
tuplicate from two different RT reactions and 28S
rRNA was used as a normalization standard in all
experiments. As shown in Fig. 1D, CD81 is upregu-
lated after cocaine treatment and its expression raises
4.6-fold in the NAcc. No changes in CD81 expression
were found in the Hipp and the tegmentum. Controls
in which RTase had been omitted or in which just one
primer had been used in the PCR were always neg-
ative. These data clearly indicate that CD81 upregu-
lation is specific for certain brain regions and that
CD81 may play a major role in the response to
cocaine.
Localization of CD81 mRNA in the Rat Brain
We performed in situ hybridization with a riboprobe
corresponding to the coding sequence of CD81 mRNA
(Fig. 1A). Controls with sense riboprobe consistently
yielded no signals. CD81 distribution throughout the
brain is shown in Fig. 2 on coronal sections in a rostral-
to-caudal direction.
In general CD81 expression is abundant in typically
glial structures, confirming the immunocytochemical
observations made by Geisert and colleagues (Sullivan
and Geisert, 1998). The glia limitans, the layer of astro-
cytic cells lying beneath the pial surface, was positive
for CD81 (not shown). However, only the minor part of
these cells was stained, as could be seen by comparison
with Nissl-stained consequent sections (not shown).
The same was true for the ependymal lining of ventri-
cles. In many cases one or more layers of ependymal
cells were stained at the inner surface of the ventricles
(Figs. 3A and 3B). However, we have found some ex-
ceptions to this general rule. As can be clearly seen in
Figs. 3B and 3C, the extensive staining is present in the
ventral part of the third ventricle where the tightly
joined, labeled ependymal cells form a chain-like struc-
ture, though in the more dorsal part of the ventricle, the
staining disappears completely. We also found the
CD81 signal in circumventrical organs, namely in the
choroid plexus (ChP) (Fig. 2E) and the subfornical or-
gan (Fig. 2D). While comparing the two subsequent
sections, stained for CD81 mRNA and Nissl substance,
respectively (Figs. 3D and 3E), we observed that the
staining for CD81 in ChP was especially strong for the
external layer of cells facing the ventricular cavity filled
with cerebrospinal fluid. However, the internal cells of
the ChP were unstained for CD81.
In addition to these purely glial structures, we could
find other positively stained regions, not described thus
far, where the staining was not equivocally confined to
glial or neuronal cells.
Olfactory areas. In the olfactory bulb, the internal
granular layer was most extensively labeled with CD81,
whereas both the external and the internal plexiform
layers as well as the mitral cell layer were moderately
stained (Fig. 4A). Of all other regions related to the
olfactory system, the piriform cortex and the induseum
griseum were the most intensively labeled (see, for
example, Fig. 2A). Less CD81 staining was found in the
anterior olfactory nucleus (not shown), tenia tecta (Fig.
2A), dorsal endopiriform nucleus (Fig. 2B), and nucleus
of the lateral olfactory tract (Fig. 2E), and a very faint
signal was seen in the olfactory tubercle.
Cortex. The parietal cortex was the least intensively
marked zone, compared to the other cortical regions
(see, for example, Fig. 2B). At the cellular level, CD81
expression was absent in cortical layer I, most pro-
nounced in layer II with small, quite densely packaged
cells, and then equally distributed in lower cortical
layers, where the cells were in general larger and more
diffusely distributed (Fig. 4B).
Septum. The posterior septum was not labeled with
CD81 probe. The lateral septum was moderately la-
beled throughout, including its dorsal, intermediate,
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and ventral parts (Fig. 2C). However, the most specific
CD81 labeling was found in the medial septal division.
The nucleus of the diagonal band of Broca (DB) was
extensively labeled (Figs. 2B and 5C). Only a very spe-
cific restricted subset of cells was positive for CD81, as
seen by comparison with a Nissl-stained subsequent
section (Figs. 4D and 4E). Nissl staining clearly shows at
least two different cell types, small and large ones (Fig.
4E), and CD81 staining is almost exclusively confined to
large cells, probably cholinergic and/or peptidergic
neurons. Small cells are either GABAergic interneurons
or astrocytes and are CD81-negative, so it is very im-
probable that expression is confined to glial cells in that
region.
Hippocampus. Moderate CD81 staining was found
in the pyramidal cell layer of the hippocampal forma-
tion, as well as in the granule cell layer of dentate gyrus
(Fig. 2G).
Amygdala and extended amygdala. Moderate CD81
expression was found in the bed nucleus of the stria
terminalis (BST) (Fig. 2D) and in the central amygdaloid
nucleus (Fig. 2F). Other amygdala subdivisions con-
tained very few CD81 message-positive cells.
Thalamus. Faint CD81 staining of mainly medium-
sized neurons was found in medial habenular (Fig. 2G),
paraventricular (Figs. 2E–2G), and reuniens (not
shown) thalamic nuclei. However, more specific and
extensive labeling was in the anterodorsal nucleus (AD)
(Figs. 2F and 6A). These neurons were bigger and
rounded and contained large nuclei (Fig. 5C). Interest-
ingly, the AD contains the highest density of large-size
neurons compared to other thalamic subregions. As a
result of this morphological particularity the borders of
the nucleus can be easily appreciated in Nissl-stained
sections even at low magnification (Fig. 5B). Some cells
show a specific triangular pattern of CD81 labeling,
possibly reflecting mRNA concentration in a region of
the axon hillock (Fig. 5C).
Hypothalamus. In the preoptic regions, the median
preoptic nucleus was highly positive for CD81 mRNA
labeling (Fig. 2C). Both the medial preoptic area and the
medial preoptic nucleus were moderately stained (Figs.
2C–2E). In the periventricular zone, the suprachias-
matic nucleus was moderately labeled (Fig. 2C), and
arcuate (Fig. 2G) and paraventricular (PVH) (Figs. 2F
and 7B) nuclei were both very extensively stained. The
specificity was pronounced in PVH with much higher
labeling in the lateral magnocellular part compared to
medial parvocellular and ventral parts (Fig. 6B). The
massive CD81 staining in the lateral part is probably
confined to magnocellular neurosecretory cells (Fig.
6D). Again some cells show the triangular pattern of
CD81 labeling in the area of the axon hillock. In the
supraoptic nucleus (SO), expression is also probably
confined to magnocellular neurosecretory cells (Figs.
7A and 7B). In the tuberal region, the ventromedial
nucleus is slightly labeled (Fig. 2F). In the mammillary
region, the supramammillary and lateral mammillary
nuclei are slightly labeled (not shown). In general, dis-
perse staining was present throughout the entire hypo-
thalamus.
Brain stem. Several regions were moderately la-
beled in brain stem, including the central gray area, the
interpeduncular nucleus, the substantia nigra (SN), and
the linear raphe nucleus (Fig. 2H).
Colocalization of CD81 and Tyrosine Hydroxylase
Messages in Rat Brain as Shown
by in Situ Hybridization
The modified expression of CD81 message following
cocaine administration and in regions related to dopa-
minergic brain system suggested that, under normal
conditions, CD81 might be localized in dopaminergic
neurons. Therefore we compared the CD81 distribution
with one for tyrosine hydroxylase (TH) in subsequent
brain sections. Both CD81 and TH staining were often
found in the same brain regions, including olfactory
bulb, hypothalamic nuclei, and SN. However, TH is
more specific and touches only very limited subgroups
of cells, for example in SO (Figs. 7B and 7C) and SN
(data not shown). Without double-labeling experi-
ments, it cannot be said as a general rule that both
messages are colocalized, especially with our observa-
tions that CD81 is not at all expressed in the A10 and
A11 groups of dopaminergic cells, nor is TH expressed
in many CD81-positive areas.
CART Overexpression in the Nucleus Accumbens
of Cocaine-Treated Rat Brain
The CART (cocaine and amphetamine-regulated
transcript) peptide is a putative neurotransmitter and
trophic factor. CART is one of the messages known to
be overregulated in the striatum upon acute psycho-
stimulant application. More precise localization and
functional significance of such overexpression have yet
to be demonstrated. However, such a signal could be
still present 24 h after acute cocaine treatment, when the
expression of acutely induced, immediate early genes is
already terminated. Thus, we decided to use the CART
probe as a positive control of cocaine-induced gene
expression in our in situ hybridization studies. As ex-
pected, CART message was overexpressed in the stria-
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tum 24 h after acute cocaine (data not shown). More-
over, we have shown that this overexpression is
specifically confined to the ventral part of striatum, or
the NAcc. The signal seemed to be particularly strong in
the shell of the NAcc; however, this statement needs
additional experimental support. Concerning the gen-
eral expression of CART message in rat brain, we ob-
served localization similar to that found in previously
published results (Douglass et al., 1995), namely in ol-
factory areas, PVH (Fig. 6C), and SO, but we could not
find any signal in the central amygdala region (Fager-
gren and Hurd, 1999).
CD81 and CART Colocalization in Brain
Because both CD81 and CART were found to be
overexpressed upon cocaine treatment in the NAcc, it
was interesting to compare their general distribution
patterns in adult rat brain. In fact, we could observe
both signals in different olfactory regions, including
tenia tecta, induseum griseum, anterior olfactory nu-
cleus, and piriform cortex. In addition, we found both
messages in particular hypothalamic regions, including
the PVH, arcuate, and SO nuclei, which are highly
heterogeneous at the cellular level, even though they
have a common function in the regulation of endocrine
and autonomic functions. However, whereas CD81 lo-
calization was primarily confined to the magnocellular
part of the PVH (Fig. 6B), CART signal was preferen-
tially concentrated in the parvocellular region (Fig. 6C).
Another striking difference in hybridization signal dis-
tribution of the two probes was in the basal ganglia
region. Whereas CART mRNA is found there in very
high concentration, especially in the NAcc, ventral pal-
lidum, and globus pallidus, CD81 was not expressed in
any of these regions.
DISCUSSION
CD81 Is Involved in Cocaine Action
In the present study we have shown the upregulation
of CD81 in the NAcc following cocaine treatment. The
expression was region-specific and not observed in
other regions examined (lateral striatum, tegmentum,
and Hipp). The absence of CD81 induction in the teg-
mentum suggests that the effect is mediated by cocaine
action on postsynaptic part of the ventral tegmental
area (VTA)–NAcc axis, probably involving dopamine
(DA) receptors in the NAcc. The DA hypothesis of
action is fortified by the fact that DA and its metabolite
levels are increased specifically in the NAcc of CD81-
deficient mice, as opposed to other neurotransmitters
(Michna et al., 1999; submitted for publication).
Although we found CD81 in classical glial structures
(ChP, ependyma, glia limitans) in accordance with pre-
viously published data (Sullivan and Geisert, 1998), it is
not exclusively glial, as many other groups of CD81-
FIG. 5. CD81 in situ hybridization in the anterodorsal nucleus of the
thalamus. (A) Low magnification; (B) an adjacent Nissl-stained sec-
tion; (C) CD81 staining at high magnification. Staining of axon
hillocks is indicated by arrows. AD, anterodorsal thalamic nucleus;
sm, stria medullaris of the thalamus. Scale bars, 250 mm (in A, B) and
25 mm (in C).
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positive cells in the PVH, SO, or DB show a typically
neuronal morphology.
CD81 Is Associated with Circuits Controlling
Cardiovascular Responses and Fluid Homeostasis
Our study shows high expression of CD81 in brain
circuits involved in cardiovascular responses and fluid
homeostasis. These circuits consist of two parts: (a) the
sensory part composed of ChP, subfornical organ, vas-
cular organ of lamina terminalis, and median preoptic
nucleus and containing receptors for insulin, vasopres-
sin (AVP), atrial natriuretic factor, and angiotensin II
and (b) the motor or effector part composed of the
magnocellular cells of PVH and SO in hypothalamus
secreting AVP and oxytocin (TO), two hormones influ-
encing body fluid homeostasis through regulation of
blood pressure as well as through water retention by
the kidney (Tohyama and Takatsuji, 1998). In these
hypothalamic nuclei, but also in other AVP-positive
areas (the suprachiasmatic nucleus, DB, BST, and Hipp)
or in regions projecting to PVH and SO (DB, BST, and
medial preoptic nucleus), CD81 is expressed at higher
levels. Together these results suggest a functional role
FIG. 6. CD81 in situ hybridization in the paraventricular hypothalamic nucleus. (A) Schematic view of coronal rat brain section in the region
of anterior hypothalamus, with inset represented in CD81 (B) and CART (C) hybridized micrographs. (D) CD81-positive cells in PaLM at high
magnification. PaLM, lateral magnocellular part; PaMP, medial parvocellular part; PaV, ventral part. Scale bars, 100 mm (in B), 250 mm (in C),
and 25 mm (in D).
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for CD81 in the neuroendocrine regulation of cardio-
vascular and fluid homeostasis.
CD81 Is Associated with Galanin Pathways
We found striking similarities in brain localization of
CD81 and galanin (Gal) (Table 1). CD81 and Gal colo-
calization specificity is maintained within the same re-
gion: in PVH, for example, both are strongly expressed
in the lateral part and weakly in the medial and ventral
parts (see Table 1). The specificity was striking in the
thalamus where high expression of both Gal and CD81
is found in only one thalamic nucleus, AD of anterior
group, a part of limbic Papez’s circuit (Heimer, 1995).
AD inhibits the hypophysoadrenal system under basal
and acute stress conditions (Suarez et al., 1998), again
providing a link of CD81 to neuroendocrine function.
From our study it is difficult to say if CD81 and Gal
are colocalized at the cellular level, without double-
labeling experiments. However, the expression of CD81
in a subset of DB and AD neurons with the character-
istic size of peptidergic neurons strongly favors this
hypothesis.
Gal modulates the dopaminergic function. Direct in-
teraction between Gal and the DA pathway leads to
rapid increase of prolactin and growth hormone secre-
tion following intraventricular injections of Gal (Me-
lander et al., 1987). Gal release from noradrenergic neu-
rons of locus coeruleus (Hokfelt et al., 1999) inhibits the
activity of VTA dopaminergic cell bodies, thus indi-
rectly interfering with the reward pathway. This results
in two of the principal symptoms seen in depression,
decreased motor activation and anhedonia (Weiss et al.,
1998). The codistribution of CD81 and Gal indicates
functional relations between the two molecules and
could explain CD81 involvement in drug addiction.
CD81, for example, may provide a link between the first
site of cocaine action (NAcc) and the Gal pathway,
ultimately altering dopaminergic responses and influ-
encing the reward pathway. The involvement of CD81
in long-lasting cocaine effect is supported by the obser-
vation of modified cocaine-elicited behavior in CD81-
deficient mice (Michna et al., 1999; submitted for publi-
cation).
Cocaine Interacts with Neuroendocrine Function
The cocaine-induced expression of CD81 and its pu-
tative role in neuroendocrine function provide addi-
tional evidence of an interaction between hormonal
function and the actions of drugs of abuse (Torres and
Rivier, 1992). The best examples of such interaction
include reciprocal cocaine regulation of the HPA axis
and OT–AVP system.
Cocaine induces changes in the HPA axis, often in
“binge” protocols very similar to the one used in the
present study. Acute binge cocaine alters hypothalamic
and extrahypothalamic/limbic corticotropin-releasing
factor (CRF) concentrations in rats (Sarnyai, 1998), lead-
ing to the release of adrenocorticotropic hormone, b-en-
dorphin, and corticosterone and activation of the HPA
axis (Moldow and Fischman, 1987; Zhou et al., 1999).
Chronic binge cocaine administration is coupled to CRF
decrease in the hypothalamus and activation of CRF
gene expression in extrahypothalamic regions, which
has implications in the behavioral responses to cocaine
(Zhou et al., 1996). Finally, cocaine withdrawal elicits
TABLE 1
The Codistribution of CD81 and Galanin in Rat Brain
Brain region CD81 Galanin
Olfactory system
Olfactory bulb 1 1/2
Anterior olfactory nucleus 1 1
Cortex 1 1
Septum
Nucleus of the diagonal band 111 111 11
Hippocampus 11 1
Thalamus
Paraventricular nucleus 1 1
Anterodorsal nucleus 111 11
Amygdala and extended amygdala
Bed nucleus of the stria terminalis 11 11
Hypothalamus
Suprachiasmatic nucleus 1 1
Arcuate nucleus 11 11
Supraoptic nucleus 111 111
Periventricular nucleus 1 11
Paraventricular nucleus, lateral
magnocellular part 111 111
Paraventricular nucleus, medial
parvocellular part 1 1
Paraventricular nucleus, ventral part 1 1
Medial preoptic area 1/2 1
Medial preoptic nucleus 11 11
Anterior hypothalamic area 1 1 1
Lateroanterior nucleus 1 1
Tuber cinereum area 1 1 11
Accessory neurosecretory nuclei 111 111
Brain stem
Interpeduncular nucleus 1 1
Note. CD81 expression was assessed in the present study. We have
arbitrarily defined four grades of in situ hybridization signal in our
reactions (from “1/2” to “111”, according to its intensity under
light microscopy at high magnification). The data on galanin local-
ization were taken from the published sources (Hamill et al., 1986;
Melander et al., 1986).
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anxiety-like behavior and alterations of CRF concentra-
tion in the hypothalamus, amygdala, and basal fore-
brain (Sarnyai, 1998).
Exposure to stress increases vulnerability to self-ad-
minister psychostimulants. Plasma corticosterone is
necessary for cocaine reinforcement. The mechanism by
which corticosteroids interact with the mesocorticolim-
bic dopaminergic system remains to be determined, but
the medial prefrontal cortex is probably one brain re-
gion where DA and adrenocorticosteroids interact to
affect cocaine reinforcement (Goeders, 1997).
Both acute and chronic cocaine administration in-
duces changes in the OT and AVP contents in the
hypothalamus and in limbic structures (Van de Kar et
al., 1992). AVP inhibits, whereas OT facilitates, the de-
velopment of behavioral sensitization to cocaine (Sarn-
yai, 1998). OT also inhibits acute cocaine-induced loco-
motor hyperactivity, exploratory activity, and
stereotyped behavior in rodents. Interaction of OT with
dopaminergic neurotransmission in the NAcc has been
postulated as a mechanism of action to modulate neu-
roadaptation to cocaine (Sarnyai, 1998).
A more recent example concerns the CART upregu-
lation in the striatum after acute cocaine treatment
(Douglass et al., 1995). CART is involved in the regula-
tion of feeding behavior, sensory processing, and stress
(Couceyro et al., 1997, 1998; Kuhar and Dall Vechia,
1999). CART expression was also observed in our pro-
tocol of cocaine treatment. We have found the expres-
sion of CART and CD81 mRNAs in functionally sepa-
rate hypothalamic cell groups, suggesting a distinct role
for the two proteins in normal and cocaine-treated
brain.
These studies strongly support the hypothesis that
cocaine action affects expression of proteins important
for hypothalamic functions, such as cardiovascular and
fluid homeostasis control, stress response, and feeding
behavior.
In the present study CD81 was found to be upregu-
lated in the NAcc upon cocaine treatment. DA level is
increased in the NAcc of CD81-deficient mice, and their
behavioral responses to cocaine are modified (Michna et
al., 1999; submitted for publication). In addition we
show the expression of CD81 in brain regions function-
ally related to the regulation of cardiovascular function
and fluid homeostasis and its codistribution with Gal
and AVP. These findings add to previous data suggest-
ing a connection between the brain reward pathways
and the centers regulating endocrine and autonomic
functions and may show a relation of the neurochemi-
cal, behavioral, and somatic consequences of drug
abuse.
EXPERIMENTAL METHODS
Drug treatment. Eight-week-old, male Sprague–
Dawley rats (Taconic Farms, Germantown, NY) were
injected subcutaneously with saline or 30 mg/kg co-
caine–HCl (Sigma Chemical Co., St. Louis) every 2 h for
four injections and were sacrificed 24 h after the last
injection (Gawin, 1991). Brains were extracted and stri-
atum, hippocampus, and tegmentum were dissected as
follows: a coronal slice through the caudal third of the
olfactory tubercle was made. A second coronal slice was
made through the anterior hypothalamus. Lateral stri-
atum and accumbens were isolated from the resulting
coronal section. Accumbens tissue around the anterior
commissure was first dissected, followed by striatal
tissue to the corpus callosum. On exposure of the dorsal
side of the remaining undissected mid- and hindbrain,
the telencephalon was pushed forward and the Hipp
lifted free. At the leading edge of the superior collicu-
lus, a diagonal coronal incision was made in the rostral-
to-caudal direction. Similarly a caudal-to-rostral cut
was made at the trailing edge of the inferior colliculus.
The resulting wedge of tissue contains the colliculi on
its dorsal face and a section of the cerebral peduncle on
its ventral face. Recumbent on its posterior plane, the
peduncle was removed and a vertical incision was
made ventral to the cerebral aqueduct. The resulting
strip of tegmentum contained the cell bodies of the
midbrain dopaminergic system.
RNA isolation and differential display analysis.
Total RNA was extracted, with the RNAqueous kit
(Ambion), from the selected brain regions of control or
cocaine-treated rats. Differential display was then per-
formed essentially as described (Brenz Verca et al.,
1998). Briefly, 1 mg total RNA was reverse transcribed
with the modified oligo(dT) primer sets. Reaction con-
ditions were set as described (Liang and Pardee, 1992).
Subsequent PCR was performed with the same sets of
oligo(dT) primers in addition to arbitrary primers XAp1
to XAp20. PCR was performed as follows: 5 cycles at
low stringency (94°C for 60 s, 40°C for 120 s, 72°C for
60 s) followed by 35 cycles at high stringency (94°C for
45 s, 56°C for 60 s, 72°C for 60 s). A typical PCR reaction
was carried out in 20 ml final volume with the following
final reagent concentrations: dNTPs, 2 mM; 39-anchor-
ing primer, 1 mM; arbitrary primer, 1 mM; MgCl2, 1 mM.
One-fiftieth of the cDNA obtained from RT, 1–2 mCi
[a-32P]dATP at 3000 Ci/mmol (Hartmann Analytic),
and 1.5 U Taq polymerase (Gibco BRL) were used for
each PCR. Reaction products were resolved on 6% de-
naturing sequencing gels which were dried and ex-
313Cocaine-Induced CD81 and Hypothalamic Function
posed to Fuji X-ray film overnight. Excised gel slices
were rehydrated in 100 ml 13 TE at 80°C for 10 min.
Reamplifications were carried out in 40 ml total volume
with the following final reagent concentrations: dNTPs,
250 mM; reamplification primers, 1 mM each; MgCl2, 2.5
mM; Taq DNA polymerase, 1.5 U/reaction; DNA, 5 ml
eluate/reaction. Cycling conditions were 5 cycles (94°C
for 45 s, 40°C for 60 s, 72°C for 60 s), followed by 35
cycles at high stringency (94°C for 60 s, 62°C for 60 s,
72°C for 60 s) and a 15-min extension step at 72°C. PCR
products were sequenced by Microsynth GmbH either
directly or after cloning into pBluescript KS(1) vector.
Quantitative end-point RT-PCR. Total RNA was
extracted using an RNAqueous kit (Ambion, AMS Bio-
technology, Ltd., Lugano, Switzerland) from the NAcc
of control or cocaine-treated rats. Reverse transcription
was performed essentially as described (Liang and
Pardee, 1992; Brenz Verca et al., 1998). Primers for PCR
were designed based on CD81 mRNA GenBank se-
quence for rat (TAPA-1) and mouse (MD3). The up-
stream primer was 59-ACT TTT CCT GTC ACC TTT
TGG-39; the downstream primer was 59-TCT TGA AAT
GGA GGC AGG AAA-39. PCR was carried out in 20 ml
final volume with the following final reagent concen-
trations: dNTPs, 250 mM; both primers, 1 mM; MgCl2,
1.5 mM. Four 10-fold serial dilutions of cDNA from RT
reaction and 2 U Taq polymerase (Gibco BRL) were
used for each PCR. PCR was performed as follows:
initial denaturation step at 94°C for 4 min followed by
35 reamplification rounds (94°C for 30 s, 60°C for 30 s,
72°C for 60 s).
Quantitative real-time RT-PCR. Total RNA was
extracted using an RNAqueous kit (Ambion, AMS Bio-
technology Ltd.) from the selected brain regions of con-
trol or cocaine-treated rats. RT was performed essen-
tially as described (Liang and Pardee, 1992; Brenz Verca
et al., 1998). Primers for quantitative PCR were designed
using PrimerExpress software (PE Applied Biosystems,
Foster City, CA) based on CD81 GenBank sequences for
rat (TAPA-1). The 28S ribosomal RNA (rRNA) was
used as an endogenous control. The forward and re-
verse primers for CD81 were, respectively, 59-GGC
TAG GCT CCA ACC CTT CT-39 and 59-GAC TGC GGT
GTG GCT ATT GAG-39. Primers for the control 28S
rRNA were 59-CAG CGA AAC CAC AGC CAA G-39
and 59-CTT CTT TCC CCG CTG ATT CC-39. Up to five
independent real-time PCRs were carried out on an
iCycler (Bio-Rad). The measure of SYBR green fluores-
cence was used for quantification of PCR product. The
reaction was carried out in 50 ml final volume contain-
ing 25 ml SYBR Green PCR Master Mix (PE Applied
Biosystems), 300–900 nM each primer, and variable
amount of cDNA template. PCR was performed as
follows: initial denaturation step at 94°C for 10 min
followed by 40 annealing–extension cycles (94°C for
15 s, 60°C for 60 s). The relative fluorescence at the
threshold cycle was used to calculate the relative ex-
pression of CD81, using the 28S rRNA as endogenous
control.
In situ hybridization. In situ hybridization was per-
formed essentially as described (Braissant and Wahli,
1998). Briefly, DIG- or fluorescein-labeled sense and
antisense probes were produced using T3, T7, or SP6
promoters from plasmids containing the clones of in-
FIG. 7. CD81 in situ hybridization in the supraoptic magnocellular
cells at (A) low magnification and (B) high magnification. (C) TH
hybridization at the same magnification as in (B). Scale bars, 100 mm
(in A) and 25 mm (in B, C).
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terest. Before the in vitro transcription reaction the plas-
mids were digested nearest the insert with suitable
restriction enzymes to prevent the contamination of
probe with vector sequences. The mouse MD3 (CD81)
complete cds clone in pCRII vector, the rat CART com-
plete cds clone corresponding to the short form of
CART peptide in pBSII SK(1) vector, and the rat TH
partial cDNA clone (’1500 bp) in pSPT18 vector were
kindly provided by E. Tsitsikov (Harvard), S. Hastrup
(Novo Nordisk, Denmark), and N. Faucon Biquet
(CNRS, Paris, France), respectively. TH probe was hy-
drolyzed for 3 min in 0.2 M carbonate buffer (80 mM
NaHCO3/120 mM Na2CO3, pH 10.2) at 60°C to the final
fragment length of ’500 bp. Serial dilutions of ribo-
probes were spotted on positively charged nylon mem-
brane together with serial dilutions of DIG-labeled an-
tisense neo-RNA (Boehringer Mannheim) of known
concentration as standard, to estimate the efficiency of
the labeling reaction. In addition, probes were loaded
on 2% agarose gel to check for RNA size and integrity.
Rat brains were rapidly frozen in isopentane upon
extraction and stored dry at 280°C. Twenty-five-mi-
crometer sections were cut on a cryostat, then dried at
room temperature, and stored at 220°C. For in situ
hybridization, sections were postfixed for 10 min in 4%
paraformaldehyde in phosphate-buffered saline (PBS),
incubated 2 3 15 min in PBS containing 0.1% active
diethylpyrocarbonate, rinsed briefly in 53 saline so-
dium citrate (SSC), and prehybridized for 1–2 h in
hybridization buffer containing 50% formamide, 53
SSC, and 40 mg/ml salmon sperm DNA at 58–61°C.
Hybridization was then carried out in the same buffer
and at the same temperature with 50–100 ng/ml DIG-
or fluorescein-labeled probe overnight. After hybridiza-
tion sections were washed for 30 min at room temper-
ature, then for 1 h at 65°C in 23 SSC, and for 1 h at 65°C
in 0.13 SSC. For in situ hybridization with TH probe,
the additional step of RNase treatment (30 mg/ml at
30°C) after hybridization was necessary to remove non-
specific staining. After washing the detection was per-
formed with anti-DIG or anti-fluorescein Abs coupled
to alkaline phosphatase and color development with
NBT/BCIP substrate (all reagents from Boehringer
Mannheim). Nonspecific staining was then removed by
washing for 1 h in 95% EtOH. The images of entire
sections were digitalized using videocamera and Image
Store 5000 hardware (UVP). Photomicrographs were
prepared by capturing the images with a Spot Camera
(Diagnostic Instruments, Inc.) on a Zeiss Axiophot light
microscope.
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humans and other animals [1,19] and is a major drug of and clear Plexiglas walls. Three of the four chambers were
abuse. The primary site of action in regard to the reinforc- lined with absorbent paper while the fourth chamber was
ing action of cocaine is the nucleus accumbens [4,13–15]. designated as the bare compartment chamber. After each
With its repeated administration, both tolerance and sen- mouse, compartments were thoroughly cleaned and paper
sitization develop to many of the behavioral effects of lining the floor was changed.
cocaine and such changes may mediate the symptoms of The place preference study consisted of three phases:
‘craving’ and ‘relapse’ which renders cocaine abuse a baseline, conditioning, and testing. All phases occurred at
tenacious problem [6,7]. Although the molecular mecha- the same time each day and in an isolated room. In the
nism mediating the development of this tolerance and/or baseline phase (3 days), subjects were placed in the neutral
sensitization remains elusive, it is thought that cocaine compartment and were allowed free access to the entire
may induce changes in the expression of membrane apparatus for 15 min. The amount of time spent in each
proteins on its target cells and that these proteins, in turn, chamber was recorded. During the conditioning phase (12
alter neuronal plasticity in response to the drug [7,8]. days), subjects were given an i.p. injection of either
The objective of our initial study [3] was to identify cocaine HCl (10 mg/kg) or an equal volume of saline, on
molecular cues induced by the acute administration of an alternating schedule (six cocaine and six saline). Five
cocaine. Having identified CD81 as such a cue, we then minutes after injection, animals were locked into a specific
assessed the neurochemical and behavioral effects of chamber for 15 min. If receiving cocaine, animals were
cocaine administered to CD81-deficient mice. The be- placed in the bare chamber while, after saline, animals
havioral paradigms employed for this later objective were were placed into one of the three lined chambers. For the
locomotor activity (used to assess the stimulant properties post-conditioning phase, subjects were tested for their
of the drug) and place preference conditioning (used to preference in a drug-free state. Each mouse was placed in
assess the reinforcing efficacy of the drug). Finally, since the neutral compartment and was allowed free access to
deficits in place preference conditioning were observed, a the entire chamber for 15 min. The amount of time spent in
water maze task was employed to determine if these each chamber was then recorded and presented as the
deficits were consequent to non-specific impairments in the percentage of time spent in the bare ‘cocaine-associated’
behavioral ability of CD81-deficient mice. chamber divided by the amount of time spent in the lined
‘saline-associated’ chambers.
2. Materials and methods 2.3. Activity
2.1. Subjects The locomotor activity test apparatus consisted of a
43343 cm Plexiglas chamber, surrounded by a 12312Eighteen male and 18 female CD81-deficient mice with grid of photo cells. The chamber was thoroughly cleaned
a C57BL/6 background (initially obtained from E. Tsit-
after testing each mouse. On separate days, animals
sikov; see [18]) and their controls, 18 male and 18 female
received i.p. injections of saline or cocaine HCl (0.3, 1, 3C57BL/6 mice (Charles River Laboratories, Raleigh, NC,
or 10 mg/kg) 15 min prior to placement in the chamberUSA), approximately 3-months-old and weighing 28–35 g for 10 min. Horizontal motor activity was recorded by
at the beginning of testing were used. The CD81-deficient photocell beams.
mice were of the sixth generation of breeding into the
C57BL/6 background. Animals were housed individually
in pan cages containing woodchip bedding in a colony 2.4. Water maze
room with a 12 h light /dark cycle (lights on at 7.00) and
were given free access to food and water. Experimentation The water maze (61 cm diameter and 28 cm high) was
took place during the light phase of the cycle and was filled with opaque, room-temperature water to a depth of
conducted at the same time each day. Six mice of each 15 cm and was located in a test room measuring 3.232.1
strain and sex were used in the following studies.
m. A 7.5 cm diameter platform was submerged 2.5 cm
below the water surface and was located 18 cm from the
2.2. Place preference side. Trials were initiated by placing a mouse in one
quadrant of the maze and allowing it to swim to the
Place preference tests were performed in an opaque platform with a maximum 60 s trial. Four trials were
Plexiglas apparatus (20320330 cm) divided into four conducted each day, each starting from a different quad-
separate compartments (1238310 cm) with a central rant. Trials were conducted for 5 successive training days,
neutral compartment. The neutral compartment was used followed by 3 days without training and concluded by 2
as the place of introducing the animal on baseline and test successive days of retention trials conducted in the same
days. The neutral compartment had a black Plexiglas floor manner.
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2.5. Neurochemistry
Upon the completion of behavioral tests, animals were
sacrificed, striatum and nucleus accumbens dissected and
stored in liquid nitrogen until assayed by HPLC
(Bioanalytical Systems, West Lafayette, IN). Tissue was
homogenized in 0.3 ml of 0.4 N perchloric acid with 0.1
mM ethylenediaminetetra-acetic acid (EDTA) added to
inhibit biochemical degeneration. Samples were cen-
trifuged at 20,000 g for 20 min at 48C and supernatant
assayed for dopamine, serotonin, and their metabolites,
dihydroxyphenylacetic acid (DOPAC), homovanillic acid
(HVA), and 5-hydroxyindoleacetic acid (5-HIAA). The
mobile phase consisted of 0.1375 M sodium phosphate
(dibasic), 0.0625 M citric acid, 5.0 mg EDTA and 14%
methanol with a flow rate of 0.7 ml /min.
3. Results
3.1. Place preference
On the last baseline day, there were no difference in
preference for lined or bare chambers between male or
female C57BL/6 versus CD81-deficient mice. After con-
ditioning, both male (Fig. 1A) and female C57BL/6 (Fig.
2A) mice spent more time in the bare, cocaine-paired
chamber than in the lined, saline chamber. These differ-
ences were statistically significant and were seen on all
three test days (see figure legend for F-values).
Likewise, female CD81-deficient mice (Fig. 2B) spent
significantly more time in the bare, cocaine-paired
chamber on the first day after conditioning, but this effect
Fig. 1. Place preference behavior for male mice during 3 days of testing.disappeared by the second day of testing. Finally, after
Test days followed 12 days of conditioning during which cocaine wasconditioning, male CD81-deficient mice spent approxi-
paired with the ‘bare’ chamber. Data represent percentage of time mice
mately equal time in the lined compared to the bare
spent in the bare ‘cocaine-associated’ chamber divided by the amount of
chamber (Fig. 1B). time spent in the lined ‘saline-assoicated’ chambers. (A) C57BL/6:
(F 532.92; P50.0001); (B) CD-81 deficient: P.0.05. *significantly5,25
greater than 100%, Fisher’s LSD test; P,0.05.3.2. Activity
Male C57BL/6 mice were more active than male CD81- tion, both strains exhibited full retention after a 3 day
deficient mice following 0.1 mg/kg of cocaine (Fig. 3A). delay, again, with no differences between strains.
Cocaine at 10 mg/kg increased the activity of the CD81-
deficient mice but not the C57BL/6 mice. Female C57BL/
6 mice were more active than female CD81-deficient mice 3.4. Neurochemistry
under baseline conditions as well as following 0.1 and 3
mg/kg cocaine (Fig. 3B); however, this effect reversed In the striatum, there were no significant differences
itself following 1 mg/kg cocaine. between the male C57BL/6 and CD81-deficient mice in
the levels of dopamine, serotonin, DOPAC, HVA or 5-
3.3. Water maze HIAA. In the accumbens, there was a significant increase
in the concentration of dopamine in the CD81 knockout
There was a significant improvement in performance mice (t 52.4; P50.03) along with a significant increase10
over the five training days for male (Fig. 4A) and female in the concentration of DOPAC (t 53.12; P50.01) (Table10
(Fig. 4B) C57BL/6 and knockout mice but there were no 1). In females, there were no significant differences in the
differences between these strains for either sex. In addi- striatum or accumbens between the C57BL/6 and CD81-
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Fig. 3. Activity levels of male (A) and female (B) C57BL/6 and
CD81-deficient mice under baseline (saline) conditions or following the
Fig. 2. Place preference behavior for female mice during 3 days of
administration of cocaine. Male (F 53.6; P50.013) and female (F 54,4 4,4testing. The test days followed 12 days of conditioning during which 7.4; P50.0001) C57BL/6 mice were significantly more active than their
cocaine was paired with the ‘bare’ chamber. Data represent the per- CD81 K/O counterparts at each dose and, for females, there was a
centage of time mice spent in the bare ‘cocaine-associated’ chamber
significant dose by strain interaction (F 510.3; P50.0001).4,40divided by the amount of time spent in the lined ‘saline-associated’
*significantly different from C57BL/6; P,0.05, Fisher’s LSD test.
chambers. (A) C57BL/6: (F 55.86; P50.001); (B) CD-81 deficient: 15,25 significantly different from saline; P,0.05, Fisher’s LSD test.(F 53.23;P50.02. *significantly greater than 100%, Fisher’s LSD test;5,25
P,0.05.
in these cells that predispose the individual to continue to
deficient mice in the levels of dopamine, serotonin, crave cocaine as well as rendering this individual more
DOPAC, HVA or 5-HIAA. prone to relapse following cocaine withdrawal [7]. In a
previous study, we demonstrated that the administration of
a high-dose regimen of cocaine to rats caused an induction
of the CD81 gene. This gene was expressed 24 h after the
4. Discussion last cocaine injection and, more important, was observed
exclusively in the nucleus accumbens [3]. Furthermore,
4.1. Cocaine induces CD81 expression in rat accumbens although it was initially thought that central CD81 expres-
sion was restricted to glia cells [5,16], we demonstrated its
Cocaine is considered to be a major drug of abuse presence in a variety of neurons, especially those associ-
world-wide. Its reinforcing effects are mediated in a large ated with hypothalamic regulation of cardiovascular func-
part through the dopaminergic neurons in the nucleus tion [3]. However, the fact that CD81 expression was
accumbens. With its repeated use, molecular changes occur selectively induced in the nucleus accumbens by cocaine
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Table 1
Transmitter and metabolite levels
Dopamine DOPAC HVA Serotonin 5-HIAA
Males
Striatum
CD81 K/O 6.61 0.579 0.821 0.461 0.276
(1.296) (0.118) (0.165) (0.087) (0.05)
C57BL/6 6.415 0.557 0.757 0.45 0.25
(0.827) (0.07) (0.078) (0.015) (0.009)
Accumbens
CD81 K/O 4.42* 0.64* 0.76 0.714 0.364
(0.832) (0.058) (0.087) (0.083) (0.029)
C57BL/6 1.99 0.375 0.614 0.673 0.279
(0.564) (0.062) (0.149) (0.095) (0.038)
Females
Striatum
CD81 K/O 6.562 0.772 1.053 0.581 0.384
(0.767) (0.069) (0.121) (0.052) (0.013)
C57BL/6 4.779 0.632 0.989 0.49 0.314
(0.491) (0.052) (0.121) (0.036) (0.015)
Accumbens
CD81 K/O 1.593 0.276 0.298 0.687 0.327
(0.377) (0.051) (0.059) (0.038) (0.05)
C57BL/6 1.921 0.239 0.262 0.733 0.222
(0.244) (0.025) (0.014) (0.015) (0.008)
Values reported are in mg/g tissues6(S.E.M.). *significantly different
from C57BL/6.
ence for the bare chamber only during the first day of
testing; thereafter, they also exhibited no preference for the
cocaine-paired chamber. One interpretation of these data is
that the CD81-deficient mice are less sensitive to the
reinforcing effects of cocaine.
However, an alternative interpretation might be that the
CD81-deficient mice have a poor retention of learned
Fig. 4. Water maze data for male (A) and female (B) C57BL/6 and tasks. This interpretation can be ruled out on the basis ofCD81-deficient mice. All groups showed a significant improvement over
the results obtained on the water maze retention task. Infive training days (males: F 513.09; P50.0001; females: F 537.18;6,60 6,60
this study, CD81-deficient mice exhibited nearly identicalP50.0001). There was no significant deficit in retention for any of the
groups and there were no significant differences between strains for either acquisition and retention curves as compared to their
sex. *significantly different from C57BL/6; P,0.05, Fisher’s LSD test. C57BL/6 controls. Thus, it appears that this deficit in
1
significantly different from day 1; P,0.05, Fisher’s LSD test. place preference performance can not be attributed to a
non-specific disruption of learning or memory processes.
An alternative interpretation of the deficit in place
prompted us to evaluate the reinforcing efficacy of this preference performance exhibited by the CD81-deficient
widely-abused drug in CD81-deficient mice. mice might be that C57BL/6 mice were used as controls in
place of wild-type littermates. However, since the CD81-
deficient mice have been backcrossed into the C57BL/6
4.2. Diminished sensitivity to cocaine-induced place strain for six generations, the possibility of difference in
preference in CD81-deficient mice place preference but not water maze performance being
due to strain differences is remote. Finally, the molecular
Male and female C57BL/6 mice exhibited a strong corroboration of these data (i.e. CD81 induction in only
place preference conditioning clearly preferring the bare the accumbens following cocaine [3]) point convincingly
chamber following cocaine conditioning. In contrast, male to this gene mutation being involved in the altered
CD81-deficient mice exhibited no place preference con- sensitivity to the reinforcing efficacy of cocaine. It still
ditioning whatsoever, while the females exhibited prefer- remains to be determined if the deficit in place preference
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performance exhibited by the CD81-deficient mice is Taken together with our previous report [3], these data
restricted to cocaine or is evident for other drugs of abuse. may indicate that this protein is involved in mediating the
acute and/or long-term neural responsiveness to cocaine.
4.3. Activity levels in CD81-deficient mice following
cocaine
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2INTRODUCTION
Synucleins are small (120-140 amino acids) proteins
sharing structural resemblance with apolipoproteins
(Clayton and George, 1999). Four members, a-, -, g-
synucleins and synoretin, have been described in
different organisms, including humans, rodents, fish
and birds. a- and b-synucleins are predominantly
presynaptic proteins (Iwai et al., 1995). b-synuclein is
highly homologous to a-synuclein, but it lacks 11
amino acids in the region corresponding to the NAC
peptide (Lavedan, 1998). The most distinct member of
the family, g-synuclein/persyn, lacks a conserved C
terminal domain of a- and b-synucleins and displays
different spatial and temporal expression, being
distributed diffusely throughout the cell body and
axons, at least in peripheral neurons (Buchman et al.,
1998). Recently the fourth member, synoretin, has been
identified in retinal cells and in the brain where it plays
a role in the regulation of the Elk1 pathway
(Surguchov et al., 1999).
Synucleins have attracted much attention because of
their involvement in several neurodegenerative
disorders. In Alzheimer disease (AD) a-
synuclein/NACP (non-Ab component of amyloid
precursor) is the precursor of the NAC peptide, the
intrinsic component of amyloid plaques. In Parkinson's
disease (PD) two point mutations in a- ynuclein are
genetically linked to the disorder (Polymeropoulos et
al., 1997; Lavedan, 1998) and the protein forms the
major fibrillary component of Lewy bodies (Clayton
and George, 1999). Mutations in the a-synuclein may
change the secondary structure of otherwise unfolded
protein promoting the formation of aggregates.
Interestingly, one of the point mutations is naturally
present in rodent orthologues of a-synuclein, as well as
in human g-synuclein. b- and g-synucleins were also
observed in axons of patients with PD or Lewy body
dementia (Galvin et al., 1999). In addition g-synuclein
stimulates breast cancer invasion and metastasis (Jia et
al., 1999). Synucleins are mainly expressed in neurons,
but they are also a component of glial cytoplasmic
inclusions which are characteristic of multiple system
atrophy and amyotrophic lateral sclerosis (Lavedan,
1998) and are abundant in the brain stem, basal
ganglia, and cortical white matter (Gai et al., 1999).
Several studies indicate a role of synucleins in synaptic
plasticity. Synucleins interact with intracellular signal
transduction cascades. They contain KTKEGV repeat
sequences homologous to Rho-GTPases, and play a
role in neuritogenesis (Mackay et al., 1995). They are
powerful inhibitors of phospholipase D2 (Jenco et al.,
1998), whose function in cytoskeletal organization is
well established (Colley et al., 1997). In addition g-
synuclein/persyn, influence neurofilament network
integrity by increasing the susceptibility of NF-H to
calcium-dependent proteases (Buchman et al., 1998).
The expression of synucleins is up-regulated in the
substantia nigra (SN), the cortex and the hippocampus
during the postnatal period, when synaptic contacts
develop (Coyle, 1977; Kholodilov et al., 1999a;
Petersen et al., 1999). In the SN synuclein mRNA is
also up-regulated upon injury, the overexpression
being exclusively restricted to surviving, non-
apoptotic, neurons (Kholodilov et al., 1999a), probably
as a major compensatory reaction. The down-
regulation of a-synuclein was also described, e.g. upon
intrastriatal injection of 6-hydroxydopamine as
dopamine neurons die (Kholodilov et al., 1999b) or in
patients with early-onset of PD (Neystat et al., 1999).
In a screening for genes differentially expressed after
cocaine withdrawal we found that g-synuclein was a
major up-regulated candidate. For this reason we
investigated in more detail the distribution of a-and g-
synucleins in the adult rat brain and present here a
distinct pattern of expression for each protein.
METHODS
Drug treatment. Eight week old, male Sprague-Dawley
rats (Taconic Farms, Germantown, NY) were injected
subcutaneously with 30 mg/kg cocaine-HCl (Sigma
Chemical Co., St Louis) every 2hrs for 4 injections.
Control animals received the saline injections under the
same schedule. The rats were sacrificed 24 hours after
the last injection, and tegmental area was dissected out
and used for mRNA isolation.
RNA isolation and Differential Display analysis. Total
RNA was extracted using an RNAqueous kit
(AmbionTM, AMS Biotechnology Ltd., Lugano,
Switzerland) from the tegmental tissue of saline- or
cocaine-treated rats. Differential display was then
performed as described (Brenz Verca et al., 1998).
Briefly, 1 µg total RNA was reverse transcribed with
modified oligo(dT) primer sets. Reaction conditions
were set according to Liang & Pardee (Liang and
Pardee, 1992). Subsequent PCR was performed with
the same sets of oligo(dT) primers in addition to
arbitrary primers XAp1 to XAp20. PCR was performed
as follows: five cycles at low stringency (94°C, 60";
40°C, 120"; 72°C, 60") followed by 35 cycles at high
stringency (94°C, 45"; 56°C, 60"; 72°C, 60''). A typical
PCR reaction was carried out in 20 µl final volume
with the following reagents: 2 µM dNTPs, 1 µM 3'-
anchoring primer, 1µM arbitrary primer, 1 mM MgCl2,
1/50 of the cDNA obtained from a reverse
transcription, 1-2 µCi [32P]-dATP at 3000 Ci/mmol
(Hartmann Analytic) and 1.5 U Taq polymerase (Gibco
BRL) were used for each PCR. Reaction products were
resolved on 6% denaturing sequencing gels, which
were dried and exposed to Fuji X-ray film overnight.
Excised gel slices were rehydrated in 100 µl 1x TE at
80 ˚C during 10 min. Reamplifications were carried out
in 40 µl total volume with the following reagents: 250
µM dNTPs, 1µM reamplification primers, 2.5 mM
MgCl2, 1.5 U/reaction Taq DNA polymerase, 5 µl
cDNA eluate/reaction. Cycling conditions were five
cycles (94°C, 45"; 40°C, 60"; 72°C, 60") followed by
335 cycles at high stringency (94°C, 60"; 62°C, 60";
72°C, 60'') and a 15 min extension step at 72 ˚C. PCR
products were cloned into pBluescript KS+ vector.
Clones were subjected to analytical restriction analysis
with RsaI and the prominent sequences were
sequenced by Microsynth GmbH.
In situ hybridization. In situ hybridization was
performed essentially as described (Braissant and
Wahli, 1998). Briefly, digoxigenin (DIG)- or
fluorescein-labeled sense and antisense probes were
produced using T3, T7 or SP6 promoters from
plasmids containing the clones of interest. Before the
in vitro transcription reaction the plasmids were
digested nearest the insert with suitable restriction
enzymes to prevent the contamination of probe with
vector sequences. The rat synuclein-1 (a-synuclein)
complete cds clone in pGEM-T vector, the rat sensory
synuclein (g-synuclein) clone in pT7T3Pac vector and
the tyrosine hydroxylase (TH) partial cDNA clone
(»1500bp) in pSPT18 were kindly provided by
N.Kholodilov (Columbia University), K.Scott (Iowa
University) and N. Faucon Biquet (CNRS, Paris,
France) respectively. TH probe was hydrolyzed for 3
min in 0.2M carbonate buffer (80mM
NaHCO3/120mM Na2CO3, pH 10.2) at 60°C to the
final fragment length of »500bp. Serial dilutions of
riboprobes were spotted on positively charged nylon
membrane together with serial dilutions of DIG-labeled
antisense neo-RNA (Boehringer Mannheim) of known
concentration as standard, to estimate the efficiency of
the labeling reaction. In addition, probes were loaded
on 2% agarose gel to check for RNA size and integrity.
Rat brains were rapidly frozen in isopentane upon
extraction and stored dry at –80°C. 25 µm sections
were cut on a cryostat, then dried at RT and stored at
–20°C. For in situ hybridization, sections were
postfixed for 10 min in 4% paraformaldehyde in PBS,
incubated 2x15 min in PBS containing 0.1% active
diethylpyrocarbonate, rinsed briefly in 5x saline
sodium citrate (SSC) and pre-hybridized for 1-2 hrs in
hybridization buffer containing 50% formamide,
5xSSC, and 40 µg/ml salmon sperm DNA at 58-61°C.
Hybridization was then carried out in the same buffer
and at the same temperature with 50-100 ng/ml DIG-
or fluorescein-labeled probe overnight. After
hybridization sections were washed for 30 min at RT,
then for 1 hr at 65°C in 2xSSC, and for 1 hr at 65°C in
0.1xSSC. For in situ hybridization with TH probe, the
additional step of RNase treatment (30 µg/ml at 30°C)
after hybridization was necessary to remove unspecific
staining. After washing the detection was performed
with anti-DIG or anti-fluorescein antibodies coupled to
alkaline phosphatase and color development with
NBT/BCIP substrate (all reagents from Boehringer
Mannheim). Non-specific staining was then washed
out with 95% EtOH for 1 hr. The images of entire
sections were digitalised using videocamera and Image
Store 5000 hardware (UVP). Photomicrographs were
prepared by capturing the images with a Axiocam on a
Zeiss Axiophot light microscope, labeling was
performed using Adobe Photoshop (Adobe Systems)
and Freehand (Macromedia) software.
RESULTS
Induction of -synuclein after cocaine treatment by
Differential Display
To examine the changes in gene expression in the
dopaminergic brain system upon acute cocaine
treatment, we used a modified protocol for differential
display (Brenz Verca et al., 1998). Patterns of
expression were compared for mRNAs isolated from
tegmental area of saline- or cocaine-treated rats.
Diff rential display screening was performed in
duplicate from two independent reverse transcriptions
and resulted in 15 candidates with up- or down-
regulation in tegmentum following cocaine. All
candidate tags were cut out from differential display
gel, and cloned. Each fragment was checked for
sequence homogeneity by means of analytical
restriction of about 10 independent clones with RsaI.
The representatives of the most abundant restriction
patterns were processed to further analysis, including
sequencing and search for homology in Genbank
database. The validity of the differential display
screening was supported through the finding of genes
known to be modified by cocaine treatment. For
example, the NADH dehydrogenase subunit 6, an
mRNA product of the mitochondrial genome, was up-
regulated, in accordance with the literature (Couceyro
et al., 1997). Among the candidates with altered
expression after cocaine treatment a gene with 100%
homology with sensory neuron synuclein (rat
homologue of g-synuclein) (Fig.1) displayed a pattern
of “all-or-none” up-regulation in the tegmental area.
The homology was found in the 3’ region of mRNA
sequence. This region is not included in the high
homology region, defining the synuclein family
(Fig.2), thus we could un-equivocally identify our
message as g- ynuclein.
Expression of - and -synuclein in the rat brain
In situ hybridization was performed with a g-synuclein
probe on rat brain coronal sections (Fig.3 and Table 1).
The probe was prepared from the g-synuclein clone in a
region with no homology to other members of the
synuclein family. g-synuclein is homologous to a-
synuclein, a protein involved in the pathogenesis of
several neurodegenerative diseases. We have compared
the distribution of both mRNAs with a view to better
understand their respective functions. The distribution
of a-synuclein message has already been described
elsewhere (Maroteaux and Scheller, 1991) and
confirmed in our experiments. In the following section
we will focus on differential expression of the two
proteins. In general a-synuclein displays a very
characteristic pattern of expression, confined to
specific nuclei, whereas g-synuclein is more widely
expressed throughout the brain.
Cerebral cortex
In the cerebral cortex, the expression of a-sy uclein is
confined primarily to layers II and V of cerebral cortex
(Fig.3, 4A) with the lowest expression in parietal and
highest expression in insular and piriform cortices
respectively. In contrast g-synuclein is distributed more
4uniformly within the different cortical layers and is
expressed at low levels, particularly within layer V.
Both proteins display a very complementary pattern of
expression throughout most of the cortex.
Ependyma and circumventricular organs
Ependymal cells lining the ventricles as well as those
of the choroid plexus were positive for g-, but not for
a-synuclein. g-synuclein is a strong marker of the
ependymal layer of the ventricles. The expression is
very dense and confined to virtually all ependymal
cells (Fig.4D). We found high expression of g-
synuclein in both the olfactory (Fig.3B) and the lateral
(Fig.3D) ventricles and also a dense labeling in the
subfornical organ (Fig.4C).
Olfactory System and Basal Ganglia
a-synuclein was very strongly expressed in almost all
olfactory areas, including the anterior olfactory nucleus
(Fig.3C, 5A), the tenia tecta, the piriform cortex
(Fig.3C,E, 5C) and the nucleus of the lateral olfactory
tract (Fig.5E). g-synuclein was present in all these
regions, but to a much lesser extent (Fig.3D, 5B,F). On
the other hand the semilunar nucleus was positive
exclusively for g-synuclein (data not shown). g-
synuclein was highly expressed in the olfactory
tubercle (Fig.3D), the ventral pallidum (Fig.5B) and
the caudate-putamen (Fig.3F) and to a lesser extent th
ventral striatum (nucleus accumbens (NAcc)). In addition,
g-synuclein is a suitable marker for the matrix
compartments of the caudate-putamen (Fig.5D). In
contrast a-synuclein was only faintly expressed in the
basal ganglia.
Clearly a-synuclein is expressed mostly in olfactory
areas and g-synuclein mostly in the basal ganglia. -
synuclein labeling clearly delimits the border between
the piriform cortex and the olfactory tubercle (Fig.5C),
as well as between the anterior olfactory nucleus and
the NAcc (Fig.3C). By contrast expression of g-
synuclein in these regions is relatively homogeneous
(Fig.3D), because of its lower expression in olfactory
areas (anterior olfactory nucleus and piriform cortex)
and its higher expression in basal ganglia (olfactory
tubercle and NAcc).
Septum, extended amygdala and hippocampus
All septal nuclei were positive for g-synuclein mRNA
(Table 1 and for example Fig.3F). The labeling was
very dense, even if restricted to a limited number of
cells, in the nucleus of the horizontal limb of the
diagonal band (Fig.6B). a-synuclein was present only
in a limited group of septal nuclei (Table 1). In the
extended amygdala, g-synuclein was present non-
specifically in all amygdaloid nuclei and more
extensively in the bed nucleus of the stria terminalis
(Fig.6D), whereas a-synuclein was particularly
confined to the basolateral amygdaloid nucleus
(Fig.6A), and faintly present elsewhere. Both mRNAs
were present in the hippocampus at a relatively high
level.
Thalamus and hypothalamus
In the thalamus, a-synuclein was present in a very
limited number of nuclei including central medial,
paraventricular and rhomboid thalamic nuclei (Fig.3G),
with highest level of expression in the paraventricular
ucleus (Fig.6C). In contrast g-synuclein is practically
omnipresent in all thalamic regions, including for
example the large ventral thalamic nuclei (Fig.3H, 6D).
In the hypothalamus, only the tuberomammillary
nucleus was positive for a-synuclein, whereas g-
synuclein was largely presented in this brain region.
Fig.7 shows some examples, including the medial
preoptic zone (A) and ventromedial and arcuate
hypothalamic nuclei (D). Its expression was scattered
throughout the lateral hypothalamus, where it was low
in the majority of cells, but very high in a subset of
large, diffusely distributed neurons (Fig.7B). Only the
g-synuclein message was present in paraventricular and
supraoptic hypothalamic nuclei (Fig.3H). Interestingly,
the signal in the paraventricular nucleus was mostly
confined to subsets of neurons involved in the control
of the autonomic nervous system (Fig.7C), including
the neurons of the dorsal medial cup and the ventral
group, as well as oxytocin-secreting neurons of the
medial magnocellular group.
Brain stem
g-synuclein was present in several brain stem nuclei
including the Edinger-Westfal and the red nuclei
(Fig.10). A particular distribution of a- and g-synuclein
was found in midbrain dopaminergic nuclei (see
below).
Expression of synucleins in dopaminergic nuclei
Both a- and g-synucleins are related to
neurodegenerative disorders affecting the
dopaminergic system. In addition, results from the
present study show g-synuclein over-expressed in the
tegmentum upon cocaine treatment. In light of these
findings, we compared the distribution of synucleins
and TH, a marker of catecholaminergic neurons, to
assess the expression of synuclein staining in
dopaminergic neurons.
Some hypothalamic nuclei are known to contain
dopaminergic neurons, e.g. the paraventricular and
supraoptic nuclei (Fig.8B,D). g-synuclein is expressed
in both nuclei but not exclusively in dopaminergic
cells, as  clearly seen when comparing its pattern of
expression with the expression of TH on a subsequent
section (Fig.8A,C).
The most prominent dopaminergic group of cells is
found in the ventral midbrain and comprises the SN
and the ventral tegmental area (VTA). Very low levels
of expression of synucleins are found in the VTA, but
their expression is mostly confined to neurons in the
SN (Fig.9). a-synuclein expression is highly correlated
with TH, confirming previous findings (Kholodilov et
al., 1999a; Abeliovich et al., 2000), whereas g-
synuclein is poorly correlated with TH and is present in
addition in several other nuclei, e.g. the red nucleus,
devoid of TH and a-synuclein. These results clearly
show a distinct pattern of expression for a- and g-
synuclein in relation to the dopaminergic system.
5Expression in cocaine-treated brains
The expression of a- and g-synuclein mRNAs in the
tegmental area of saline- and cocaine-treated rat brains
have been compared with the expression of TH on
subsequent sections, to assess their distribution
dopaminergic cell bodies (Fig.10). We could not find
obvious differences in the expression of both
synucleins, neither in the VTA nor in the SN. However
g-synuclein overexpression upon cocaine is changed in
the red nucleus (Fig.10) and its expression is clearly
modified at the Edinger-Westfal nucleus. Together
these observations confirm our results found by
differential display.
DISCUSSION
This study demonstrates that g-synuclein is up-
regulated in the tegmentum after 24 hrs withdrawal
from acute cocaine treatment and it compares the brain
distribution of a- and g-synuclein mRNAs. The two
members of the synuclein family show a distinct
distribution pattern, further suggesting distinct
functions for these highly related proteins.
g-synuclein is implicated in neurodegeneration, e.g. in
Parkinson’s disease. Its cocaine-induced up-regulation
opens new insights on a possible relation between
Parkinson’s and drug addiction, both of which are
related to tegmental dopaminergic neurons. Given the
common anatomical substrate for these disorders,
attempts to find correlation between their mechanisms
of development have been made but were unsuccessful,
at least on the symptomatic level. For example, chronic
heavy cocaine abuse does not cause parkinsonism
(Dhopesh et al., 1997). The absence of correlation
could be explained by mostly parallel processing of
information by nigral and ventral tegmental
dopaminergic fibers, respectively, with completely
different projection targets, so that changes in one
system will not alter the functioning of another.
However, at the genetic and molecular level it is
reasonable to expect similar molecules and pathways to
be involved in both drug addiction and Parkinson’s
disease. Some examples are discussed below.
1. The dopamine transporter (DAT) is responsible for
the removal of dopamine from the synaptic cleft
after its release under normal conditions, and is the
target both for selective dopaminergic neurotoxins
(MPTP and 6-OHDA, used for simulation of
parkinsonism-like states in animals), and for
psychostimulant drugs such as cocaine or
amphetamine. It is unknown whether the causes of
neurotoxin-induced parkinsonian symptoms are the
same in the etiology of Parkinson’s disease in
humans, but there is evidence that DAT is uniquely
expressed on neurons that are primary targets of
parkinsonian neurodegeneration. Transgenic mice
with TH promoter-driven DAT over-expression
show over 50% greater loss of dopaminergic
neurons following MPTP treatment than wild-type
control mice. These same mice display enhanced
reward conferred by cocaine, as measured by
conditioned place preference. These demonstrate
the importance of DAT for both substance abuse
vulnerability and dopaminergic neurodegeneration
(Donovan et al., 1999). Chronic cocaine treatment
and also 6-OHDA induced Parkinson’s disease both
significantly reduced the levels of DAT mRNA in
the rat SN, pars compacta and VTA (Burchett and
Bannon, 1997; Letchworth et al., 1999). The
changes in the TH mRNA levels somehow mirror
that of DAT and is increased in SN upon chronic
cocaine treatment as well as in patients with either
PD and AD (Vrana et al., 1993; Ito et al., 1999).
Common adaptive processes involving the
dopaminergic system may occur in different
pathological conditions and also during aging. DAT
and TH mRNA decrease in the SN with age, a fact
probably relevant for the observed increased
susceptibility to Parkinson’s in elderly and also for
the age-dependent sensitivity to drug actions,
youngest subjects (rhesus monkeys) being less
sensitive to cocaine effects on several brain
functions than older ones (Paule et al., 1998).
2. As another example, the kappa opioid receptor
(KOR) mRNA is down-regulated in the VTA and
the NAcc by chronic ethanol and repetitive cocaine
(Spangler et al., 1996; Rosin et al., 1999) while it is
expressed at very low levels in the SN from
Parkinson’s patients and may play a role in the
etiology of the disease (Yamada et al., 1997). On
the other hand there is a loss of enkephalin- and
dynorphin-like immunoreactivity in the SN (Waters
et al., 1988) from Parkinson's patients, but
subchronic administration of cocaine (20
mg/kg/day for 4 days) increases the striatonigral
levels of dynorphin without altering the levels of
Met5-enkephalin (Sivam, 1989).
3. An interesting correlation is also found between the
involvement of glutamate transmission in
parkinsonism and in cocaine action. Stimulation of
NMDA receptors of the striatonigral projection
may induce a slow neurodegeneration in
Alzheimer's and Parkinson's disease due to a raise
of the intracellular calcium concentration. Indeed
nigrostriatal dopaminergic neurons containing
calcium-binding proteins are less vulnerable to
degeneration (Loopuijt and Schmidt, 1998),
whereas neurotoxic effects of cocaine are strongest
in the presence of anti-parvalbumin antibodies
(Glezer et al., 1999). Also the development of
behavioral sensitization towards cocaine parallels
the elevation of extracellular glutamate in the VTA,
probably by an increase in the capacity of neurons
expressing D1 receptors to release glutamate after
stimulation (Kalivas and Duffy, 1998), an effect
probably mediated by neurotrophins. A significant
increase in the expression of trkB is observed in the
caudate-putamen ipsilateral to the 6-OHDA
injection (Numan and Seroogy, 1997) while acute
cocaine injection also results in a transient increase
in NT-3 in the VTA and NT-3 contributes to the
initiation of behavioral sensitization to cocaine by
activating the Ras/MAP kinase signal transduction
system (Pierce et al., 1999).
4. Furthermore both cocaine treatment (either acute
or chronic) and the development of Parkinson’s
6disease alter the oxytocin content in hypothalamus
(Purba et al., 1994; Sarnyai, 1998). Oxytocin-
releasing cells of the paraventricular hypothalamic
nucleus are also dopaminergic. Decreased
oxytocin levels could provide a neural basis for
some autonomic and endocrine disturbances in
Parkinson’s disease  (Purba et al., 1994) but
oxytocin also modulates different cocaine-induced
behavioral phenomena  (Sarnyai, 1998).
Together these data clearly demonstrate a correlation
between the mechanisms involved in development of
neurodegenerative diseases and in drug addiction.
Nevertheless the precise function of g-synuclein in
cocaine action remains unexplained. From the protocol
used in our present study, a role for g-synuclein in
long-lasting adaptations to the drug rather that in the
acute response is suggested. Such a role is in
agreement with functions proposed for g-synuclein in
the regulation of axonal growth and changes of axonal
morphology, probably as a result to modifications of
the integrity of the neurofilament network. Other
plasticity related proteins, e.g. CART and EphA5, are
also up-regulated following our protocol of drug
treatment. CART has neurotrophic actions on
dopaminergic neurons in vitro, increasing dopamine
uptake, survival and neurite outgrowth (Louis, 1996).
EphA5 is an axon guiding molecule involved in the
establishment of mesostriatal dopaminergic projections
during development (Yue et al., 1999). Therefore
CART, EphA5 and g-synuclein together could
participate in local plasticity following cocaine
treatment.
In conclusion, our study establishes an up-regulation of
g-synuclein in cocaine-treated brain which probably is
associated with drug-induced plasticity changes in the
dopaminergic system and suggests mechanisms
common in the development of neurodegenerative
diseases and drug addiction.
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Table 1. The distribution of - and -synucleins mRNAs in rat brain. The relative intensity of expression is
indicated (from +/- to +++ as the level of signal increases).
Brain region -synuclein -synuclein
Cortex
Layer II
Layer V
Other layers
Parietal, area 1
Insular
Piriform
Other cortical areas
Claustrum
Dorsal endopiriform nucleus
Ependyma
Subfornical organ
Olfactory system
Anterior olfactory nucleus
Nucleus of the lateral olfactory tract
Tenia tecta
Induseum griseum
Semilunar nucleus
Islands of Calleja
Septum
Nucleus of the horizontal limb of the diagonal band
Nucleus of the vertical limb of the diagonal band
Lateral septal nucleus, dorsal part
Lateral septal nucleus, intermediate part
Lateral septal nucleus, ventral part
Basal ganglia
Caudate putamen
Nucleus accumbens, shell–+
Nucleus accumbens, core
Ventral pallidum –
Olfactory tubercle
Claustrum ++
Hippocampus
Thalamus
Medial habenular nucleus
Paraventricular nucleus, posterior
Paraventricular nucleus, anterior
Paratenial nucleus
Central medial nucleus
Rhomboid nucleus
Xiphoid nucleus
Intermediodorsal nucleus
Anteroventral nucleus
Ventral reuniens nucleus
Ventrolateral nucleus
Laterodorsal nucleus
Mediodorsal nucleus
+
++
-
+/-
++
+++
+
++
+
-
-
+++
+++
+++
++
-
-
+
-
+
-
-
+/-
+/-
+/-
-
+/-
++
+++
++
++
+++
-
++
++
++
++
-
-
-
-
-
+
+/-
+
+
+
++
+
+
+++
++
++
+
+
+
+
++
+++
+++
+
+
+
+
+
++
+
++
++
+
+
+
++
++
++
++
++
++
++
++
++
++
++
++
9Interanteromedial nucleus
Ventral posterolateral nucleus
Ventral posteromedial nucleus
Anteromedial nucleus
Reticular nucleus
Reuniens nucleus
Gelatinosus nucleus
Zona incerta
Subincertal nucleus
Hypothalamus
Medial preoptic zone
Arcuate nucleus
Supraoptic nucleus
Paraventricular nucleus
Periventricular nucleus
Ventromedial nucleus
Dorsomedial nucleus
Magnocellular nucleus of the lateral hypothalamus
Suprachiasmatic nucleus
Tuberomammillary nucleus
Medial preoptic nucleus
Amygdala and extended amygdala
Posterolateral cortical amygdaloid nucleus
Basomedial nucleus
Central nucleus
Lateral nucleus
Basolateral nucleus
Bed nucleus of the stria terminalis
Amygdalohippocampal area
Amygdalohippocampal area, posteromedial part
Amygdalopiriform transition area
Midbrain
Substantia nigra, pars compacta
Substantia nigra, pars lateralis
Substantia nigra, pars reticulata
Red nucleus, magnocellular part
Ventral tegmental area
Edinger-Westfal nucleus
Oculomotor nucleus
Interpeduncular nucleus
-
-
-
-
-
-
-
+
-
-
-
-
–
-
-
-
-
-
++
-
++
+
+++
+
+
-
++
+++
+++
+
+/-
-
+/-
-
+/-
-
-
++
++
++
++
++
++
++
++
++
++
+++
+++
+++
+++
++
++
++
+++
++
+++
+/-
+/-
+
+
+
++
+/-
+/-
+/-
++
+/-
-
+++
-
+++
++
++
Figure 1. γ-synuclein over-expression in differential
display. sT: saline tegmentum, cT: cocaine tegmentum; 1
and 2 correspond to two duplicate PCR reactions starting
from independent reverse transcription reactions; γ-synuclein
band is indicated by arrows (at approximately 120 bp).
Figure 2. Alignment of synuclein tags used in the present
study with the sequences from Genbank. Genbank mRNA
sequences are given without poly(A) tail. The region of highest
homology between two synucleins is indicated. γ-synuclein
DD fragment: the sequence of tag found to be up-regulated in
tegmentum upon cocaine in differential display experiment.
α-synuclein in situ probe
α-synuclein (Genbank)
γ-synuclein (Genbank)
γ-synuclein in situ probe
γ-synuclein DD fragment
900 bp
1006 bp
706 bp
317 bp
70 bp
5’
5’
5’
5’
5’
3’
3’
3’
3’
3’
Region of highest homology
sT cT sT cT
1 2
fmi
aca
5
3
2
4
C
fmi
aca
4
5
3
2
D
2.7
gcc
6
7
E
gcc
6
7
F
0.7
cc
a b
c
98
11
10
G
cc
98
11
10
H
-1.8
aci
1
BBregma
4.7
aci
1
A
α-synuclein γ-synuclein
Figure 3. In situ hybridization of synucleins mRNA
distribution throughout the adult rat brain.
Photomicrographs are shown for coronal 25 µm sections
hybridized with α- (A,C,E,G) or γ- (B,D,F,H) synucleins
probes. To facilitate the localization of particular structures,
Bregma stereotaxic coordinates are indicated. In addition,
some key structures are labeled by abbreviations: aca:
anterior commissure, anterior part; aci: anterior commissure,
intrabulbar part; cc: corpus callosum; fmi: forceps minor
of the corpus callosum; gcc: genu of the corpus callosum.
Note the differential distribution of two mRNAs in the
cortex and especially on the coronal section at Bregma –1.8.
α-synuclein staining is predominantly present in the cortex,
in the hippocampus and in few thalamic nuclei, labeled by
dashed arrows and letters a-c. γ- synuclein staining is more
widespread. Other differentially labeled regions are indicated
by numbered arrows: 1: ependymal layer of the olfactory
ventricle; 2: lateral ventricle; 3: nucleus accumbens; 4:
anterior olfactory nucleus; 5: olfactory tubercle, pyramidal
layer; 6: lateral septal nucleus; 7: olfactory tubercle; 8:
ventral thalamic nuclei; 9: caudate putamen; 10:
paraventricular hypothalamic nucleus; 11: supraoptic nucleus.
a: central medial thalamic nucleus; b: paraventricular
thalamic nucleus; c: rhomboid thalamic nucleus.
Figure 4. Expression of synucleins in the cortex,
subfornical organ and ependyma. In the cerebral cortex,
the expression of α-synuclein is confined primarily to
cortical layers II and especially V (A), whereas γ-
synuclein is present at lower intensities but distributed
equally at all layers (B). Cortical layers are indicated
by roman numbers. C: γ-synuclein staining in the
subfornical organ. D: γ-synuclein in the ependymal cells
lining the lateral ventricle. Scale bar: 20 µm (in A,B,E),
25 µm (in C) and 50 µm (in D).
A II
V
B II
V
C D
Figure 5. Expression of synucleins in the olfactory system
and basal ganglia. α-synuclein staining is shown in
panels A,C,E; γ-synuclein – in panels B,D,F. A: anterior
olfactory nucleus; B: ventral pallidum (VP) and piriform
cortex (PC); C: piriform cortex (PC) and olfactory
tubercle (OT); D: caudate-putamen. Note the specific
labeling by γ-synuclein of matrix compartment of the
striatum. E,F: nucleus of the lateral olfactory tract. Scale
bar 100 µm.
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Figure 10. Expression of synucleins in saline- and cocaine-
treated brains. Probes for TH, α-, and γ-synucleins were
hybridized to six subsequent coronal sections of brains from
saline- or cocaine-treated animals. The Edinger-Westfal
nucleus is indicated by arrows on γ-synuclein-stained
sections. Note the lower and more scattered expression in
saline-treated brain. The red nucleus is indicated by dotted
arrows on γ-synuclein-stained sections. Note the higher
signal in cocaine-treated brain. SN: substantia nigra; VTA:
ventral tegmental area.
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